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1.1 Regenerative medicine and cell therapy 
Skin wounds remain a challenging clinical problem with early or late complications 
presenting a frequent cause of morbidity and mortality (Natarajan et al., 2000). Both humans 
and animals experience different types of wounds during the course of their lives. Particularly, 
veterinary patients are frequently affected by complex skin wounds (Theoret, 2009b). During 
the past few decades, various wound healing technologies for promoting cell activity or 
minimizing scar formation have been developed and some of them are being actively used at 
present (You and Han, 2014). Regenerative medicine is an emerging and rapidly evolving 
field of research  developed with therapeutics aim to restore, maintain and improve body 
functions (Polak et al., 2008). Ultimately, this might provide a treatment for conditions where 
current therapies are failing or are inadequate (Ramakrishna et al., 2011). Cell therapy is a 
part of the broad field of regenerative medicine and can be defined as a set of strategies which 
use live cells with therapeutic purposes (Yolanda et al., 2014).  
 1.2 Definitions and types of stem cells  
Cells used in cell therapy can be categorized as stem cells and adult/differentiated cells. In 
traditional textbooks, it was taught that stem cells were at the origin of all major tissue types 
and that once cells partly or totally differentiated into a cell type they became terminal cells 
and could not be dedifferentiated. However, now it is known that stem cells are ‘plastic’ and 
indeed dedifferentiate (You and Han, 2014). There are two major types of stem cells, the 
embryonic stem cells (ESC), which are derived from the inner cell mass of an early embryo, 
and the adult stem cells (ASC), which have been found in almost every tissue of every human 
and animal (Figure 1.1). ASC are the prime source for cell-based therapies as they are 
relatively easy to obtain through in vitro culturing and they escape the ethical issues 
associated with ESC (Volk and Theoret, 2013a). So far, fibroblasts, keratinocytes, adipose-
derived stromal vascular fraction cells, bone marrow (BM) stem cells and platelets have been 
used to stimulate wound healing in clinical practice (You and Han, 2014). Details of cell 
based skin wound therapy can be found in Chapter 2 of this thesis.  
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Figure 1.1 Classification of stem cells. Schematic overview of embryonic stem cells (ESC) and adult stem 
cells (ASC) with more emphasis on mesenchymal stem cells (MSC) and epithelial stem cells (EpSC) and 
their differentiation potential to most commonly cited skin cells. The zygote formed following fertilization 
undergoes serial cleavage to form the inner cell mass (ICM) of a blastocyst, which contains ESC. ASC can 
be isolated from various tissues of the three germ layers. MSC are derived from the mesoderm, whereas 
skin EpSC are isolated from dermis  (mesodermal origin) and epidermis (ectodermal origin). Both stem 
cell types can be induced to differentiate into various adult cell types including keratinocytes and 
fibroblasts. 
1.3 Animal models for stem cell based skin wound therapy 
Different experimental animal models are currently being used to establish relevant 
preclinical data for developing human (regenerative) therapies (Campillo et al., 2014). 
Veterinary patients, including companion animals (dogs, cats and horses) and farm animals 
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(cattle, sheep, goats and pigs) are increasingly being used and recognized as translational 
models for the evaluation of novel agents for the treatment of human diseases. Compared to 
rodents and rabbits, all of the above mentioned animals are considered as “large” 
experimental animal models (Volk and Theoret, 2013a). “Small” animals, such as mice, rats 
and rabbits, have been extensively used as models for a number of preclinical and clinical 
studies evaluating cell-based therapies for cutaneous wounds. The advantages of these 
“small” species  are the different available strains, low costs, short reproduction turnover and 
less  ethical concerns in comparison to “large” animal models.  The shorter life cycle and 
smaller size of rodents enhance the power of studies within a shorter timeframe. However, it 
is questionable whether results from “small” animal studies can be translated/extrapolated to 
humans (Volk and Theoret, 2013b). In comparison, “large” animal studies are assumed to 
generate results that are more alike results to be expected in humans. Indeed, the basic 
biochemical and physiological processes in large animal models resemble more closely those 
in humans compared with rodents (Parker et al., 2010). Moreover, studies show that some 292 
canine, 163 feline, 142 bovine and 109 equine genetic diseases are homologous with human 
genetic defects (Lenffer et al., 2006).  Nevertheless, in some cases the pathophysiology and 
resulting phenotype of such mutations are still undefined or may vary from that in humans  
 The advantages of “large” animal studies include the longer lifespan, availability of outbred 
offspring and exposure to external and environmental factors. Furthermore, long-term follow-
up and repeated biologic sampling are more feasible in “large” animal models and enhance 
the ability to detect side effects of novel therapies which minimize both veterinary and human 
patient risks. In addition, the increase in demand for sophisticated, state-of-the-art care for 
companion animals has led to a surge in clinical trials in veterinary patients (Volk and 
Theoret, 2013a). For all the aforementioned reasons, “large” animal models are considered to 
be indispensable for advancing stem cell therapies for both human and veterinary clinical 
applications.  
1.4 Isolation and characterization of adult stem/progenitor cells  
In the field of veterinary medicine, different isolation methods and identification techniques 
have been described for obtaining different (stem) cell types. However, in contrast to human 
mesenchymal stem cells (MSC), no uniform characterization criteria are available for 
veterinary stem cells to date (De Schauwer et al., 2011b; Dominici et al., 2006). While MSC 
from multiple species can be identified by their ability of plastic-adherence under standard 
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culture condition in tissue culture flasks and tri-lineage differentiation towards adipocytes, 
osteoblasts and chondroblasts (Dominici et al., 2006), other stem cell types may possess 
substantially different properties, such as survival in suspension and differentiation towards 
keratinocytes and myo-epithelial cells  (Broeckx et al., 2014e; Dominici et al., 2006; Dontu et 
al., 2003). For all these reasons, the isolation and characterization techniques are critical 
parameters before assessing any cell-based product in a clinical application. 
1.4.1 Bone marrow-derived nucleated cells 
In the center of most large bones there is a soft tissue, the so-called bone marrow (BM), which 
is a network of soft, sponge-like material that contains immature blood cells in an organized 
structure. Post-natal BM has traditionally been considered as an organ composed of two main 
systems or compartments rooted in distinct lineages: the hematopoietic tissue and the 
associated supporting stroma (Bianco et al., 2001; Jackson et al., 2001). The hematopoietic 
compartment provides the organism with mature blood cells of all lineages and the stromal 
cell compartment functions as the microenvironment for self-renewal, proliferation and 
differentiation of hematopoietic stem cells (HSC). In addition, the stromal cell compartment 
harbors vascular progenitor cells (Jackson et al., 2001) and MSC capable of differentiation 
into cells of most connective tissues (Bianco et al., 2001). HSC are a well-characterized 
population of self-renewing cells that produce progenitors that differentiate into every type of 
mature blood cell in a well-defined hierarchy (Kondo et al., 2003). To date, HSC and MSC 
are the stem cell types having received a lot of attention from the scientific community 
because of their potential use as a regenerative medicine (Volk and Theoret, 2013a).  
Bone marrow-derived MSC (BM-MSC) have great potential in tissue engineering and clinical 
therapy and various methods for isolation and cultivation have been reported. However, the 
isolation and cultivation techniques have not yet been optimized (Zhang et al., 2014). BM 
tissue has been harvested/aspirated to isolate BM-MSC from bone marrow-derived nucleated 
cells (BMNC). The BM-MSC are then cultured, expanded and injected back into the host 
(autologous cell therapy) to promote osseous or soft tissue healing (Ishihara et al., 2013). 
Isolation of BM cells is being performed by aspiration of this substance from various sites of 
the animal or human. To date, BM has been harvested from humerus, iliac crest or tibia in 
dogs and cats, and from the sternum and tuber coxae in horses (Volk et al., 2012). In rabbits, 
guinea pig, mouse and chicken, BM has mainly been aspirated from the tibia (Sundberg and 
Chapter 1   
7 
 
Hodgson, 1949). In addition, it can also be isolated from the iliac crest (Awad et al., 2000; 
Sundberg and Hodgson, 1949) and femur (Powsner and Fly, 1962). In this thesis (Chapter 4.1 
and 4.2), BM has been aspirated aseptically from tibia of experimental rabbits under general 
anesthesia. BM aspirates consist of a heterogeneous cell population, including fibroblasts, 
adipocytes and mononuclear cells (BMMNC) (Wu et al., 2007a). BM-MNC include HSC, 
BM-MSC, endothelial progenitors and cellular precursors (Taylor and Zenovich, 2008). 
Unfortunately, MSC constitute only a small percentage of the BM populating cells, and 
therefore, subsequent cultivation of BM-MSC is advisable when their specific effects are 
being studied.  
Several methods are currently available for BM-MSC isolation and cultivation. Although 
separation methods that include immune-magnetic beads or flow cytometry generate BM-
MSC with higher purity, the expense, procedural complications and cell damage that occur 
during this process, restrict their usage (Zhang et al., 2014). Alternatively, BM-MNC can be 
concentrated by using volume reduction protocols or gradient centrifugation techniques such 
as Ficoll or Percoll density gradient (Kasten et al., 2008; Zhang et al., 2014). The number of 
MSC isolated from different tissues may vary in terms of the yield, quality and purity, even 
when the cells have been obtained from the same donor (Phinney et al., 1999).  
Studies reveal that BM cells, most notably MSC, play a major role in skin regeneration 
(Brittan et al., 2005; Crigler et al., 2007; Deng et al., 2005; Kim et al., 2013b) and 
vascularization (Asahara et al., 1999). BM has been used as concentrated autologous BM-
MNC or as BM-MSC, which have been isolated from the BM concentrate and expanded and 
characterized in vitro before clinical use (Altaner et al., 2013). MSC are characterized based 
on their ability to self-renew, differentiate towards different cell types of the mesodermal 
germ layer and express certain cell surface markers (Dominici et al., 2006). Population 
doubling levels are an estimate for the growth efficiency and proliferation potential of MSC 
(Kang et al., 2013). A study in humans has shown that doubling time of cultivated BM-MSC 
is age dependent. Indeed, BM-MSC from older persons possess higher doubling times than 
their younger counterparts (Altaner et al., 2013). With regard to their differentiation potential, 
BM-MSC have to differentiate into osteoblasts, adipocytes and chondroblasts, according to 
the proposed minimum criteria set by International Society for Cellular Therapy (ISCT) 
(Dominici et al., 2006). In this regard, a number of studies have demonstrated the in vitro and 
in vivo differentiation potential of MSC along multiple lineages at a preclinical and clinical 
Chapter 1   
8 
 
level (Kraus and Kirker-Head, 2006; Martinello et al., 2010a).  These lineages consist of cell 
types from all germ layers of the embryo, such as mesodermal cells (skeletal muscles, 
cardiomyocytes), but also ecto- and endodermal cells, e.g. neuronal cells, glial cells, 
keratinocytes and hepatocytes (Bajek et al., 2011; Bieback et al., 2012). Particularly 
interesting for the present thesis is the ability of BM-MSC differentiate to different skin cells 
and secrete wound healing factors as reported in the following studies. In an experimental 
murine model, adult BM-derived stromal cells gave rise to epidermal keratinocytes, follicular 
epithelial cells, sebaceous gland cells, dendritic cells and endothelial cells after transplantation 
(Goodell et al., 2001; Ratajczak et al., 2004). Direct transdifferentiation of remotely recruited 
BM-MSC types into epidermal keratinocytes was also reported by a number of researchers 
(Borue et al., 2004a; Brittan et al., 2005). Additionally, experiments by different groups 
(Sasaki et al., 2008; Tamai et al., 2011) also showed that BM-MSC, rather than some 
hematopoietic progenitors, are able to undergo direct epidermal transdifferentiation. In 
addition to the wound healing effect of BM-MSC through differentiation and/or 
transdifferentiation into different skin cells, a number of researchers have also reported this 
could be possible through the release of paracrine factors by BM-MSC including growth 
factors, cytokines and chemokines (Chen et al., 2008b; Kim et al., 2013b). In fact there have 
been evidences against and for plasticity of ASC in general, which made it a subject of 
debate. Even though some techniques which have been used to assess in vivo and in vitro 
plasticity are convincing, issues of cell to cell fusion and lack of reproducibility of findings in 
other laboratories are the two primary controversies in BM-MSC plasticity (Grove et al., 
2004; Herzog et al., 2003; Zhang and Alexanian, 2014). However, it is not yet known whether 
fusion is responsible for much of the plasticity data (Grove et al., 2004). While 
transdifferentiation of MSC is still controversial, these unique properties make MSC an ideal 
autologous source of easily reprogrammable cells (Zhang and Alexanian, 2014).  Therefore, 
there is a need for accurate and sensitive technique to establish the in vivo and in vitro works 
to confirm plasticity/transdifferentiation of MSC and to better understand ASC plasticity that 
can be used for treating diseases and tissue injuries in patients. In the present thesis, an in-
depth review concerning wound healing potential of MSC through their differentiation, 
transdifferentiation and paracrine effect can be found in Chapter 2. 
MSC have been isolated from humans and a variety of animal species (Penny et al., 2012). 
Successful isolation and differentiation of MSC from different sources such as BM, adipose 
tissue, umbilical cord blood, Warton’s jelly, amniotic fluid or peripheral blood (Cremonesi et 
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al., 2008a; Kang et al., 2013; Koch et al., 2007; Martinello et al., 2010a; Spaas et al., 2013b; 
Spaas et al., 2013c), shoulder tissue (Utsunomiya et al., 2013), gingival tissue (Ge et al., 
2012), placenta (Wang et al., 2012), muscle and periosteum (Kisiel et al., 2012) have been 
reported. However, currently there is no consensus on how these cells should be identified 
and characterized. This is particularly due to the lack of standardized specific cell markers for 
MSC (De Schauwer et al., 2011b; Penny et al., 2012) and limited availability of monoclonal 
antibodies for animals, which are the two major factors complicating successful research on 
MSC (De Schauwer et al., 2011b). In human medicine, the Mesenchymal and Tissue Stem 
Cell Committee of the ISCT proposed three criteria to define human (h) MSC: i) plastic-
adherent when maintained under standard culture conditions, ii) express specific surface 
antigens and iii) possess a multipotent differentiation potential (Dominici et al., 2006) (Table 
1.1). These minimum criteria apply only to hMSC.  
Table 1.1 Minimum criteria to define hMSC as proposed by ISCT (Dominici et al., 2006) 
hMSC 
Culture 
characteristic 
Differentiation 
potential 
Expression of surface antigen 
Positive  Negative 
Plastic adherent in 
standard culture 
conditions (in vitro) 
Osteoblasts, 
adipocyte, 
chondroblasts 
CD73, CD90 & CD105 CD34, CD45, CD14 or 
CD11b, CD79α or CD19, 
MHC class II antigens 
 
CD = Cluster of Differentiation; hMSC = human Mesenchymal Stem Cells; ISCT = International Society for Cellular 
Therapy 
Although rabbit bone marrow mesenchymal stem cells (rbBM-MSC) have been used 
extensively, especially in translational research, these cells have neither been defined 
morphologically and ultra-structurally, nor been compared with their human counterparts 
(hBM-MSC) concerning multi-lineage differentiation ability. According to a study by Tan et 
al. (2013) rbBM-MSC expressed CD29, CD44, CD73, CD81, CD90 and CD166 but were 
negative (or dim positive) for CD34, CD45, CD117 and HLD-DR (Tan et al., 2013). A recent 
study by Zhang et al. (2014) also reported BM-MSC isolation from rabbits on the basis of 
positive expression of CD29, CD44, CD90, CD105 and no expression for hematopoietic 
markers and endothelial markers such as CD14, CD34, CD45 and CD184 (Zhang et al., 
2014). However, even though MSC have been isolated and characterized from a variety of 
animal species including rodents, dogs, horses and rabbits (Penny et al., 2012), there is no 
consensus concerning common standards and harmonized isolation and characterization 
protocols, which are important to identify the used cell type and ensure safety and efficacy 
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(Bieback et al., 2012). Moreover, MSC of animal origins do not express all of the 
abovementioned surface molecules (Gronthos et al., 2001; Peister et al., 2004). When hMSC 
have been correctly isolated from a biopsy, the expression of some surface markers can also 
be attributed to the presence of different factors excreted by other mononuclear cells present 
at initial passages (Gronthos et al., 2001). A summary of the currently available 
characterization methods including marker expression on MSC of different tissues and 
animals is shown in Table 1.2. In addition, it is also challenging for clinicians to utilize 
cultured BM-MSC for the purpose of wound healing due to issues regarding the approval by 
the food and drug administration (FDA). Autologous whole BM transplantation is a simpler 
method and does not require FDA approval because it is considered as a single-step surgical 
procedure when immediately applied to the same patient. Accordingly, in the present thesis, 
whole autologous BM-derived cells have been used after volume reduction (as indicated in 
the materials and methods of Chapters 4.1 and 4.2) for treating full thickness skin wounds of 
rabbits. 
1.4.2 Skin-derived epithelial-like cells 
In recent years, different classes of stem cells have been investigated for their ability to 
regenerate organs and tissues after injury. The skin, which is the largest organ of the mammal 
body is a rich and easily accessible source of stem cells. So far, stem cells have been isolated 
from different skin compartments including the isthmus (i.e. above the bulge, where the 
sebaceous gland duct inserts) (Gordon and Andersen, 2011), sweat glands (Lu et al., 2012), 
the bulge of the hair follicle, sebaceous glands, dermis and epidermis as discussed/shown in 
Chapter 2 (Broeckx et al., 2014e; Draheim and Lyle, 2011; Frances and Niemann, 2012; Ito, 
2005; Plikus et al., 2012; Taylor et al., 2000; Toma et al., 2001; Toma et al., 2005). 
The skin is a tissue which undergoes continuous self-renewal throughout the lifetime of an 
organism and also has an extensive ability to repair inconsistencies (Nowak and Fuchs, 2009). 
It has been well documented that tissue homeostasis and wound repair are ensured by stem 
cells, located within a specialized microenvironment, being the skin “niche”. Each niche is 
tailored to accommodate the regenerative needs of its tissue. However, some tissues like skin 
epithelium harbor multiple stem cell niches, each with their own responsibility for 
maintaining cellular balance within their particular domain (Blanpain and Fuchs, 2014). 
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Table 1.2 Overview of frequently cited self-renewal methods, differentiation potential and marker 
expression of MSC derived from different tissue sources and animals. 
Reference Cell 
type 
Source, 
animal 
Self- renewal Diff Marker 
Positive Negative 
(De Schauwer et al., 
2014) 
MSC UCB, 
horse 
PDT O, A, C CD29, CD44, CD73, 
CD90, CD105,  
MHC-I 
CD45, D79a, 
Mo/Mφ, MHC-II 
UCM, 
horse 
PDT A, C ” ” 
PB, 
horse 
PDT O, A, C ” ” 
(Tan et al., 2013) ” BM, 
rabbit 
PDT, 
proliferation 
” CD29, CD44, CD73, 
CD81, CD90, CD117, 
CD34, CD45, HLA-
DR 
BM, 
human 
” ” CD29, CD44, CD73, 
CD81, CD90 
CD34, CD45, 
CD117, HLA-DR 
(Spaas et al., 2013c) ” PB, 
horse 
CFU, PDT ” CD29, CD44, CD90, 
CD105 
CD45, CD79α, 
MHC-II, Mo/Mφ 
(Carvalho et al., 2013) ” PB, 
horse 
ND A, C CD44,   CD90 CD13 
(De Schauwer et al., 
2011a) 
” UCB, 
horse 
Sphere, PDT O, A, C CD24 ND 
(Martinello et al., 
2010a) 
” PB, 
horse 
Telomerase, 
proliferation, 
PDT 
O, A, M CD44, CD90, CD117, 
CD13 
CD34, CD45 
(Kim et al., 2013b) ” BM, 
dog 
ND ND CD29, CD44 CD34, CD45 
(Sasaki et al., 2008) ” BM, 
mice 
ND O, A, C CD29, CD44 , CD90 CD34, CD31 
(Wu et al., 2007b) ” BM, 
mice 
ND O, A, C CD29, CD44, CD105, 
CD90, Sca-1 
CD34, CD45, CD14, 
CD3, CD19 
(Badiavas and Falanga, 
2003) 
MNC BM, 
human 
ND ND CD31 CD68, CD34 
(Badiavas et al., 2007) MNC BM, 
human 
CFU A, E, F CD146, CD133, 
CD14 
N/D 
(Kasten et al., 2008) MNC BM, 
human 
CFU O, A, C CD13, CD44, CD73, 
CD90, CD105, HLA-
A, B, C 
CD14, CD34, CD45, 
CD271, HLA-DR 
 
A = Adipocyte; BM = Bone Marrow; CD = Cluster of Differentiation; CFU = Colony Forming Unit; C= Chondroblast; Diff 
= Differentiation capacity; E = Endothelial cell; F = Fibroblast; HLA-DR = Human Leukocyte Antigen D-related; M = 
Myocyte; MHC = Major Histocompatibility Complex; MNC = Mononuclear Cell; Mo/Mφ = Monocyte/Macrophage; MSC = 
Mesenchymal Stem Cells; ND = Not Determined; O = Osteoblast; PB = Peripheral Blood; PDT = Population Doubling Time; 
UCB = Umbilical Cord Blood; UCM = Umbilical Cord Matrix  
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The role of EpSC during wound healing is not limited to regenerating stratified epidermis. By 
studying the regenerative response in large cutaneous wounds, it has been discovered that 
epithelial cells in the center of the wound can acquire greater morphogenetic plasticity and, 
together with the underlying wound dermis, can engage in an embryonic-like process of hair 
follicle neogenesis (Plikus et al., 2012). However, in severe pathological cases, such as burn 
wounds, chronic wounds, and ulcers, the endogenous skin repair mechanisms might be 
insufficient. For this reason, exogenous purification and multiplication of EpSC might be 
useful in the treatment of these skin diseases.  
In correspondence with the characterization of other ASC, specific functional and 
immunophenotypic properties have been identified to characterize skin stem cells. These 
techniques include sphere formation assessment, self-renewal assays, multilineage 
differentiation evaluation and assessing the presence of specific cell surface or intracellular 
markers (Table 1.3). Sphere formation has been reported from both crude dermal suspensions 
cultured on adherent surfaces (Toma et al., 2005) and epidermis-derived cells seeded at clonal 
density under ultralow attachment conditions (Broeckx et al., 2014e). Besides the evaluation 
of population doubling times (Broeckx et al., 2014), there is only limited information 
available on the self-renewal capacity of skin stem cells. Indeed, the survival and proliferation 
rate of sphere-initiating cells under different culture conditions and after serial passaging 
remains to be elucidated.  
Concerning the differentiation capacity of skin stem cells, several reports confirm their 
multipotent properties. In this regard, it has been described that rodent skin-derived precursors 
(SKP) differentiated into both neural and mesodermal cell types, including neurons, glia, 
smooth muscle cells, and adipocytes (Toma et al., 2001). Also human scar tissue-derived stem 
cells (hSTSC) were able to form neurogenic progenitor cells (Yang et al., 2010). Moreover, it 
has been recently reported that equine epidermal-derived stem cells  differentiated towards 
two major skin cell types, being keratinocytes  and adipocytes (Broeckx et al., 2014e)-. For 
immunophenotypic characterization of skin-derived stem cells several types of surface 
molecules have been tested so far. In one of the studies on murine dermal cell suspensions, 
phenotypic analysis revealed that a small population of CD45+ cells and a large population of 
CD45- cells expressed CD34, CD117 and stem cell antigen-1 (Meindl et al., 2006). This 
indicates that a certain degree of cell impurities were present in these spheres. A study by 
Broeckx et al. characterized equine epidermis EpSC by means of positive expression for 
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CD29, CD44, CD49f, CD90, Casein Kinase 2β, p63 and Ki67, low expression for cytokeratin 
(CK)14, and negative expression for CD105, CK18, Wide CK and Pan CK (Broeckx et al., 
2014e). The authors reported no cellular impurities in the three screened isolates.  
Table 1.3 Summary of the currently available characterization criteria used by different researchers 
including self-renewal assessment method, differentiation potential and marker expressions on epithelial 
stem cells of different sources.  
Reference Cell type, 
species 
Source, 
animal 
Self- 
renewal 
Differentiation       Marker Other 
method Positive Negative 
(Broeckx et al., 
2014e) 
EpSC, 
horse 
Epidermis Sphere 
formation, 
PDT 
K/A CD29, CD44, 
CD49f 
CD105 ND 
(Frances and 
Niemann, 2012) 
HFSC, 
mice 
HF ND Sebocyte Sox 9, Lrig1 ND LR 
(Lu et al., 2012) SGP,  
mice 
Epidermis 
and 
dermis 
CFA ND Sca-1, CD29, 
CD49f, CD24, 
Sox9 
ND LR 
(Toma et al., 
2005) 
SKP, 
human 
Dermis Sphere, 
PDT 
Neurons, glia, 
adipocytes, 
SMC 
ND ND LR 
(Toma et al., 
2001) 
SKP,  
mice 
Dermis 
 
Sphere, 
PDT 
Neurons, glia, 
adipocytes, 
SMC 
ND ND LR 
(Cotsarelis et al., 
1990; Taylor et 
al., 2000) 
Bulge 
stem cells, 
mice 
HF, ND HF ND ND LR 
(Jones and Watt, 
1993) 
Epidermal 
stem cells, 
human 
Epidermis CFA ND CD29 ND ND 
A = Adipocyte; C = Chondrocyte; CD = Cluster of Differentiation; CFA = Colony Forming Assay; EpSC = Epithelial-like 
Stem cells; HF(SC) = Hair Follicle (stem cells); K = Keratinocyte; LR = Label Retention; Lrig1 = Leucine-rich repeats and 
immunoglobulin-like domains protein 1; MHC = Major Histocompatibility Complex; M = Myogenic; ND = Not Determined; 
O = Osteocyte; PDT = Population Doubling Time; SC = Schwann cells; SKP = Skin-Derived Precursor; SMC = Smooth 
Muscle Cells; Sox9 = Sry-related high mobility group box; SGP = Sweat Gland Progenitor cells 
1.5 Administration routes of stem cells and evaluation of wound healing 
Various cell-based therapies have been clinically administered using local delivery or 
systemic infusion. Local application consists of topical product delivery (in the form of a gel, 
liquid, patch, etc.), intradermal/injecting the wound edges or intramuscular injection. For 
clinical transplantation, cells can be derived from the same animal (autologous), from an 
animal within the same species (allogenic) or from an animal of a different species 
(xenogenic) (Gade et al., 2012). Systemic injections on the other hand, involve injecting into 
the blood of the local vein or artery, or into the general circulation. More details concerning 
the different routes of administration of cell-based therapies to different wound types in 
different animal models are shown in Table 2.2 of Chapter 2 in the current thesis. 
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The process of wound healing is dynamic and takes place over months , during which 
angiogenesis, continued wound contraction and connective tissue remodeling occur (Junker et 
al., 2014). Evaluation of the skin wound healing following transplantation of cells can be 
performed by using different scoring systems as developed by different researchers (Abramov 
et al., 2007; Babaeijandaghi et al., 2010; Bigbie et al., 1991). This evaluation includes 
macroscopic wound evaluation and histologic evaluation. The macroscopic wound evaluation 
can include the status of swelling, the time to detection and completeness of epithelium/skin 
resurfacing, the wound size/contraction, the wound scores of granulation tissue formation, the 
vascularity and dermal thickness (Table 1.4). The histologic evaluation includes the status of 
inflammatory cell infiltration, the vascular proliferation, fibroplasia, the presence and depth of 
scar tissue, the epithelialization rate and the absence of adnexa including hair follicles, 
apocrine glands and smooth muscle (Table 1.4). In the present thesis, some modifications 
were made for the evaluation of different wound healing parameters in rabbits and horses. 
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Table 1.4 Scoring system for macroscopic and histologic evaluation of wound healing. Adopted from 
Bigbie et al. (1991), Abramov et al. (2007) and Babaeijandaghi et al. (2010) in wound models of horse, 
rabbit and mouse, respectively. 
Parameter Score 
0 1 2 3 
Macroscopic evaluation 
Quantity of exudate Exudate is evident and 
slight pressing results in 
excessive exudation 
Moist wound and 
slight exudate on 
pressing 
Wound is most 
but no oozing on 
pressing 
Apparently 
dry wound 
Type of exudate Purulent Fibrinious Slight dry  cast - 
Peripheral swelling Marked Moderate No/slight 
swelling 
- 
Granulation tissue Elevated above skin 
edge 
Proliferated to the 
level of skin 
Depressed 
below skin edge 
Absent 
Color of granulation tissue Pale  Pale red Pink - 
Histologic evaluation 
EPIDERMIS 
Dermal-epidermal 
separation 
Diffuse Focal None - 
Crust formation Present Absent - - 
Re-epithelialization None Partial Complete but 
immature or thin 
Complete and 
mature 
Acanthosis Severe (> 15 layers) or 
moderate irregular 
Moderate regular 
(10-15 layers 
Mild (5-10 
layers) 
None 
DERMIS 
Edema Severe Moderate Mild None 
Acute inflammation Abundant moderate Scant None 
Depth of inflammation Deep myonecrosis Superficial 
myonecrosis 
Lower dermis Upper dermis 
Chronic inflammation Abundant moderate Scant None 
Granulation tissue amount Abundant moderate Scant None 
Granulation tissue 
fibroblast maturation 
None Mild Moderate Full 
Collagen amount None Scant Moderate Abundant 
Neovascularization 
(Number of capillaries per 
200x field) 
None Up to five vessels  6-10 vessels  More than 10 
vessels 
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Abstract 
Mammal skin plays a key role in several life-preserving processes such as hydration, 
protection against chemicals and pathogens, initialization of vitamin D synthesis, excretion 
and heat regulation. Severe damage of the skin may therefore be life-threatening. Skin wound 
healing is a complex, yet well-orchestrated process that involves the interaction of various cell 
types, growth factors and cytokines aiming at closure of the skin and preferably resulting in 
tissue repair. Despite a variety of therapeutic modalities proposed to accelerate the healing of 
acute and/or chronic wounds over the past decades, the development of novel approaches for 
wound treatment remains a clinical challenge. The time-consuming conservative wound 
management is often limited to wound maintenance rather than restitution of the tissue 
integrity (the so-called “restitutio ad integrum”). Therefore, more efficacious wound therapies 
are urgently required to reduce health care burden, provide patients with long-term relief and 
ultimately scar less wound healing. Recent advances in regenerative medicine provide 
encouraging results both from in vitro and in vivo studies of skin wound regenerative 
therapies in animals as a model for humans. Nevertheless, more protracted studies will have 
to determine whether regeneration can be achieved rather than reparation. For all the 
aforementioned reasons, this article reviews the emerging field of regenerative skin wound 
healing in mammals with particular emphasis on growth factor- and stem cell-based 
treatments.  
Key words: Regenerative veterinary medicine; Skin wound healing 
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2.1 Introduction 
The skin is the largest organ of vertebrates (+ 10% of body mass) and is critical for defense as 
well as survival. Therefore, each injury may induce loss of the skins’ integrity with functional 
imbalance accompanied by disability or even death  (Theoret, 2009). Skin injury initiates 
mechanisms to limit damage and to subsequently induce repair. Both phenomena cover a 
complex cascade of temporal and spatial events that are required for tissue homeostasis. 
These events include induction and resolution of inflammation on the one hand, and 
remodeling and formation of tissue on the other hand. This way complete reconstruction of 
the wounded area should be achieved (Clark, 1996a). Regeneration is expected to specifically 
substitute the lost tissue, however, repair of adult skin lesions is often achieved by an 
unspecific form of wound healing by fibrosis and scar formation (Reinke and Sorg, 2012). 
Repaired skin in adults usually heals as a scar which is weaker than the original skin because 
it contains disorganized extracellular matrix (ECM) (Soo et al., 2003; Gurtner et al., 2008). 
This repair process differs from regeneration, as the latter tissue is almost indistinguishable 
from the original intact tissue (Gurtner et al., 2008, Dudas et al., 2008). In this context it 
should be mentioned that the mammalian fetal skin regenerates perfectly in contrast to adult 
skin. The underlying regulation of this switch in repair mechanism potential during 
mammalian development has not yet been completely resolved (Kawasumi et al., 2013)  
Full-thickness skin wounds may result in extensive damage to the different skin structures. 
This damage compromises the homeostatic mechanisms involved in spontaneous healing and 
therefore clinical intervention is often needed. The primary aim of clinical skin wound 
treatment is to promote rapid wound repair with functional and aesthetical satisfactory scar 
tissue formation (Singer and Clark, 1999).  
Today, skin wound therapies are categorized as either conservative/conventional or 
regenerative. Conservative skin wound management includes debridement of necrotized 
tissue, restoration of adequate tissue perfusion, limitation of pressure at the wound site, use of 
several types of wound dressings, control of infection and of any underlying health problem 
that could alter the healing process (Singer and Clark, 1999). Wounds healed by conventional 
therapy are characterized by scar formation with cosmetic and possible functional 
impairment. For example, skin scars are less resistant to ultraviolet radiation, and nor sweat 
glands nor  hair follicles grow back within scar tissues (Kraft and Lynde, 2012). Regenerative 
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skin wound therapy is a novel and rapidly expanding field of biomedical research that focuses 
on the development of innovative therapies aiming at restoring the damaged cells and 
diseased skin tissue without scar formation. Since quality care is a critical requirement for 
wound healing (Edlich et al., 1983), regenerative strategies should not be considered as a 
substitute for certain indispensable conservative treatments. Selecting an appropriate 
therapeutic strategy depends on the condition of the wound and is crucial for its successful 
wound healing in order to minimize the risk of complications, enhance the speed of this 
process and minimize scar tissue formation. Therefore, in the present review information has 
been gathered on preclinical and clinical studies regarding regenerative therapies for mammal 
skin wound management with particular emphasis on growth factor- and stem cell-based 
therapies. 
Literature search 
The standard research databases like PubMed and Web of Science between January 1955 and 
April 2014 and the Google Scholar search engine were consulted for collection of full papers 
and abstracts.  
2.2 Mammalian skin and wound healing 
2.2.1 Adult mammalian skin anatomy and physiology 
Mammalian skin is the largest organ of the adult body and consists of several layers: (i) the 
superficial epidermis, (ii) the intermediate dermis (Stashak and Theoret, 2007; Theoret, 2009) 
and (iii) the hypodermis, and is supported by a matrix of loose connective tissue (Stashak and 
Theoret, 2007) (Fig. 2.1).  
Noteworthy, there are significant differences in the anatomy and physiology of each skin 
layer between species (Wong et al., 2011). Consequently, these differences result in a 
difference in wound healing (Sllivan et al., 2001). For instance, in animals with a more 
“loose” skin such as rats and mice, healing occurs very rapidly as a result of wound 
contraction due to the presence of the panniculus carnosus muscle in their subcutaneous 
tissues. On the other hand, in “tight-skinned” species such as human and porcine, which lack 
this muscle, wound contraction is not rapid thus heal mainly through re-epithelialization 
(Wilmink et al., 2001; Theoret and Wilmink, 2013). Striking differences in wound healing can 
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even be exhibited within the same species, which have been observed at gross, cellular and 
molecular level. For example more rapid onset and resolution of wound inflammation leading 
to more rapid wound contraction and epithelialization was detected in ponies in comparison to 
horses (Wilmink et al., 2001; Wilmink and van Weeren, 2005). This difference in wound 
healing was attributed to differences in local inflammatory responses, where leukocytes in 
ponies were found to produce more inflammatory mediators. The inflammatory mediators 
resulted in better local defense, faster cellular debridement, faster transition to the repair phase 
and more wound contraction (Wilmink and van Weeren, 2005).   
Mammalian epidermis, which is a terminally differentiated and stratified squamous 
epithelium consists of 4 to 5 sublayers (Fig.2.1). The basal cell layer is the innermost cell 
layer of the epidermis and is a single layer consisting of basal cells including an epidermal 
stem cell subpopulation. This stem cell population can give rise to distinguished types of cell 
layers, such as prickle, granular and horny cell layers, when these cells move from the basal 
layer outwards and progressively differentiate. The prickle cell layer or stratum spinosum is 
composed of many layers interconnected by prickle-like structures, which compose of 
desmosomes with keratin tonofibrils that form a supportive mesh in the cytoplasm of the cells. 
Desmosomes in turn are composed of the structural molecules cadherins, desmogleins and 
desmocollins (Hopwood et al., 1978). The main component of the granular layer is released as 
corneum lipid into the intercellular space of the horny cell layer. The latter is the outer most 
layer where keratinocytes enucleate and become corneocytes as a terminal differentiation 
phase. Additionally, there are several more specialized cells in the epidermis, including 
melanocytes, Langerhans cells, dendritic cells and Merkel cells (Theoret, 2009, Kawasumi et 
al., 2013). Similar to a wall the cornified layer consists of hard building blocks (i.e. the 
individual corneocytes) stuck together with space filling mortar (i.e. the inter-corneocytal 
lipids). The barrier function of normal epidermis depends on the quality of its bricks and 
mortar (Nemes and Steinert, 1999; Zhang and Michniak-Kohn 2012). Epidermis and dermis 
are physically separated by the basement membrane or basal lamina, a highly specialized 
ECM structure, which provides a stabilizing and dynamic interface (Breitkeutz et al., 2009). 
Besides providing structural adhesion of the epidermis to the dermis, the basement membrane 
has a gate-keeping function strictly controlling diffusion of cells (Iozzo, 2005) and bioactive 
molecules in both directions (Iozzo, 2005; Breitkeutz et al., 2013). On the other hand, it binds 
a variety of cytokines and growth factors, hence, acts as a reservoir for a controlled release 
during physiologic remodeling and repair processes after injury (Iozzo, 2005).  
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The dermis is situated directly beneath the epidermis and is composed of the papillary and 
reticular layers (Fig.2.1). The upper papillary layer edges into the epidermis across the 
basement membrane and nourishes it. This layer consists of (i) cellular components, including 
fibroblasts, mast cells, macrophages and dermal dendrocytes and (ii) ECM components 
namely stromal components (e.g. collagen and elastic fibers) and matrix component 
(glycoproteins and proteoglycans, etc.). The lower reticular layer is characterized by an ECM-
containing network of coarse collagen, elastic fibers and fibroblasts (Kawasumi et al., 2013). 
The dermis is vascularized, innervated and invaded by epidermal appendages. The 
hypodermis is the layer located beneath the dermis and contains a considerable amount of 
adipose tissue (Fig. 2.1). It is well vascularized and contributes both to the mechanical and 
thermoregulatory properties of the skin (Theoret, 2009). The epidermis of the skin and its 
appendages (e.g. hair follicles, sebaceous glands, sweat glands and nails) are derived 
embryologically from the prospective epidermal ectoderm and neural crest cells, which are 
also ectodermal in origin. Nevertheless, the skin appendages have their roots in the dermis or 
even in the hypodermis, both of which are derived from embryonic mesoderm (Kawasumi et 
al., 2013). 
Every disruption of the normal anatomic structure of a tissue with consecutive loss of its 
function can be described as a wound (Lazarus et al., 1994). Wound healing is a critical 
survival factor for mammals (Lau et al., 2009). Skin wound healing relies on a complex 
dynamic process which involves interaction of multiple cell types, growth factors, cytokines 
and chemokines (Singer and Clark, 1999; Maxson et al., 2012). Dysregulation of this process 
leads to problems such as chronic, non-healing wounds or excessive healing in the form of 
keloids and hypertrophic scars (Ko et al., 2011). However, there are reports which indicate 
that even when this balance is disrupted, the deficiency of a cell type or the absence of a 
mediator can be compensated (Eming et al., 2007a). Adult skin wounds heal by repair and/or 
regeneration. There is a clear difference between both types of healing. Repair refers to the 
physiologic adaptation of an organ after injury in an effort to re-establish continuity without 
aiming at the exact replacement of lost/damaged tissue. Regeneration on the other hand, refers 
to the replacement of lost/damaged tissue with an ‘exact’ copy, so morphology as well as 
functionality of the tissue are completely restored. It should be remarked that the mammalian 
skin does not regenerate spontaneously, but heals with scars (a typical feature of the repair 
process). 
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Figure 2.1 Schematic representation of mammalian skin structure and its cell populations. The skin 
contains three layers: epidermis, dermis and hypodermis. The epidermis is a stratified epithelium 
composed of 4 to 5 layers: stratum corneum (a), stratum lucidum (b), stratum granulosum (c), stratum 
spinosum (d) and stratum basale (e). Other structures in the skin include the hair (f), sweat glands (g), 
sebaceous glands (h), hair follicles (i), nerves (j) and blood vessels (k). 
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Wound healing occurs in three overlapping time windows: inflammation, repair and 
remodeling (Singer and Clark 1999; Theoret, 2004; Knox et al., 2006; Maxson et al., 2012; 
Warner and Grose, 2003). When there is injury and damage to cutaneous blood vessels, 
platelets will get exposed to ECM proteins, and immediate coagulation resulting in fibrin clot 
formation will occur (Clark, 1996b). Some authors consider this hemostasis as one of the time 
windows of wound healing, thus dividing the healing process into 4 phases (Li et al., 2007) 
(Fig. 2.2). This phenomenon is followed by an inflammatory phase, characterized by 
infiltration of neutrophils and macrophages (Fig. 2.2). Contaminants and dead tissue liberate 
mediators such as cytokines and growth factors from phagocytes sustaining this immune cell 
influx (Theoret, 2004; Guo and Dipietro, 2010). The proliferative phase of repair becomes 
apparent as inflammation signs subside. It is characterized by formation of granulation tissue 
and epithelialization (Theoret, 2009; Guo and Dipietro, 2010). In the reparative dermis, 
fibroblasts and endothelial cells proliferate and are the most prominent cell types present, 
supporting capillary growth, collagen formation and formation of granulation tissue (Guo and 
Dipietro, 2010). The last phase of repair is the remodeling which involves reduction in wound 
size by a process known as wound contraction as well as reorganization and maturation of the 
ECM (Theoret, 2009; Guo and Dipietro, 2010). Wound contraction is achieved by 
myofibroblasts, which differentiate, invade and repair injured tissue by secreting and 
organizing the ECM and by developing contractile forces. Different precursor cells have the 
ability to form myofibroblasts, but the major contribution is from local recruitment of 
connective tissue fibroblasts. However, when local fibroblasts are not able to satisfy the 
requirement for these cells during repair, myofibroblasts can also be derived from non-
fibroblast sources such as local mesenchymal stem cells (MSC), bone marrow-derived MSC 
and cells derived from an epithelial-to-mesenchymal transition process (Henz et al., 2007; 
Micallef et al., 2012). 
2.2.2 Mammalian embryo and amphibians as a model for scarless skin wound 
healing  
Adults of humans and other mammals have a limited capacity to regenerate and restore their 
tissues and organs. This can be achieved either through the activation of somatic stem cells 
located in a niche or by inducing differentiated cells to proliferate (Jopling et al., 2011). 
Accordingly, the wound healing process in adult mammals is imperfect and less restorative 
than in the juvenile or in the embryo (Kawasumi et al., 2013). 
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Figure 2.2 Schematic representation of the basic steps of cutaneous wound healing. Following injury 
wound healing proceeds in four interrelated dynamic phases which overlap in time. 
In contrast, skin wounds in early mammalian embryos can heal perfectly without scar tissue 
formation and with complete restitution of normal skin architecture (Whitby et al., 1991). 
There are many differences between the healing process of embryonic and adult wounds. 
Although this is mainly attributed to the tissue development itself, fetal scarless wound 
healing mechanisms are intrinsically different. In fact, fetal wounds heal with a markedly 
diminished inflammatory response (Wulff et al., 2012), a faster production of ECM molecules 
such as fibronectin and tenascin, a high hyaluronic acid content and altered profiles of growth 
factor expression. In an embryonic wound site, the levels of transforming growth factor 
(TFG)-β1 and TGF-β2 are lower while TGF-β3 is higher than in an adult wound site (Cowin 
et al., 2001). A further key difference between fetal and adult wound repair relates to the 
mechanism of wound contraction and epithelialization. Unlike adult wound closure, fetal 
wounds close through an actin cable which acts like a purse string (Martin and Lewis, 1992). 
Adult wound closures involve active movement of connective tissue and epidermis in order to 
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bring two wounded edges in close proximity to allow the epidermis to migrate and cover the 
exposed connective tissue (Nodder and Martin, 1997). 
In contrast, some other vertebrate species like amphibians have extensive regenerative 
capacities that in certain cases stretch as far as replacing a complete limb (Dent, 1962; 
Odelberg, 2004). However, many aspects of amphibian skin wound healing remain unclear, 
while some studies have suggested that the initial phase of wound healing shares mechanisms 
with that in mammals (Kawasumi et al., 2013). Despite the histological similarities between 
amphibian and mammalian skin and the common process of their early healing, their 
subsequent regenerative ability differs remarkably. Unlike  mammalian wound healing, 
amphibian wound healing results in no scar formation indicating that skin wound healing is 
perfect and ends up with restoration of tissue architecture and function (Seifert et al., 2012). 
Complete regeneration of the limb in some amphibians occurs as a result of dedifferentiation 
and proliferation of cells adjacent to the wound and re-patterning by molecular mechanisms 
similar to those for developmental limb formation (Muneoka and Sassoon, 1992). 
Regeneration of amphibian skin shares cellular and molecular features of the early events of 
limb regeneration which depends on expression of the Prx1 gene. Thus, it has been recently 
proposed that Prx1 itself, through activation of tenascin-C, may contribute to scarless skin 
wound healing (Seifert et al., 2012). Hence, comparing the wound healing capacities of 
different species might lead to novel insights in the field of skin regeneration. 
2.2.3 Role of stem cells in wound healing  
Most epithelia self-renew through a mechanism called tissue homeostasis, in which the 
number of cell divisions creates a balance with the number of lost cells (Blanpain and Smona, 
2013). Tissue homeostasis is guaranteed by stem cells (SC) present within specialized 
microenvironments, the so-called niches. Each niche is tailored to accommodate the 
regeneration needs of its tissue (Morrison and Spradling, 2008). The skin epidermis and its 
appendages harbor spatially distinct SC niches (Blanpain and Fuchs, 2014) (Fig.1). For 
instance, the hair follicle fated bulge stem cells only generate a transient amplifying progeny 
toward wound epidermis as a part of an “emergency” repair strategy (Ito et al., 2005). In 
marked contrast, a later experiment by Levy et al (2007) reported that there are follicular 
progenitors distinct from bulge SC which are able to permanently convert into interfollicular 
epidermis SC in response to wounding in mice.  
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Adult SC are considered to replace lost cells and are therefore identified as central players in 
tissue regeneration. They deliver daughter cells to renew the lesioned tissues by 
differentiation and/or by releasing paracrine factors to attract progenitor cells (Chen et al., 
2008). When a SC compartment is being inflicted, other SC can be recruited to enhance lesion 
repair. However, the fate and differentiation potential of epithelial cells can also adapt during 
wound regeneration. In some cases, unipotent progenitors acquire multipotency, whereas in 
other cases normally committed cells revert to a SC-like state. The cellular plasticity observed 
in adult epithelial tissues have not been associated with “trans”differentiation into completely 
unrelated fates, but rather with contribution to the repair of the tissue from which the cells 
originated. In this regard, the plasticity seems to arise through a process of “de”- and/or “re”-
differentiation (Blanpain and Fuchs, 2014). 
2.3 General skin wound management 
Mammalian skin has a large potential for efficient and functional repair, because of the 
constant natural cellular turn-over, indicating a high intrinsic regenerative capacity. The 
purpose of skin wound management is to restore a skin defect and regain, at least partially the 
lost integrity, tensile strength and barrier function (Mustoe et al, 2002). Wound healing in 
mammalian patients is affected by several factors including blood supply, wound size, tension 
and mobility of wound margins, susceptibility to infection, and the type and condition of the 
underlying tissue (Knox et al., 2006). The ultimate goal of wound management is to decrease 
the risk of opportunistic infection and to induce rapid development of granulation tissue and 
epithelialization with a minimum of scar tissue (Woods et al., 1997).  
Improperly managed wounds can be life threatening, functionally disabling and cosmetically 
devastating. There are a variety of modes of wound healing/repair, which include healing by 
primary, secondary and tertiary intention (Bae et al., 2012). Primary intention involves re-
epithelialization, in which the skin’s outer layer closes over the wound. Wounds that heal by 
primary intention are most commonly superficial wounds that either involve only the 
epidermis (such as superficial burn), or show no loss of dermal tissues (such as sutured large 
surgical incisions). Second intention wounds heal by granulation formation, contraction and 
epithelialization. Wound care must be performed to prevent infection and to encourage 
granulation tissue formation (Han et al., 2012a). Tertiary intention wounds are initially left 
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open and closed after several days by approximation or by the use of tissue grafts. This type 
of healing may be desired in cases of contaminated wounds (You and Han, 2014). 
The earliest written records of wound management date to Sumerian carvings more than 
4,000 years ago. During history, a cornerstone of therapy has always been topical treatment 
(Murray et al., 2008). Currently conventional methods of local wound management include 
mechanical cleansing, disinfection with antiseptic solutions, wound debridement, wound 
closure, topical antibiotic treatment, dressing and use of negative pressure devices 
(Komarcevic, 2000; Jeffcoate and Harding, 2003; Chung et al., 2009). In general, 
conventional wound treatment results in wound healing by ‘repair’ rather than by 
regeneration. Moreover, each conventional treatment method has its advantages and 
limitations.  
For readers interested in the details of conventional therapies, which are not included here 
because they do not fall within the scope of this review, we would like to refer to previous 
excellent and comprehensive review papers (Komarcevic, 2000; O'Meara et al., 2000; Leaper 
and Durani, 2008; Jull et al., 2013; O'Meara et al., 2013). 
The development of advanced wound healing technologies has triggered the use of growth 
factors and cells to overcome the limitations of conventional wound treatments. 
2.4 Regenerative therapies for skin wound management 
Regenerative medicine is defined as a new and rapidly expanding field of biomedical research 
that focuses on the development of innovative therapies allowing the body to replace, restore 
and regenerate damaged or diseased cells, tissues and organs (Dieckmann et al., 2010). This 
can potentially be accomplished using the process of dedifferentiation (which involves 
terminally differentiated cells reverting back to a less differentiated stage within their own 
lineage), transdifferentiation (a processes which takes dedifferentiation a step further and cells 
differentiate into a cell type of another lineage) and reprogramming (which aims to induce 
differentiated cells into a pluripotent state) (Jopling et al., 2011). Regenerative therapy 
combines several technological approaches including the use of soluble molecules, gene 
therapy, stem cell transplantation, tissue engineering and the reprogramming of cell and tissue 
types (Greenwood et al., 2006). In this review we are only surveying the existing cell-based 
and growth factor-based in vitro and in vivo studies and therapies that are at preclinical and 
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clinical level. For readers interested on the remaining regenerative therapies, which are not 
included in this review, we would like to refer to previous review papers (Branski et al., 2007; 
Branski et al., 2009; Dieckmann et al., 2010; Eming et al., 2007b; Gauglitz and, Jeschke , 
2011). 
2.4.1 Growth factor-based therapies 
Growth factors (GF’s) are signaling proteins (tissue hormones) that regulate the metabolism 
of other cells (Fortier and Smith, 2008). GF's are released at the wound site and are required 
for communication between a variety of cells like fibroblasts, myofibroblast, smooth muscle 
cells, endothelial cells, keratinocytes and immune cells. Many experimental and clinical 
studies have demonstrated a variety of effects of exogenous growth factors on the healing 
process (Steel and Group, 1995; Warner and Grose, 2003). Accelerated healing of the wound 
is based on wound characteristics and the function of GF's (Fu et al., 2000). Different studies 
in human patients have confirmed that GF's such as platelet-derived growth factor (PDGF) 
play a role in shortening wound healing time from 1 to 4 days in acute wounds and even 
provide complete healing in chronic wounds (Robson et al., 1992a; Robson et al. 1992b; 
Mandracchia et al., 2001).  
The main GF's involved in the wound healing process includes PDGF, epidermal growth 
factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF1, IGF2), vascular 
endothelial growth factor (VEGF), TGF-β (Koveker 2000; Grazul-Blska et al., 2003; 
Jeffcoate et al., 2004; Falanga 2005) and keratinocyte growth factor (KGF) (Grazul-Blska et 
al., 2003). To date only PDGF has been approved by the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) for clinical application in patients 
(Papanas and Maltezos, 2007; Murphy and Evans, 2012). An overview of the most cited GF-
based therapies for skin wound management in animals models are summarized in Table 2.1. 
Platelet-Rich plasma (PRP) 
PRP (or autologous platelet concentration) is blood plasma that has been enriched with 
platelets through specific centrifugation. The platelet count is often two to four times higher 
than normal (Fortier and Smith, 2008). Platelets are cytoplasmic fragments derived from bone 
marrow megakaryocytes and they contain (and release through degranulation) several 
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different types of growth factors and cytokines that might stimulate wound healing (Sandoval 
et al., 2013).  
Table 2.1 Overview of most cited growth factor-based therapies for skin wound management in animals 
and their functional effects. 
Reference Therapy In vivo 
model 
Type of 
wound 
Functional in vivo effects 
Carter et al., 
2003; 
DeRossi et 
al., 2009 
Autologous 
PRP-gel 
Horse Full thickness Rapid epithelialization and collagen organization 
Monteiro et 
al., 2009 
Autologous 
PRP 
Horse Full thickness No quality improvement or healing enhancement 
Iacopettietal., 
2011 
Autologous 
PRP-gel 
Horse Torn wound No exuberant granulation and minimum scarring 
Kim et al., 
2009 
Autologous 
PRP gel 
Dog Chronic Reduced swelling and hair regrowth at wound margin 
Man et al., 
2001 
Autologous 
PRP-gel 
Human Surgical flap Improved healing with short recovery time 
Galiano et 
al., 2007 
Autologous 
VEGF 
Diabetic 
mice 
Full thickness Enhanced re-epithelialization, matrix deposition and 
cellular proliferation 
Tsuboi and 
Rifkin, 1990 
Rec hFGF-2 Diabetic 
mice 
Full thickness Improved re-epithelialzation, increase of 
macrophages, fibroblasts, neovascularization and 
granulation tissue. 
Shi et al., 
2013 
Rec hbFGF Rabbit /rat Full thickness Stimulate fibroblast growth, reduce scar formation 
and regulate inflammatory response 
Brown et al., 
1993; Brown 
et al., 1994 
Rec hPDGF 
and Rec 
hTGF-alpha 
Normal 
and 
diabetic 
mice 
Full thickness Enhanced collagen deposition, granulation tissue 
formation and maturation. 
Kim et al., 
2010 
Rec hEGF Mice Full thickness Reduced scaring, suppressing inflammation, 
decreasing TGF-β1 and mediating collagen formation 
Yu et al., 
2007 
Rec hIGF Diabetic 
mice 
Full thickness Increased hypoxia-inducible factor 1-α protein 
synthesis and function in diabetic wounds 
Tsuboi et al., 
1995 
hIGF-I and 
IGF-1 binding 
protein 
Diabetic 
mice 
Normal 
rabbit 
Full thickness Increased granulation tissue formation and capillary 
number 
Yoshida et 
al. 2003 
Rabbit HGF Mice Full thickness Enhanced re-epithelialization, neovascularization and 
granulation tissue formation 
Li et al., 
2013 
hHGF Diabetic 
rat 
Full thickness Enhanced re-epithelialization, neovascularization and 
granulation tissue formation 
 
bFGF = Basic Fibroblast Growth factor; EGF = Epidermal Growth Factor; HGF = Hepatocyte Growth Factor (HGF), h 
= Human; Rec = Recombinant; IGF = Insulin-like Growth Factor; PDGF = Platelet Derived Growth Factor; PRP = 
Platelet Rich Plasma; TGF-α = transforming growth factor-alpha; VEGF = Vascular endothelial growth factor. 
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They activate the inflammatory process by releasing cytokines (i.e. Interleukin: IL-1α, IL-1β, 
IL-6 and tumor necrosis factor: TNF-β), stimulate collagen synthesis (FGF-2, IGF-1, TGF-β), 
activate transformation of fibroblasts to myofibroblasts (TGF-β), start angiogenesis (EGF-2. 
VEGF-A, TGF-β) and support the re-epitheliaization process (EGF, FGF-2, IGF-1, TGF-α) 
(Bennett and Schultz, 1993;Warner and Grose, 2003; Li et al., 2007). The main difficulty in 
assessing the therapeutic effects of PRP is to define which growth factor(s) were at the origin 
of the observed effects since PRP delivers a mixture of growth factors associated with natural 
scar healing (Fortier and Smith, 2008).  
There are a number of in vivo studies in dogs and horses regarding the use of PRP for 
cutaneous wound therapy. Carter et al. (2003) and DeRossi et al. (2009) reported PRP gel 
promoting epithelial differentiation and regeneration during equine wound healing. In the 
same species, a case study reported by Iacopetti et al. (2011) indicated that topical treatment 
with autologous PRP enhanced healing of clinical large torn wound of dorsal elbow region. In 
contrast to the above findings, evaluation of the effect of PRP on wounds of the distal aspect 
of forelimb in horses indicated excessive granulation tissue development and a significantly 
slower wound healing (Monteiro et al., 2009). Recently, Broeckx et al. (2014a) also reported 
on the inferior regenerative effect of PRP treatment in comparison to skin-derived SC for the 
treatment of experimental full thickness skin wounds induced dorsally on the musculus 
gluteus medius region of horses, but this experiment lacks placebo control. On the other hand, 
Kim et al. (2009) studied the curative effect of PRP on a large cutaneous lesion on dorsal tail 
of  a dog and found that the autologous PRP was beneficial in the management of large skin 
defects or in delayed wound healing.  
In humans, PRP has been applied as a medical tool for several diseases and injuries, such as 
cutaneous wounds. PRP received special attention because of its use in treating sport injuries 
in professional athletes (Hall et al., 2009). A study by Man et al. (2001) demonstrated 
quantitative improvements of human skin wound healing after topically treating cutaneous 
flaps with autologous PRP. Other studies on human patients with chronic wounds of various 
etiologies treated with PRP gel also showed some degree of improvement, reflected by 
reduction of wound area, volume and wound closure (Mazzucco et al., 2004; Frykberg et al., 
2010).  
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Platelet-derived growth factor (PDGF) 
PDGF is one of the first factors produced in response to injury and induces cellular responses 
throughout all phases of the wound healing process. PDGF exists in three isoforms: PDGF-
AA, PDGF-BB, and PDGF-AB (Kiritsy et al., 1993). It is mainly secreted from the α-granules 
of the platelet (Pananas and Maltezos, 2007), and is also produced by other cells involved in 
early wound healing, i.e. macrophages, keratinocytes, fibroblasts and endothelial cells 
(Warner and Grose, 2003; Pananas and Maltezos, 2007). The level of PDGF and PDGF 
receptor expression have been shown to be low in diabetic and aged mice that have a delayed 
response to injury (Werner and Grose, 2003). Similarly PDGF levels are depressed within 
non-healing human ulcers (Pierce et al, 1995) probably because of underproduction and/or 
excessive protease mediated degradation. Therefore, wound treatment using exogenous PDGF 
has been investigated and was found to be beneficial for those patients with chronic wounds 
(Brown et al., 1993; Leahy and Lawrence, 2007). As a result of FDA approval, PDGF-BB has 
been extensively used for the treatment of diabetic ulcers (Leahy and Lawrence, 2007; 
Demidova-Rice et al., 2012). Despite this approval, there have been reports showing a limited 
clinical success. This might be due to low expression of PDGF receptor by the cells residing 
within chronic wounds (Flanga, 2005), or could be caused by rapid degradation of the GF by 
proteolytic enzymes within the chronic wound bed (Tomic-Canic et al, 2008). Moreover, the 
complexity and persistence of the chronic wound bed suggests that delivery of a single entity 
may not be sufficient as a corrective therapeutic measure. Therefore, sustained GF delivery 
systems with a combined and/or patient specific approach to chronic wound treatment might 
be required to enable optimal healing and wound closure (Hinchliffe et al., 2008, Beenken and 
Mohammadi, 2009; Demidova-Rice et al., 2012). Recently, a combination of AMD3100 
(which mobilizes marrow-derived progenitor cell) and PDGF-BB therapy on experimental 
full thickness skin wound on the dorsum of mice, has synergistically shown to improve 
progenitor mobilization and trafficking, resulting in significantly improved diabetic wound 
closure and neovascularization (Allen et al., 2014).  
Fibroblast growth factor (FGF) 
FGF-1, FGF-2, FGF-7, FGF-10 and FGF-22 are all being expressed upon dermal injury 
(Barrientos et al., 2008). FGF-1 and -2, also known as acidic and basic FGF, respectively, are 
produced by inflammatory cells, vascular endothelial cells, fibroblasts and keratinocytes and 
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play roles in re-epithelialization, angiogenesis and granulation tissue formation (Warner and 
Grose, 2003; Xie et al., 2008). In addition to their direct role in wound healing, FGF-7 and 
FGF-10 also stimulate the production of TGF-α by dermal keratinocytes, indirectly 
contributing to epithelialization (Niu et al., 2007). 
Studies in animal models showed that there is abnormal expression of FGF-1, FGF-2 and 
FGF-7 in wounds of diabetic aged animals (Komi-Kuramochi et al., 2005). Administration of 
FGFs successfully improved wound healing in these animals (Bing et al., 2007). In this 
regard, Tsuboi and Rifkin (1990) reported that bFGF (FGF-2) accelerated wound healing of 
full thickness skin wounds on the dorsum in diabetic mouse model. Another study by Shi et 
al. (2013) reported that bFGF regulated ECM synthesis and degradation via interference in 
collagen distribution, α-smooth muscle actin (α-SMA) and TGF-1 expression. Moreover, 
bFGF application resulted in reduced scarring and promoted wound healing by inhibiting the 
TGF-1/SMAD-dependent pathway. Therefore, it has been suggested that bFGF possesses 
favorable therapeutic effects for hypertrophic scars in vitro and in vivo (Shi et al., 2013). 
Based on the aforementioned promising animal models, clinical trials in humans were 
performed where FGF-1 and -2 were used for treating chronic (burn) wounds and resulted in a 
modest improvement in the healing rates in some studies (Robson et al., 2001; Barrientos et 
al., 2008). In another study by Ma et al. (2007), human recombinant FGF-1 mostly for 
treatment of deep partial-thickness burn or skin graft donor site the treatment resulted in fast 
healing. Future studies may provide better insights on the beneficial effects of different types 
of FGFs in different patient groups. 
Transforming growth factor-β (TGF-β) 
The TGF-β family includes TGF-β1-3, bone morphogenic proteins (BMP) and activins. TGF-
β1, TGF-β2 and TGF-β3 are the main forms found in mammals, but TGF-β1 predominates in 
cutaneous wound healing. They are produced by macrophages, fibroblasts, keratinocytes and 
platelets (Barrientos et al., 2008). TGF-β is a multifunctional growth factor that attracts new 
fibroblasts and macrophages to the wound site, stimulates fibroblast proliferation and collagen 
synthesis, decreases extracellular matrix degradation (Cromack et al, 1991) and modulates the 
immune system (Finnson et al., 2012).  
TGF-β1, -β2, and -β3 have overlapping but distinct functions during wound healing. Both 
TGF-β1 and -β2 are prominent inducers of fibroblast-myofibroblast differentiation, ECM 
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deposition, contraction, and scar formation, whereas TGF-β3 has been shown to inhibit 
scarring (Barrientos et al., 2008). Much of the current knowledge on TGF-β action in wound 
healing has been obtained from animal studies using incisional and/or excisional wounding 
models (Finnson et al., 2012). Preclinical studies indicated that intradermal injection of 
avotermin (TGF-β3) to both margins of adult rat cutaneous wounds resulted in a significant 
reduction in scarring and a considerably improved dermal architecture (Saha et al., 1994; Saha 
et al., 1995). Moreover, phase II clinical trials showed that intradermal injections of avotermin 
in scar revision surgery (So et al., 2011) and bilateral leg wounds (McCollum et al., 2011) 
were well tolerated and resulted in significantly improved scar appearance compared to 
placebo. In addition, other phase II clinical trials demonstrated significant improvement in 
scar appearance with avotermin treatment as well (Occleston et al., 2011).  
Vascular endothelial growth factor (VEGF) 
During wound healing, VEGF is secreted by platelets, macrophages, fibroblasts, and 
keratinocytes where it acts in a paracrine way on endothelial cells, inducing and/or supporting 
wound angiogenesis (Warner and Grose, 2003). Topical VEGF application has shown to 
accelerate diabetic wound repair through increased epithelialization, angiogenesis, granulation 
tissue deposition and minimum scar formation in a mouse model (Galiano et al., 2004). In 
another study using mice, treatment with the angiogenesis inhibitor endostatin caused a delay 
in wound healing, and  this effect was nearly completely reversed after application of topical 
VEGF (Delgado et al., 2005), confirming the strong angiogenic capacity of this growth factor. 
However, recombinant VEGF requires frequent repeated topical applications for sustained 
drug level in the local tissue, which may be a reason why it has not been successful in clinical 
trials for diabetic foot ulcers (Brem et al., 2009). Recently, Tan et al. (2014), have used 
collagen scaffolds with VEGF in a diabetic rat wound model and found that the treatment 
resulted in a higher wound healing rate, better vascularization and higher level of VEGF in 
the granulation tissue. A limited number of human clinical trials has been published on testing 
VEGF in diabetic wound healing models. A phase I trial on safety of topical recombinant 
human VEGF (telberim) in patients with chronic diabetic foot ulcers by Hanft et al. (2008) 
showed that the treatment was well tolerated and reduced time to complete ulcer healing.  
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Epidermal growth factor (EGF) 
EGF is secreted by platelets, macrophages, fibroblasts, and bone marrow–derived 
mesenchymal stem cells (Barrientos et al., 2008). EGF helps maintain tissue homeostasis by 
regulating epithelial cell proliferation, growth, and migration. It also induces angiogenesis, 
which provides nutritional support for tissue and thus plays an important role in wound 
healing and tissue generation (Girdler et al., 1995). It has been reported that treatment of 
cultured epithelial cells with EGF, stimulated outwards migration of keratinocytes within 
colonies (Barrandon and Green, 1987). It has also been demonstrated that EGF stimulates 
keratinocyte division and epidermal regeneration in vitro and in vivo, respectively (Schultz et 
al., 1991; Nanny, 1991).  
Experimental studies in animals have shown that the topical application of EGF accelerates 
the epidermal regeneration rate of partial-thickness wounds and second-degree burns (Brown 
et al., 1989). Kim et al. (2010) studied the role of EGF in the formation of cutaneous scars in 
mice using full thickness wounds, and concluded that local application of the EGF enhanced 
wound healing rate and reduced cutaneous scaring. They suggested EGF reduces cutaneous 
scars by suppressing inflammatory reactions, decreasing expression of TGF-β1, and 
mediating the formation of collagen. Recently, Lee et al. (2013) treated laser induced murine 
burn wounds with EGF and reported a significantly enhanced wound healing effect in the 
EGF treated group. Clinical studies concerning the influence of EGF treatment of acute skin 
wounds in humans have also shown a stimulatory function of this growth factor (Brown et al., 
1989). In another study by Brown et al. (1991), the topical treatment of human chronic 
wounds with EGF accelerated the healing in 8 out of 9 patients of the wounds which failed to 
heal with conventional therapies. EGF has not only been widely used for the treatment of 
wounds but also for cancer therapy and vaccines, based on its cell proliferation regulatory 
properties (Oldooz, et al., 2013).  
Insulin-like growth factor (IGF) 
IGF-I and IGF-II can be found in plasma at high concentration in an inactive state and also 
produced in most tissues/cells, such as liver, kidneys and fibroblasts (Kiritsy et al., 1993). In 
vitro assays of wound re-epithelialization showed that both EGF and IGF stimulate migration 
of keratinocytes and enhance the re-epithelialization process (Haase et al., 2013). In the same 
study it was found that EGF and IGF have synergistic effects on wound epithelialization. 
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Furthermore, it has been reported that levels of IGF-1 are decreased in non-healing skin 
wounds of diabetic individuals (Yu et al., 2007). Accordingly there are many studies 
indicating that the addition of exogenous IGF-1 accelerates wound healing in diabetic mice 
(Tsuboi et al., 1995; Brown et al., 1997; Yu et al., 2007), non-diabetic mice (Brown et al., 
1997) and rabbit (Tsuboi et al., 1995). In addition, an in vivo study by Greenhalgh et al.(1993) 
showed enhanced tissue repair in genetically diabetic mice when treated with PDGF and IGF-
II, again with a synergistic effect. The aforementioned studies implicate that IGF has the 
strongest effect when being used in combination with other growth factors, demonstrating the 
necessity of finding the right combination of growth factors in order to enhance the healing 
process.  
Hepatocyte growth factor (HGF) 
HGF is secreted by mesenchymal cells and is well known to regulate cell growth, motility, 
and morphogenesis in various types of cells, including epithelial and endothelial cells, 
supporting the hypothesis that it promotes epithelial repair and neovascularization during 
wound healing (Matsumoto and Nakamura, 1997; Conway et al., 2006). However, there are 
only few reports regarding in vivo studies of HGF in animal models. In this regard, an in vivo 
study by Yoshida et al. (2003) showed that when normal rabbit immunoglobulin G (IgG) or 
neutralizing anti HGF IgG was locally and continuously delivered to full thickness excisional 
wounds of mice, the number of capillary vessels decreased with the neutralization of HGF and 
there was an associated decreased expansion of granulation tissue. Likewise, neutralization of 
endogenous HGF on days 4 and 7 post-wounding resulted in retardation of re-epithelization 
and the rate of wound closure. From these finding they have concluded that HGF is involved 
in enhancing cutaneous wound healing processes, including neovascularization, granulation 
tissue formation and re-epithelialization. Similar results were reported by Li et al. (2013) in 
Wistar rats.  
What are the possible risks/side-effects of the above mentioned factors? 
It has been demonstrated that recombinant GF's used to treat chronic wounds undergo rapid 
enzymatic degradation. The GF’s that are provided exogenously in solution form into the 
wound site have low bioactivity and availability due to their relatively large size and slow 
tissue penetration. Repeated administration of high non-physiologically concentrations are 
necessary to support the healing, however, the excess concentration of GFs results in local 
Chapter 2   
48 
 
toxicity, adverse effects (Andree et al., 1994; Chen et al., 2010; Bodnar, 2013) and may lead 
to increased risk of cancer (Vasquez et al., 2004). Nevertheless, this problem might be solved 
by the major advances made over recent years in the construction of polymer-
based/biomaterial GF delivery systems which allow the controlled release of growth factors 
(Lee et al., 2011a).  
2.4.2 Cell-based therapies 
Cell-based therapies are defined as the process of introducing new cells into a tissue in order 
to treat diseases or regenerate damaged tissue. Wound healing is a complex process, which 
requires coordinated action of multiple cell types (Martin 1997; Young and McNaught, 2011) 
which is in response to a variety of cytokines and micro-environmental conditions (Young 
and McNaught, 2011; Maxson et al., 2012). Cell-based, therapies might be considered as an 
alternative approach to growth factors for wound management. Cells so far studied for 
cutaneous wound healing effect includes stem cells, keratinocytes, fibroblasts and platelets 
which have been discussed under the previous section because of the growth factor secretion. 
An overview of the most frequently reported cell-based therapies for skin wound management 
in animals models are summarized and presented in Table 2.2. 
Cell-based therapies can regulatory be classified as human tissues and cells (Directive 
2004/23/EC) or as advanced therapy medicinal products (ATMP) (Directive 2001/83/EC and 
Regulation 1394/2007) (if not blood components or organs). The FDA has implemented a 
regulatory outline that controls cell-based products based on three topics: (i) prevention of 
using contaminated cells, (ii) prevention of handling that may cause contamination and (iii) 
clinical safety of cells used (George, 2011). There is a significant gap between promising 
laboratory-based research and approved stem cell based products (SCBP) in this fast 
emerging field (Leanne and Sarah, 2007). In order to translate SCBP from bench to bedside 
and ensure patient safety compliance with existing regulations and guidelines is required to 
ensure that the product is safe, pure and potent; and meeting good tissue practices (GTP), 
good manufacturing practices (GMP) and good clinical practices (GCP) requirements are 
indispensable (George 2011). 
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Table 2.2 Overview of most cited cell-based therapies for skin wound management in animals and their 
functional effects. 
Reference Therapy Route of 
administration 
In vivo 
model 
Type of 
wound 
Functional in vivo effects 
Wu et al., 2007 Allogenic BM-
MSC 
Edges and 
topical 
Normal 
and 
diabetic 
mice 
Full 
thickness 
Increased re-epithelialization, 
cellularity and angiogenesis. 
Stoff et al., 2009 hMSC Topical Rabbit Incisional Increased tensile strength, granulation 
tissue and reduced scar formation 
McFarlin et al, 
2006 
Allogenic BM-
MSC 
Systemic or 
local 
Rat Incisional Increased collagen production and 
early histological maturation 
Nakagawa et al., 
2005 
hMSC and Rec 
bFGF 
Topical Rat Full-
thickness 
Transdifferentiation into skin cells 
Shumakov et al., 
2003 
Allogenic BM-
MSC 
Topical Rat Deep burn Decreasing infiltration of 
inflammatory cells, increased 
neovascularization and granulation 
tissue 
Kim et al., 2013 Allogenic BM-
MSC 
Injected 
intradermally 
Canine Full 
thickness 
Increased collagen synthesis, cellular 
proliferation, angiogenesis and 
decreased expression of pro-
inflammatory cytokines 
Sasaki et al., 
2008 
Allogenic BM-
MSC 
IV (tail vein) Mice Full 
thickness 
MSC transdifferentiated into 
keratinocytes, endothelial cells and 
pericytes 
Lee et al., 2011 hESC-EPC Topical and 
subcutaneous 
Rat Full 
thickness 
Increased tensile strength, rapid 
formation of granulation tissue and re-
epithelialization 
Pratheesh et al., 
2014 
CaprineWarton’s 
jelly-derived 
MSC 
Subcutaneous     
(4 edges) 
Rabbit Full 
thickness 
Increasing wound contraction, 
epithelialization, vascularization and 
collagenization 
Spaas et al., 
2013 
Autologous 
PBSC 
Intradermal       
and IV 
Horses Chronic More rapid wound closure and crust 
formation 
 
BM = Bone Marrow; bFGF = Basic Fibroblast Growth factor; hESC = Human Embryonic Stem Cell; EPCs = 
Endothelial Precursor Cells; IV = Intravenous; MSC = Mesenchymal Stem Cells; PBSC = Peripheral Blood Stem 
cells. 
Stem cells 
Stem cells are defined as unspecialized cells that have two defined properties: the ability to 
differentiate into other cells and the ability to self-regenerate (Fortier, 2005). Stem cells may 
be categorized according to their potency: (i) totipotent (ability to form a complete organism), 
(ii) pluripotent (ability to differentiate into every cell type of the three germ layers of the 
embryo), (iii) multipotent (ability to differentiate to many but limited cell types or into closely 
related family of cells) or (iv) progenitor cells (Bongso and Richards, 2004). Stem cells 
differentiate through progenitor cells, to produce terminally differentiated cell types of the 
tissue or organ (Rodgerson and Harris, 2011). Stem cells may also be classified conferring to 
the sources they originate from. Broadly they are classified into 4 types: embryonic stem cells 
(ESC), fetal stem cells, neonatal or umbilical cord stem cells and adult stem cells (Bongso and 
Lee, 2005), or they can be categorized as embryonic and non-embryonic stem cells (Koch et 
al., 2009). Adult stem cells (ASC) could more properly be termed as tissue stem cells, post-
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natal stem cells or non-embryonic stem cells. Since ASC escape the ethical issues associated 
with ESC, they are the prime targets for cell-based therapies (Volk and Theoret, 2012) and 
hence mainly reviewed in this article. ASC, which can be at different stages of the cell cycle, 
can be harvested from a variety of sources, such as bone marrow, peripheral blood, umbilical 
cord blood, adipose tissue, skin and hair follicles (Bongso and Lee, 2005; Branski et al., 2009; 
Gauglitz and Jeschke, 2011).  
To date, especially the role of stem cells in wound healing is increasingly valued. For this 
reason, a rising number of regenerative therapies for wound healing are currently under 
development and encouraged by promising findings from both animal models and human 
studies. It has been suggested that the application of stem cells might be advantageous over 
administering single biological diffusible factors for several reasons (Lau et al., 2009). 
Indeed, stem cells have the ability to differentiate into multiple cell lineages, interact with 
their environment and release multiple wound healing enhancing factors (growth factors and 
cytokines) that makes them particularly valuable as a potential therapeutic tool (Lau et al., 
2009; Tamama and Kerpedjieva, 2012 ).  
Embryonic stem cells (ESC) 
The development and application of ESC and induced pluripotent stem cells from large 
animals is at an early stage (Volk and Theoret, 2012). Nevertheless, it has been demonstrated 
that endothelial precursor cells (EPC) derived from ESC secrete different cytokines and 
chemokines such as EGF, bFGF, granulocyte-macrophage colony stimulating factor (GM-
CSF), IL-6, IL-8, PDGF-AA and VEGF, which are well known to play an important role in 
normal wound healing (Lee et al., 2011b). To date, there are only a few reports on skin wound 
regeneration capacities of ESC or their precursor cells on laboratory animal models. An in 
vitro study in mice by Lee et al. (2011b) indicated that EPC derived from hESC improve 
proliferation and migration of dermal fibroblasts and epidermal keratinocytes and increased 
ECM synthesis. In addition, Petrova et al. recently generated epidermis from ESC and 
induced pluripotent stem cells (iPSC) (Petrova et al., 2014). Different in vivo animal models 
showed that ESC enhanced the healing of both acute and chronic cutaneous wounds (Lee et 
al. 2011c&b). Lee et al. (2011b) reported that topical and subcutaneous injection of hESC-
EPC into cutaneous excisional/acute wounds in rat resulted in accelerated wound healing and 
increased wound tensile strength, formation of granulation tissue and re-epithelization. In 
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another study of Lee et al. (2011c) an injection of ESC into diabetic/chronic wounds of rats 
resulted in enhanced wound healing effect.  
Mesenchymal stem cells (MSC) 
Adult MSC are a population of multipotent cells that can be found in any tissue including 
adipose tissue, but are abundantly present in the bone marrow, which is a typical tissue of 
mesodermal origin (Richardson et al., 2007; Fox et al., 2010). These cells represent a unique 
tool for tissue engineering. Indeed, it has been reported that MSC can differentiate into 
multiple tissue forming cell lineages such as osteoblasts, adipocytes, chondrocytes, tenocytes 
and myocytes (Krampera et al., 2006). Rather than their differentiation potential, the 
secretory/paracrine effects of MSC have been found to increasingly attribute to the 
therapeutic efficacy of MSC transplantations. In this regard, it has been demonstrated that 
MSC have important potential immunomodulatory effects. Indeed, MSC can directly 
attenuate inflammatory responses by decreasing the secretion of the pro-inflammatory 
cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin- (IL-) (Aggarwal and 
Pittenger, 2005; Kim et al., 2013) while simultaneously increasing the production of anti-
inflammatory cytokines including interleukin-10 (IL-10) and IL-4 (Aggarwal and Pittenger, 
2005). Therefore, the anti-inflammatory properties of MSC increase their importance for 
chronic wound treatment. Particularly vasculogenesis and angiogenesis, which are crucial 
steps in wound healing are also stimulated by paracrine factors released by MSC, including 
IGF-1, PDGF-BB (Chen et al., 2008), VEGF, angiopoietin-1 (Wu et al., 2007; Chen et al., 
2008), bFGF and matrix metalloproteinase-2 (Kim et al., 2013). In addition to enhancing 
wound healing, MSC are recognized to have antibacterial activity which is critical for 
protection against infection (Mei et al., 2010). This antimicrobial activity is mediated directly 
by secretion of antimicrobial factors and indirectly by secretion of immunomodulative factors 
which up-regulate bacterial killing and phagocytosis by immune cells (Krasnodembskaya et 
al. 2010; Mei et al., 2010).  
A number of parameters are used to assess experimental and clinical wound healing by using 
MSC therapy. For assessing MSC in experimental wound healing, parameters like histological 
analysis, tensiometry and tracing of the transplanted cells in the wound tissue over time are 
currently being used. The histological analyses are used to evaluate the status of infiltration of 
inflammatory cells, vascular proliferation, fibroplasia, presence and depth of scar tissue, 
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epithelialization rate and absence of adnexa including hair follicles, apocrine glands and 
smooth muscle. The parameters used to assess clinical wound healing on the other hand, 
include measuring wound size/contraction, analysis of wound scores of granulation tissue 
formation, vascularity, dermal thickness and skin resurfacing. 
Recent reports consider that allogenic as well as autologous MSC for the treatment of 
different types of wounds in humans as well as animals impact all phases of wound repair 
(Maxson et al, 2012). Animals are being used as a model for the assessment of innovative 
human regenerative therapies. In this regard, Shumakov et al. (2003) reported that MSC 
treatment of deep burn wounds in rats resulted in decreased inflammatory cell infiltration and 
accelerated the formation of new vessels and granulation tissue. It was also suggested that the 
cells produced bioactive substances that would accelerate the regeneration process. Moreover, 
Nakagawa et al. (2005) reported that MSC together with bFGF accelerated acute wound 
healing and showed that the human MSC transdifferentiated into epithelium in a rat skin 
defect model. Furthermore, a study by McFarlin et al. (2006) showed that systemic or local 
administration of bone marrow-derived MSC augments healing of surgical fascial or 
cutaneous wounds by increasing collagen production (I and III) and hence increasing wound 
bursting and tensile strength in rats. The latter study reported that MSC may also facilitate 
wound healing by trans-differentiating into myoblasts and keratinocytes after migration to the 
wound site. Transplantation of human MSC also resulted in promotion of incisional wound 
repair in rabbits and resulted in increased tensile strength, granulation tissue formation and 
decreased evidence of scar formation (Stoff et al., 2009). Experiments by Wu et al. (2007), 
Sasaki et al. (2008) and Tamai et al. (2011) demonstrated that bone marrow-derived MSC 
enhance wound healing by undergoing epidermal trans-differentiation and angiogenesis. 
Recently, Kim et al (2013) applied allogenic MSC for treating skin wounds in a canine 
experimental wound model and demonstrated that MSC-treated wounds showed rapid wound 
closure and increased collagen synthesis, cellular proliferation and angiogenesis. Apart from 
bone marrow, transplanted MSC isolated from Wharton’s jelly of caprine umbilical cord to 
full-thickness skin incision of goats Azari et al. (2011) and full thickness excisional skin 
wounds in rabbit (Pratheesh et al., 2014) resulted in less inflammation, thinner granulation 
tissue formation with minimum scar in the incisional wound and significantly higher 
percentage of wound contraction, epithelialization and collagenization with matured 
vascularization in the excisional wounds. In addition, peripheral blood-derived stem cells 
(PBSC) have been reported to enhance different wound healing parameters of chronic 
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naturally occurring wounds in horses, such as granulation tissue and scar tissue formation 
(Spaas et al., 2013). However, the latter study contained no control groups with untreated 
wounds, so further research is definitely warranted in order to confirm their conclusions. 
 
In the study by Vojtassák et al. (2006), bone marrow aspirate of a diabetic patient was applied 
directly to the foot wound, injected into the margins and finally covered with a prepared 
autobiograft. The wound was treated again on day 7 and 17 with cultured MSC. The results of 
their study showed that the treatment resulted in wound size decrease, dermal vascularization 
and thickness increase after 29 days of combined treatment. Falanga et al (2007) suggested 
that bone marrow-derived MSC contributed to accelerated skin resurfacing when used 
combined with fibrin spray applied topically up to three times as a treatment of surgical 
defects from excision of non-melanoma skin cancers. Dash et al (2009) indicated that 
simultaneous administration of cultured autologous bone marrow-derived MSC 
intramuscularly into the affected limb and topically directly onto the ulcer of non-healing 
ulcers of low extremity, accelerates the healing process and improves clinical parameters as 
compared to the control wounds treated by standard wound care alone. A similar result was 
also observed when Jain et al. (2011) used a single application (injection and topically 
application) of autologous bone marrow-derived cells for the treatment of chronic lower 
extremity wounds and compared it with whole blood (control). A double-blinded, randomized 
controlled trial by Lu et al. (2011), demonstrated the clinical benefits of parenteral 
administration of bone marrow-derived MSC for treatment of diabetic critical limb ischemia 
and foot ulcer by significantly increasin in ulcer healing rate. 
 
The major differences of using adult multipotent MSC instead of pluripotent ESC for 
therapeutic purposes is the fact that MSC, in contrast to ESC, do not have the ability to form a 
teratoma in vivo (Fong et al., 2010; Lensch et al., 2007) and can be used autologous (of the 
same individual). Indeed, in practice ESC are mainly being used in an allogenic set-up (i.e. 
derived from a different individual than the patient), which raises the concern of immune 
rejection (Menendez et al., 2005). Nevertheless, it has been shown that human (allogenic) 
ESC do not express major histocompatibility complex (MHC) II, express only low levels of 
MHC I antigens and costimulatory molecules, are not recognized by natural killer cells and 
inhibit T-cell induced-stimulation (Menendez et al., 2005), which might indicate that ESC are 
not very immunogenic. 
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Hematopoietic stem cells (HSC) 
Besides MSC, the bone marrow also contains HSC. The HSC are a well-characterized 
population of self-renewing cells (Kondo et al., 2003), which are currently mainly being used 
for the treatment of acquired and inherited bone marrow and hematologic disorders in man 
(Volk and Theoret, 2012). Krause et al. (2001) conducted research on multi-organ, multi-
lineage engraftment by a single bone marrow-derived HSC. The authors found that adult bone 
marrow cells gave rise to follicular epithelial cells, sebaceous gland cells, epidermal 
keratinocytes and even dendritic cells after their transplantation in mice. From these findings, 
they have suggested that HSC could possibly contribute to the clinical treatment of skin 
wounds. In this regard, it has also been reported that topical treatment of full thickness 
excisional wounds in diabetic mice with a side population of HSC resulted in a high 
percentage of wound closure (Chan et al., 2007). Nevertheless, more research is warranted in 
order to determine whether HSC alone have similar wound healing enhancing effects as other 
ASC types reported so far. 
Epithelial stem cells (EpSC) 
EpSC are adult SC which are quiescent but self-renew and differentiate into at least one type 
of progeny (Plikus et al., 2012). A clear distinction should be made between dermal papillae 
stem cells that contribute to multiple skin appendage formation and epidermal stem cells 
which are mainly designed to reconstitute epidermis. There are different types of EpSC which 
have been identified in the hair follicle (Plikus et al., 2012) or the basal layer of the epidermis 
(Broeckx et al., 2014a). In haired skin, progeny of bulge SC become recruited towards new 
epidermis during wound re-epithelialization (Ito et al., 2005). In a study by Yang et al., 
(2007), epidermal adult SC  were cultivated on bioengineered dermis to reconstruct artificial 
skin and successfully transplanted those artificial tissues in goats with acute full thickness 
skin defects. Their results showed that epidermal adult SC reconstructed the skin (with the 
hair observed in the restored areas). Recently, Broeckx et al. (2014a) reported the isolation 
and purification of equine epidermis-derived EpSC. The authors noticed that EpSC addition to 
PRP treatment significantly enhanced several wound healing parameters. Indeed, the dermis 
was significantly thinner and exhibited more restricted granulation tissue than the PRP-treated 
wounds. Moreover, the latter study reported a considerable increase in vascularization, elastin 
content and follicle-like structures in the EpSC-treated group. Since these cells are lineage 
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committed and preliminary experiments demonstrated similar healing enhancing capacities as 
MSC, EpSC might be considered as a valuable alternative.  
Adipose-derived stem cells (AdSC) 
AdSC represent alternative sources of multipotent cells with characteristics similar to bone 
marrow-derived MSC (Zuk et al., 2002; Izadpanah et al., 2006). Compared to BM-MSC, 
AdSC are easier to isolate and are relatively abundant, and hence considered as a better source 
for wound repair and regeneration (Lee et al., 2012). An in vitro study by Lee et al. (2012) 
showed that AdSC conditioned medium promoted wound healing of HaCaT cells (i.e. 
immortalized human keratinocytes) by increasing proliferation of HaCaT cells and fibroblasts. 
Moreover, the latter study reported an increased contraction of the fibroblast-populated 
collagen lattice. The authors concluded that the enhancing effect of AdSC on wound healing 
was partially mediated by paracrine effects on co-residing skin cells. Lee et al. (2011d) 
investigated the effects of human AdSC on the healing of cutaneous wounds in nude mice and 
they found that the AdSC promoted healing of full thickness wounds. Moreover, it has been 
demonstrated that AdSC possess anti-inflammatory, vasculogenic and angiogenic properties, 
which are lacking in other cell types, such as dermal fibroblasts. Due to these paracrine 
advantages, AdSC can be used as a substitute for fibroblasts in grafting engineered skin (Blasi 
et al., 2011). Nevertheless, more protracted studies are necessary to demonstrate the working 
mechanism of these cells. 
Differentiated cells 
Adult terminally differentiated cells are also used for skin wound treatment. At present, 
keratinocytes, fibroblasts and adipose-derived stromal vascular fraction (SVF) cells are 
actively used in a clinical setting of human skin wounds. They are usually used with artificial 
dermis as a tissue engineered dermis to optimize wound healing (You and Han, 2014). Tissue 
engineered skin was developed due to limitations associated with the use of autografts. 
Culturing autologous cells takes time and may result in donor site pain and healing 
insufficiency for patients with large skin defects, scarring, infection and/or slow healing 
(Bello et al., 2001; Han et al., 2012a). On the other hand, when allogenic sources of adult cells 
are used, immune rejection may occur and compromise the treatment outcome (Han et al., 
2012b). In recent years, skin tissue engineering has made significant advances, but there are 
still several factors that hinder its further development. Besides the critical choice of using the 
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correct cell type, it remains a challenge to create a precise and complex new skin comprising 
all the necessary cells and to arrange them in a specific 3D pattern (Michael al., 2013). Since 
mature cells are mostly terminally differentiated, these cells are not the first choice for tissue 
engineering and regenerative medicine compared to stem cells (Han et al., 2012b). For more 
information concerning several skin tissue engineering methods, the authors would like to 
refer to other review papers (Cichowski et al., 2014; Mayet et al., 2014; Nyame et al., 2014). 
Skin keratinocytes represent a constantly renewing cellular component, and have raised 
continuous interest from a scientific as well as therapeutic point of view. Keratinocyte-based  
wound healing therapies exist in a different forms. Chronic leg ulcers are being treated for a 
long time with autologous (Hefton et al., 1986; Leigh and Purkis, 1986) and allogenic 
epidermal keratinocytes (Leigh et al., 1987). Since then, several keratinocyte sources have 
been utilized in humans: own skin cells, cells from cadavers and bioengineered 
“immortalized” keratinocytes. Researchers have also used keratinocytes as one component in 
cellular constructs and reported that it contributed to improved quality of wound healing 
(Spiekstra et al., 2007; Woijtowicz et al., 2014). A retrospective study of 15 years by 
Auxenfans et al. (2013) showed that cultured allogenic keratinocytes allowed rapid healing of 
donor sites and deep second degree burns in extensively burned human patients.  
Kazemi-Darabadi et al. (2014) used allogenous skin fibroblast transplantation for diabetic 
wound in sheep and found that the treatment positively affected the wound healing by 
increasing re-epithelialization, number of fibroblasts and blood vessels Adult bone marrow 
derived cells have also been studied for experimental wounds in animals and human clinical 
cases. Accordingly a study by Yamaguchi et al. (2005) showed that adult bone marrow cells 
accelerate wound healing in rats by differentiating into wound myofibroblasts. An 
experimental burn wound model in rabbits (Oloumi et al. 2008), surgically created wounds in 
rabbits (Borena et al 2009a; Borena et al., 2010) and clinical cases in dogs (Borena et al., 
2009b) showed early disappearance of inflammatory reaction, significantly higher 
neovascularization, more fibroplasia and early maturation of collagen using an autologous 
bone marrow-derived cell transplantation. Apart from acute wound cases, a study conducted 
by Lu et al (2011) showed the clinical benefits of intramuscular injection of fresh bone 
marrow-derived mononuclear cells for the treatment of diabetic critical limb ischemia and 
foot ulcer. Badiavas and Falanga (2003) treated chronic non-healing wounds in humans by 
direct application of bone marrow derived cells and found that the treatment resulted in 
wound closure and tissue reconstitution. In this regard it has to be mentioned that both SVF 
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and BM-MNC are heterogeneous population, thus the above mentioned wound healing effects 
might be contributed by the stem cell population in the content. 
2.5 Hurdles in regenerative therapies for skin wound healing and future 
perspectives  
Due to recent advances in regenerative medicine, our understanding of skin wound healing 
mechanisms improved. However, there are several issues and questions that still need to be 
considered when administering cells or growth factors to skin wounds of patients, which 
undoubtedly will become the topic of future studies on skin regenerative therapies.  
Growth factors are indispensable for directing cell to cell and cell to matrix interactions 
during normal wound repair. However, current therapies do not consider the physiological 
interactions between growth factors to regulate the repair process. Therefore, using only one 
growth factor is possibly not the way to go. In fact, during in vivo wound repair, protein 
growth factors often interact with non-protein soluble mediators (i.e. lipids). In fact, these 
lipids act synergistically with growth factors, stimulating their function and enhancing wound 
healing.  For this reason, therapies combining growth factors and other bio-active, particularly 
lipid moieties, could be beneficial (Demidova-Rice et al., 2012). Moreover in some cases 
there is insufficient bioavailablity of growth factors, because of diminished synthesis and/or 
excessive degradation in chronic wounds (Andree et al., 1994). The therapeutic approaches 
for such type of skin wounds might need repeated administration of exogenous growth 
factors. Unfortunately, the repeated administration of high concentrations of growth factors 
for the treatment of chronic wounds might result in adverse effects (Andree et al., 1994). 
Moreover, it has been suggested that due to the complexity and persistence of chronic wound 
bed delivery, a single entity may not be sufficient as an optimal treatment. Thus, the use of a 
combination therapy and/or a patient specific approach might be required for optimal wound 
healing (Hinchliffe et al., 2008, Beenken and Mohammadi, 2009). With major advances in the 
recent years, there has been attempts to address the abovementioned problems through the 
construction of polymer-based (i.e biomaterial) growth factor delivery systems that allows 
controlled release of growth factors (Lee et al., 2011a). The main goal of drug delivery 
systems would be to ensure the stability of the growth factor in a protease environment, 
extend its function at the injury site, minimize its systemic absorption, and inhibit immune 
responses. In this regard, different types of systems have been reported such as proteinaceous 
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ECM-derived, carbohydrate-based and synthetic vehicles. Many are biodegradable or 
biocompatible and have been considered as safe by the FDA (Demidova-Rice et al., 2012). 
Still, a number of other challenges remain present and deserve more attention. These include 
i) enhancing stability of encapsulated growth factors in the biomaterial/construct to allow 
release for extended times, ii) difficulties in scaling up certain approaches and iii) determining 
the appropriate compartmentalization of delivery materials to allow multiple factors to be 
released with distinct kinetics. The interactions among growth factors in cases of multiple 
growth factor delivery system, their receptors and other ECM components are critical for the 
clinical delivery of regenerative therapies (Bielefeld et al., 2012) and needs further 
investigation. 
Some issues that remain to be determined in cell-based therapies include age of the donor 
animal, optimal time of wound treatment, dose and route of administration of cells for skin 
wound therapy. In addition, the local micro-environment of the injured tissue should be taken 
into consideration as well. As shown in Table 2.2, different researchers have used different 
cell types and routes of administration for different types of wounds. Both the in vivo study 
where MSC from old mice inhibited (rather than promoted) wound healing of diabetic mice 
(Schatteman and Ma, 2006) and the in vitro decrease of epidermal stem cell activity of skin 
cultures from old humans (Jarrold et al., 2012) confirm that the age of the donor is one of the 
concerns for stem cell therapy. In the case of enhanced fibrosis and scar tissue, cell-based 
therapies might fail due to a low blood supply and/or lack of receptors and biological 
molecules which provide the ideal environment for enhancing cell differentiation, 
proliferation and functioning (Koch et al., 2009; Kuhn and Tuan, 2010). 
The use of allogenic multipotent MSC without any adverse reactions has been described in 
both humans and horses (Broeckx et al., 2014b; 2014c; Carrade et al., 2011a; 2011b; Fang et 
al., 2007; Ringden et al., 2006; Riordan et al., 2009). Moreover, MSC can inhibit the innate 
immune activation by blocking dendritic cell maturation and suppressing macrophages and T-
cell activity (Di Nicola et al., 2002; Djouad et al., 2007; English et al., 2008; Nasef et al., 
2007; Ortiz et al., 2007). Furthermore, MSC inhibit both B-cell proliferation and production 
of IgM, IgA and IgG, (Corcione et al., 2006). Therefore, in the future studies of stem cell-
based skin wound therapy, the aforementioned parameters should be evaluated for other stem 
cell types, such as EpSC. It has to be mentioned that many studies suggest that the main 
modus operandi of cell-based therapies is their paracrine effect. If this would be the case, it 
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would implement that certain cell components or growth factors might be sufficient to achieve 
the required clinical improvements. Although the present literature study demonstrated similar 
functional in vivo effects after certain growth factor- and cell-based therapies, it does not 
allow us to conclude that stem cells only exert paracrine effects. Future studies might provide 
more answers to this complex, yet interesting matter.   
Hereby we propose that the application of cell-based and growth factor-based therapies in 
animals should be done critically and cautiously and all treatment outcomes should be 
carefully recorded and reported adequately (Koch et al, 2009).  
2.6 Conclusions 
Skin wound regenerative therapies are currently studied intensively. A number of in vitro and 
in vivo studies have been conducted on regenerative strategies for wound healing in humans 
and different animal species. Regardless promising animal studies demonstrating accelerated 
wound healing, their clinical use still remains hampered because adequate delivery methods 
need further development. Therefore, clinical validation of the use of most of the cellular- and 
growth factor-based therapies are still in an early stage. Results of fundamental studies and 
preclinical trials have not yet been confirmed in large scale controlled clinical trials. In 
addition, there is also a lack of information on long-term outcomes of skin wound treatment 
using such regenerative therapies. Nevertheless, for all the aforementioned reasons, 
researchers should be encouraged to increase the knowledge of growth factor- and cell-based 
regenerative therapies and future studies should focus on the development of a solid therapy 
for the treatment of skin wounds in mammals.  
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3.1 Background 
Mammal skin plays a pivotal role in several life preserving processes and extensive damage 
may therefore be life threatening. Selecting an appropriate wound healing strategy is 
indispensable for successful skin regeneration, since it could minimize the risk of 
complications, enhance the speed of wound healing and minimize scar formation. In this 
regard, cell-based therapies have emerged as a promising tool in those cases where 
conventional treatments fail. 
Adult stem cells can be collected from almost any tissue and are currently most frequently 
used as a regenerative medicine. The main function of stem cells in adult tissue is to repair 
and regenerate tissues in which they reside. They have the ability to self-renew and to 
differentiate into at least one mature cell type. Under physiological conditions, stem cells 
divide to produce progenitor cells that can, depending on the tissue, go through a number of 
subsequent cell divisions and differentiation steps to produce a complex web of mature cells 
(Grove et al., 2004). Bone marrow-derived nuclear cells (BMNC) and skin-derived epithelial 
stem cells (EpSC) represent two entirely different cell populations and require different 
isolation and characterization techniques. BMNC contribute to the regeneration or repair of 
many tissues including skin. For this reason, BMNC have been studied for wound healing 
enhancement in different animal species. EpSC on the other hand, are isolated from epithelial 
tissues including skin. Currently, only a limited number of studies are available on the in vitro 
and in vivo properties of these cells.  
3.2 Objectives 
For all the aforementioned reasons, the objectives of the PhD research are: 
1. To evaluate the wound-healing potential of BMNC after topical application and 
injection into wound margins of full-thickness skin wounds in rabbits (Chapters 4.1 
and 4.2). 
2. To extend the existing knowledge of EpSC purification through sphere formation in 
different culture circumstances (Chapter 5). 
3. To comparatively evaluate autologous and allogeneous EpSC treatment in 
experimentally induced wounds in horses. (Chapter 6). 
 
  
 
  
 
 
 
 
CHAPTER 4 
 
 
Evaluation of Cutaneous Wound Healing Potential of Autologous 
Bone Marrow-Derived Cells  
 
 
 
 
 
 
 
 
 
 
Adapted from: 
1. Borena, B.M., Pawde, A.M., Amarpal, Aithal, H.P., Kinjavdekar, P., Singh, R. and 
Kumar, D. Autologous bone marrow–derived cells for healing excisional dermal 
wounds of rabbits (2009). Vet Rec 165, 563-568.  
2. Borena, B.M., Pawde, A.M., Amarpal, Aithal, H.P., Kinjavdekar, P., Singh, R., 
Kumar, D. (2010). Evaluation of autologous bone marrow–derived nucleated cells for 
healing of full thickness skin wounds in rabbits. Int Wound J 7, 249-260. 
  
 
Chapter 4 
91 
 
Introduction 
Use of bone marrow aspirate has received increased attention because it is known to contain 
stem cells with the potential to repair damaged tissues. The aspirated BM needs to be reduced 
in volume in order to increase its cell content including stem cells. This can be done by 
removing some erythrocytes (non-nucleated cells) and the plasma so that only nucleated cells 
(BMNC) i.e. mononuclear stem cells as well as monocytes, lymphocytes and some 
granulocytes will be retained (Hernigou et al., 2009). BM-MSC, lymphocytes, 
monocytes/macrophages are categorized as BM-MNC. The use of BM-MNC as a source of 
BM-MSC for therapy has attracted the attention of many researchers. This is because BM-
MNC can be easily obtained and isolated in short time just before transplantation without in 
vitro expansion, which minimizes the risk of contamination (Alvarez-Viejo et al., 2013). 
Clinical studies have focused on the use of the entire BM-MNC fraction considering that 
functional effects contributed by multiple cell types and stem cell precursors in the fraction 
(Mathieu et al., 2009). Besides, the cells and precursors of the BM-MNC produce large 
amount of cytokines and trophic factors which regulate tissue regeneration (Battistella et al., 
2011). BM cells has long been reported to play roles in cutaneous wound healing in different 
animal species (Akela et al., 2013; Borue et al., 2004b; Kim et al., 2013b) as well as humans 
(Badiavas et al., 2003; Badiavas and Falanga, 2003).  
For the aforementioned reasons, the next two consecutive subchapters in the present thesis 
describe an experimental study using autologous BMNC on full thickness skin wounds in 
rabbit model. In the first subchapter (Chapter 4.1), three treatment groups namely: injection of 
autologous BMNC into wound margins (BI), topical application of BMNC over the wound 
surface (BT) or dressing with povidone iodine solution (PI) were compared. In the second 
subchapter (Chapter 4.2), injection of autologous BMNC into wound margins (BI) was 
evaluated as compared to the topical application of sterile saline solution (normal saline, NS) 
as a control. 
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Abstract 
The wound-healing potential of autologous bone marrow-derived nucleated cells was 
evaluated in full-thickness skin wounds in the thoracolumbar region of 20 clinically healthy 
rabbits. Three wounds of 2 x 2 cm, one on the left side and two right of the midline, were 
created on the dorsal lumbar region of each rabbit under xylazine-ketamine anaesthesia. The 
wounds of each animal were randomly assigned to one of three treatments: injection of 
autologous bone marrow-derived cells into wound margins (BI), topical application of bone 
marrow-derived cells over the wound surface (BT) or 5% povidone iodine solution (PI) 
(control). Wounds were observed for 28 days for granulation tissue formation, wound 
contraction, histomorphological and histochemical evaluation, and time to complete healing. 
The mean (se) time to appearance of granulation tissue was significantly less in BI-treated 
wounds (3.22 [0.22] days) than the BT-treated (3.89 [0.40] days) and PI-treated (4.89 [0.47] 
days) groups. On days 14 and 21 after surgery, wound contraction was significantly (P<0.05) 
higher in BI-treated wounds (73.00 and 97.35%) than in those treated with BT (58.75 and 
84.87%) and PI (54.84 and 84.60%). Histomorphological findings showed an earlier 
disappearance of inflammatory reaction, better epithelization, significantly more 
neovascularization, more fibroplasia and collagenation, and earlier histological maturation in 
BI- and BT-treated wounds than in control wounds. 
Key words: Bone marrow-derived cells, rabbit, skin, wound healing 
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4.1.1 Introduction 
The four stages of the wound-healing process, inflammation, debridement, epithelization, and 
remodeling and maturation, generally overlap (Fossum et al., 2007). Extensive research has 
been carried out on the use of topical medications in healing, but many of the products 
investigated in domestic animals do not affect wound healing and some inhibit it (Swaim and 
Henderson, 1990). Antiseptics such as povidone iodine are used frequently in the 
management of open wound healing by secondary intention because they reduce bacterial 
load (Leaper and Durani, 2008). An experimental study of mice suggested that adult bone 
marrow cells differentiate to epidermal keratinocytes, follicular epithelial cells, sebaceous 
gland cells, dendritic cells and endothelial cells after their transplantation (Krause et al., 
2001). Wu et al. (2007a) also found that injection of bone marrow-derived mesenchymal stem 
cells around the wound and their application to the wound bed in an excisional wound model 
enhanced healing significantly in normal and diabetic mice. Clinical trials in humans (n = 6) 
have suggested that the direct application of bone marrow-derived cells leads to dermal 
rebuilding and closure of non-healing chronic wounds of more than one year’s duration 
(Badiavas and Falanga, 2003).  
The present study was designed to evaluate the wound-healing potential of bone marrow-
derived nucleated cells (BMNC) injected into the wound margins and applied topically in full-
thickness excisional skin wounds in rabbits.  
4.1.2 Materials and methods 
Animals 
Twenty clinically healthy New Zealand white rabbits of both sexes, weighing between 920 
and 2300 g (mean weight 1487 [377.54] g) and of between three and six months of age were 
used. The Institute Animal Ethics Committee of the Indian Veterinary Research Institute, 
Izatnagar, India, approved the study. All the animals were obtained from the Laboratory 
Animals Research section of the Animal Genetics Division at the Indian Veterinary Research 
Institute. Animals were housed individually and provided with a commercial diet and water 
ad libitum. They were maintained under uniform conditions and were acclimatised to people 
approaching and handling them for a period of 10 to 15 days before the start of the study.  
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Animal preparation 
Wound creation and bone marrow aspiration were carried out aseptically under general 
anaesthesia using 6 mg/kg xylazine administered intramuscularly, followed 10 minutes later 
by 60 mg/kg ketamine intramuscularly. Anaesthesia was maintained by additional doses of 
intravenous ketamine if required. Enrofloxacin (5 mg/kg intravenously) and meloxicam (0.2 
mg/kg intravenously) were administered preoperatively. The animals were restrained in lateral 
recumbency for collection of bone marrow aspirate and in sternal recumbency for the creation 
of experimental wounds. For this purpose, the anteromedial aspect of each proximal tibia and 
the dorsum (thoracolumbar region) were prepared for aseptic surgery.  
Bone marrow aspiration and separation of nucleated cells 
Aspiration of bone marrow was done using the method described by Crow and Walshaw 
(1997), with some modifications. An 18-gauge biopsy needle was inserted with little force 
through the skin and muscle of the anteromedial aspect of the proximal tibia. Once the needle 
(with the stylet in place) had contacted with the bone, it was advanced deeper by rotating it 
slowly with steady pressure until the cortical bone had been penetrated and the needle had 
entered the marrow cavity. A sudden change to the penetration force of the needle was usually 
felt at this point, which indicated that the needle was in the marrow cavity. The stylet of the 
biopsy needle was then removed and the needle was connected to a 10 ml syringe containing 
5000 iu of heparin. A negative pressure was applied by forcefully pulling back the plunger 
and approximately 2.5 ml of bone marrow aspirate was collected from each tibia. BMNC 
were collected from the marrow aspirate using the volume reduction centrifuge ‘buffy coat’ 
protocol (Kasten et al., 2007). The bone marrow aspirate was transferred into a sterile tube 
and centrifuged at 704 g for 25 minutes. The supernatant plasma was discarded and the buffy 
coat was aspirated using a micropipette. While collecting the buffy coat, it was ensured that 
no trace of buffy coat was left in the tube by aspirating a small quantity of plasma with red 
blood cells. It was re-centrifuged for 10 minutes at 313 g to further reduce the volume. 
Finally, the concentrated nucleated cells were mixed with 0.5 ml phosphate buffered saline 
(PBS) for application to the wounds.  
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Bone marrow nucleated cell count 
The number of BMNC was calculated in two random samples to give an estimate of the 
number of cells being transplanted to the wound site in each case. The buffy coat was 
collected, diluted with PBS and centrifuged at 1252 g for 10 minutes. The PBS was then 
removed by decanting and aspiration, and the pelleted cells at the bottom with some red blood 
cells were diluted four times and centrifuged at 1252 g for 10 minutes. Re-suspension of the 
pelleted cells and counting was carried out as as per the method described by Barker.and 
Knoblock, 1982). The mean number of cells counted by this method was 1.4 x 108 cells/ml.  
Wound creation, treatment and postoperative care 
Using a clean transparency sheet template and a permanent marker, the vertices of the 
experimental wounds, two on the right side and one on the left, were outlined. Three full-
thickness skin wounds including subcutaneous tissue measuring 2 x 2 cm were excised with a 
#11 Bard-Parker blade. A gap of 2 cm was kept between the two wounds on the right side and 
wounds were created 2 cm away from the midline on either side of the dorsum. The wounds 
were created at the same location on the trunk of each animal regardless of the differences in 
the body size. Haemorrhage, if any, was controlled by applying pressure with a sterile cotton 
gauze. One of three treatments was assigned to each of the wounds randomly. For the wounds 
of the BI group, bone marrow-derived cells diluted with 0.5 ml of PBS were loaded in a 2 ml 
sterile syringe and the contents of the syringe were then injected subcutaneously around the 
wound edges. In the wounds of the BT group, bone marrow-derived cells were applied 
topically by gently spraying with the help of a syringe throughout the wound area as 
homogenously as possible. Povidone iodine 5% solution was applied topically in the wounds 
of the control (PI) group using a piece of sterile cotton gauze. The antibiotic enrofloxacin and 
the anti-inflammatory analgesic meloxicam were administered in all the animals for three 
consecutive days after surgery. The animals were monitored for restlessness, dullness, 
inappetence, panting, vocalization and elevated respiratory and heart rates.  
After the initial treatment with the respective agents, dressing with povidone iodine was done 
for all animals daily for the first 10 days and thereafter on alternate days up to day 28 after 
surgery.  
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Observations 
Granulation and epithelization: Evaluation of granulation tissue was done 3, 7, 14, 21 and 28 
days after surgery, and categorized using the method of Bigbie et al. (1991), with some 
modifications; (1) No granulation tissue seen, (2) Granulation tissue depressed below the skin 
edge, (3) Granulation tissue proliferated to the level of the skin edge, (4) Granulation tissue 
elevated above the skin edge, (5) Granulation tissue elevated above the skin edge and 
projecting over the advancing border of epithelium. The time until the appearance of 
granulation tissue was recorded as the first day when granulation tissue was observed. 
Similarly, on histological examination, the time of epithelization was recorded as the first day 
when the epithelium was seen.  
Wound contraction: Wound contraction was measured 3, 7, 14, 21 and 28 days after surgery 
as a % reduction in the wound area. A progressive decrease in the wound area was monitored 
periodically by tracing the wound margin on tracing paper and measuring the area using graph 
paper. This was divided by the total wound area of the initial wound tracing and multiplied by 
100 to calculate the percentage of contraction (Bigbie et al., 1991).  
Time to complete healing: This was recorded as the day on which the wound healed 
completely. Healing was considered to be complete when the epithelium covered the entire 
wound and the area of the remaining granulation tissue was zero (Bigbie et al., 1991).  
Histomorphological and histochemical evaluation: Four representative samples of full-
thickness skin tissue from healing wounds in each treatment group were collected 3, 7, 14, 21 
and 28 days after surgery and fixed in 10% buffered formalin. After fixation, the cut pieces 
were processed by the paraffin-embedding technique to obtain 4 to 5 µm thick paraffin 
sections. The sections were stained with haematoxylin and eosin (H&E) as described by Luna 
(1968). The H&E sections were evaluated microscopically using the histological scoring 
system described by Parameshwaraiah and Shivakumar (1998) and Smith et al. (2008), with 
some modification. The histological parameters epithelization, inflammation and fibroblast 
were scored from 1 to 4, (1) representing the most similarity to normal skin and 4 the least 
similarity. Granulation tissue width was scored as (1) Narrow or (2) Wide, and 
neovascularization was scored as 1 Resembling normal skin (zero or one new blood vessels), 
(2) Mild (two to five blood vessels), (3) Moderate (six to 10 blood vessels), or (4) Severe 
(greater than 10 new blood vessels).  
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The duplicate sections from each treatment group were stained using Masson’s trichrome 
staining (Masson, 1929) for the detection and grading of collagen fibers in the healing wound. 
The scoring was done as described by Ghamsari et al. (1996). Collagen fiber density scores 
were (1) Denser, (2) Dense and (3) Less dense, while collagen fiber thickness scores were (1) 
Thicker, (2) Thick and (3) Thin and collagen fiber arrangement scores were (1) Best arranged, 
(2) Better, (3) Worse and (4) Worst arrangement. The mean score of each parameter was 
calculated for each treatment group and compared.  
Statistical analysis 
The means of parametric observations were compared by analysis of variance (ANOVA) as 
described by Snedecor and Cochran (1989), while non-parametric observations were 
compared using a Kruskal-Wallis one-way ANOVA (Petrie and Watson, 2006). For each 
comparison, differences between groups were considered significant at P<0.05. 
4.1.3 Results 
Gross evaluation of wound healing 
Evaluation of granulation tissue: No significant difference was seen in the level of 
granulation tissue at different intervals among the various treatment groups, although higher 
scores for granulation tissue were recorded in the BI group compared with the BT and PI 
groups up to day 14 after surgery. Irrespective of the treatments given, the granulation tissue 
proliferated to the level of the skin edge by day 21 in all of the groups (Table 4.1.1). 
Table 4.1.1 Mean (se) scores for granulation tissue in the excisional wounds of rabbits following injection 
of bone marrow derived cells (BI), topical application of bone marrow-derived cells (BT) or 5% povidone 
iodine solution (PI).  
Number of days after surgery 
Treatment 3 7 14 21 28 
PI 1.55(0.11) 2.31(0.11) 2.67(0.14) 3.00(0.00) 3.00(0.00) 
BI 2.05(0.14) 2.63(0.13) 2.92(0.08) 3.00(0.00) 3.00(0.00) 
BT 1.80(0.14) 2.31(0.12) 2.67(0.14) 3.00(0.00) 3.00(0.00) 
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Granulation tissueappeared grossly, was significantly earlier (P<0.05) in BI-treated wounds 
(mean 3.22 days) than in the BT-treated (mean 3.89 days) and PI-treated (mean 4.89 days) 
groups.  
Epithelium detection: The epithelium was not clearly visible on day 3 in any of the groups. 
Regenerating epithelium seven days after surgery was seen in 100%, 75% and 75%, 
respectively in the BT, BI and PI treatment groups. By day 14, the regenerating epithelium 
was visible in all of the animals in each group.  
Wound contraction: Although the original wound created was 2 x 2 cm, almost all of the 
wounds expanded to various extents, possibly due to the loose nature of the skin of the rabbit 
dorsum; thus, after the surgery all the wounds had an area greater than 4 cm2 (Table 4.1.2). 
However, immediately after surgery, there was no significant difference in the mean wound 
area among each of the treatment groups. 
Table 4.1.2 Mean (se) wound area (cm2) of excisional wounds of rabbits and percentage wound 
contraction, following injection of bone marrow-derived cells (BI), topical application of bone marrow-
derived cells (BT) or 5% povidone iodine solution (PI).  
Treatment 
Number of days after surgery 
0 3 7 14 21 28 
PI 
6.08 (0.29) 
0.00% 
6.30 (0.30)a 
-3.63% 
4.64 (0.31) 
23.68% 
3.08 (0.42)a 
49.34% 
1.03 (0.32)a 
83.06% 
0.63 (0.30) 
89.64% 
BI 
6.04 (0.40) 
0.00% 
5.23 (0.37)bc  
13.41% 
3.81 (0.38)  
36.92% 
1.63 (0.46)b 
73.00% 
0.16 (0.16)b 
97.35% 
0.00 (0.00) 
100% 
BT 
6.74 (0.20) 
0.00% 
6.10 (0.32)ab  
9.50% 
4.43 (0.29) 
34.27% 
2.78 (0.45)a  
58.75% 
1.02 (0.49)a 
84.87% 
0.54 (0.54) 
91.99% 
 
Values with sharing the same superscripts in the same column are not significantly different (P > 0.05) 
By day 3, the mean wound area was significantly smaller (P<0.05) for the wounds treated 
with BI (5.23 cm2, 13.41% contraction) than those treated with PI (6.30 cm2, -3.63%) and BT 
(6.10 cm2, 9.50%) (Table 4.1.2). On days 14 and 21, the mean %contraction in BI-treated 
wounds was significantly higher (73.00 and 97.35%, respectively) than those treated with BT 
(58.75 and 84.87%) or PI (49.34 and 83.06%). By day 28, the difference in the mean wound 
size and % contraction between all the treatment groups was insignificant; however, 100% 
contraction was recorded in the BI-treated group only (Figure 4.1.1).  
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Figure 4.1.1 Wound contraction after the different treatments over time 
A higher percentage of wounds healed completely between days 14 and 21, as well as 
between days 21 and 28 after surgery in the BI-treated group (75 and 100%, respectively) 
than in the BT and PI treatment groups (0.00 and 25% respectively, for both treatment 
groups).  
Histomorphological and histochemical evaluation 
Table 4.1.3 shows the mean (se) scores for histomorphological and histochemical parameters 
of the wounds at different intervals following each treatment. 
By day 3, wider and more compact granulation tissue was seen in BT- and BI-treated wounds 
than in the control group (Figure 4.1.2). The mean score for inflammation was significantly 
higher (P<0.05) in the PI-treated group than in the BT group. Significantly higher scores were 
recorded for neovascularization in BI- and BT-treated groups than in the PI group. Although 
the difference was not significant, the mean scores for fibroblasts were higher in the BI- and 
BT-treated groups than in the control group.  
By day 7, there was a significantly greater inflammatory reaction in PI-treated wounds 
(P<0·05) than neither of the test wounds (BI and BT). Higher mean scores for fibroblasts and 
neovascularization, as well as denser and thicker collagen fibers, were recorded in the BI- and 
BT-treated groups than in the PI group (Figure 4.1.3), but the differences were not significant. 
By day 14, in comparison to the PI group, BI- and BT-treated wounds had more dense and 
thick collagen fibers (indicated by lower scores), and showed more fibroblasts of the collagen 
phenotype (Figure 4.1.3).  
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By day 21, no significant difference was observed in the mean score of any of the parameters 
studied among all of the treatment groups; however, by day 28, significant differences 
(P<0.05) in the mean scores for neovascularization, and collagen fiber density and thickness 
were recorded. Better neovascularization, less neovascularization and thicker collagen fibers 
were seen in wounds treated with BI and BT than in PI-treated wounds (Figure 4.1.4). 
4.1.4 Discussion 
Bone marrow cells show the broadest differentiation potential among adult somatic cell 
populations and are considered as the most promising cell sources for clinical applications 
(Krause et al., 2001, Poulsom et al., 2002). Bone marrow also contains mesenchymal stem 
cells that secrete a large number of growth factors and cytokines, which are critical in the 
repair of damaged tissues (McFarlin et al., 2006; Wu et al., 2007b).  
During the postoperative period in the present study, all the animals appeared comfortable and 
had a normal appetite. They did not show noticeable behavioural changes or alterations in 
heart and respiratory rates. However, the absence of signs of pain and discomfort may be 
attributable to the administration of analgesic. It has been reported that some topical 
treatments do not affect wound healing and actually inhibit it (Swaim and Henderson, 1990). 
However, antiseptics such as povidone iodine are frequently used in the management of open 
wound healing by secondary intention, owing to their ability to reduce bacterial load (Leaper 
and Durani, 2008). Therefore, povidone iodine was used in the control group. The time until 
granulation tissue appeared grossly was shorter in wounds treated with BI, followed by BT, 
with granulation taking longest in the control group. This was supported by the 
histopathological findings, which showed early deposition of relatively wider granulation 
tissues with more cellularity in BI- and BT-treated wounds than in control wounds. This 
might be attributed to the presence of BMNC in the BI- and BT-treated groups. Studies have 
shown that BMNC accelerate granulation tissue genesis (Badiavas et al., 2003, Badiavas and 
Falanga, 2003).  
Full-thickness skin wound healing occurs by granulation tissue formation, contraction and 
epithelization (Fossum et al., 2007). Epithelization occurs by migration of undamaged epidermal 
cells from the wound margins across the granulation bed (Swaim and Henderson, 1990). 
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Figure 4.1.2 Photomicrographs showing the healing pattern of wounds in rabbits three days after 
treatment with (BT) autologous bone marrow-derived nucleated cells applied topically over the wound 
surface or (BI) injected into the wound margins or (PI) dressing of the wound with 5% povidone iodine 
solution compared with (N) normal skin. Wounds treated with bone marrow-derived cells had more 
compact and wider granulation tissue (arrows) than those treated with povidone iodine. Haematoxylin 
and eosin. X 10. 
 
Figure 4.1.3 (a) Haematoxylin and eosin (x 10), and (b) Masson’s trichrome (x 40)-stained 
photomicrographs of granulation tissue 7 and 14 days after surgery to create a wound, and following 
treatment with autologous bone marrow-derived nucleated cells either applied topically over the wound 
surface (BT), or injected into the wound margins (BI), or following the application of 5% povidone iodine 
solution (PI). Black arrows depict granulation tissue with more neovascularization and white arrows 
depict thick and better arranged collagen fibers in BI and BT groups. 
 
 
 
BT BI PI N
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Figure 4.1.4 Haematoxylin and eosin (x 10), and Masson’s trichrome (x 40)-stained photomicrographs of 
granulation tissue 21 and 28 days after surgery to create a wound, and following treatment with 
autologous bone marrow-derived nucleated cells either applied topically over the wound surface (BT), or 
injected into the wound margins (BI), or following the application of 5% povidone iodine solution (PI). 
Recently, there has been evidence that adult bone marrow cells transplanted into the skin 
wounds of mice differentiate into epidermal keratinocytes, sebaceous gland cells, follicular 
epithelial cells, dendritic cells and endothelial cells (Kataoka et al., 2003), and fully 
differentiated skin (Krause et al., 2001; Badiavas et al., 2003; Kataoka et al., 2003). In the 
present study, early and better epithelization was observed histologically in sections from BI- 
and BT-treated wounds compared with those of the control group. This could be attributed to 
differentiation of bone marrow cells into epidermal cells. Two theories of wound contraction 
have been proposed in the past. The ‘picture frame’ theory states that  myofibroblasts located in 
the wound margins of an open wound are responsible for the centripetal forces that lead to 
wound contraction (Waldon and Zimmerman- Pope, 2003), while the ‘pull’ theory suggests that  
fibroblasts distributed throughout the granulation tissue generate the forces responsible for 
contraction (Abercrombie and others 1956). More recently, it has been suggested that wound 
contraction occurs through a combination of these two processes (Swaim et al., 2001). In vivo 
experiments by Yamaguchi and others (2005) demonstrated that bone marrow cells differentiate 
into wound myofibroblasts when they enter the micro- environment of a wound. Opalenik and 
Davidson (2005) showed that adult bone marrow-derived cells participate in wound repair by 
differentiating into wound fibroblasts. In the present study, many of the bone marrow-derived 
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cells that were injected into the wound margins could have differentiated into myofibroblasts 
and fibroblasts and resulted in the rapid wound contraction and early closure of full- thickness 
wounds observed in the BI group compared with the other treatment groups. 
It has been suggested that histomorphological assessment of healing in open wounds allows 
more precision than clinical examination (Abramo et al., 2004). Although inflammation is 
necessary for healing by fighting infection and inducing the proliferation phase, healing 
proceeds only after inflammation is controlled (Midwood et al., 2004). Thus, the early control of 
inflammation, as in the case of BI treatment in the present study, might facilitate the progress to 
the next phase of wound healing. Neovascularization occurs concurrently with fibroblast 
proliferation when endothelial cells originating from parts of uninjured blood vessels migrate to 
the area of the wound (Fossum et al., 2007). Liu et al. (2006) reported that, in response to the 
wound microenvironment, bone marrow stem cells augment wound healing through the 
responsive secretion of growth factors that enhance angiogenesis and promote wound repair. 
Wu et al. (2007a) opined that bone marrow cells enhance neovascularization and promote 
wound healing through differentiation and the release of proangiogenic factors. The 
significantly higher neovascularization in the early phase of wound healing in the BI- and BT-
treated wounds than in control wounds in the present study may have been due to one or a 
combination of these factors. There were more fibroblasts up to day 14 after surgery and better 
collagenation was recorded throughout the observation period in the test wounds than the 
control group. These findings are in agreement with those of Fathke et al. (2004), who reported 
that bone marrow- derived cells were able to contract a collagen matrix and transcribe collagen 
types I and III. By day 28 after surgery, there were significantly denser and thicker collagen 
fibres in the test wounds than the control wounds. Epithelization was also more similar to the 
normal skin in the test wounds than the control wounds. These findings indicate earlier histo- 
logical maturation of the test wounds than the controls, which supports the observations of Liu 
et al (2006) who reported that wounds treated with BMNC were found to be histologically 
mature sooner than untreated wounds. The histological and histochemical findings in the BI and 
BT treatment groups were comparable. 
Injection of bone marrow nucleated cells into the wound margins has therefore been shown to 
accelerate the rate of wound healing in excisional full-thickness skin wounds in rabbits. Besides, 
the histological findings showed that both BI and BT- treatment augmented the wound healing 
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activity. Therefore, topical application or injection of bone marrow-derived cells might be 
among the candidates to be used clinically in the management of large wounds in pet rabbits. 
There have been some limitations during the in vivo study using BMNC on rabbit skin wound 
healing in the present thesis. i. BM aspiration: it is routinely performed and it is efficient by 
drilling of diaphysis of long bones. Metaphysis of long bones can be alternative sources of 
BM cells (Chung et al., 2008). Accordingly, due to lack of bone drill, manual aspiration of 
BM from medial aspect of anterior tibia (tibial metaphysis) using biopsy needle, which was 
relatively easy was performed in the present thesis. ii. BMNC count: Both aspiration of BM 
and induction of experimental wounds were done under general anesthesia, thus 
intraoperative manual counting of BM cell from all the 20 rabbits was difficult. For this 
reason counting was performed only from two samples in order to have an overview about the 
cells being transplanted. Therefore, future research is warranted to determine the exact 
number of cells at each transplant, immunophenotypic characterization of the BM-MSC after 
volume reduction as well as to determine survival and proliferation of the transplanted cells at 
wound site. 
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Abstract 
The aim of the study was to evaluate the potential of autologous bone marrow-derived 
nucleated cells to enhance the rate of healing of full-thickness excisional skin wounds in 
rabbits. The study was conducted on 20 New Zealand white rabbits of either sex. Two 2cm × 
2cm full-thickness skin (thoracolumabar region) excisional wounds were created; one on 
each side of the dorsal midline in each animal.  The wounds were randomly assigned to 
either injection of autologous bone marrow-derived nucleated cells into the wound margins 
(BI), or topical application of sterile saline solution (normal saline, NS), which served as 
control. The wound healing was assessed by evaluation of granulation tissue formation, 
wound contraction, epithelization and histopathological and histochemical changes up to 28 
days after creation of the wound. Granulation tissue appeared significantly faster in BI-
treated wounds (3.22 ± 0.22 days) than in NS-treated wounds (4.56 ± 0.47 days). Better 
epithelization was seen histologically in BI-treated wounds than in NS-treated wounds. 
Wound contraction was significantly more in BI-treated wounds when compared with NS 
wounds on 21 days post-surgery. Histopathological examination of the healing tissue showed 
early disappearance of inflammatory reaction, significantly more neovascularization, and 
more fibroplasias and early lay down and histological maturation of collagen in BI wounds 
than in control wounds. It was concluded that injection of autologous bone marrow-derived 
nucleated cells in the wound margins induced faster and better quality healing of excisional 
skin wounds in rabbits when compared with normal saline. The injection of autologous bone 
marrow-derived nucleated cells can be used to promote healing of large full-thickness skin 
wounds in rabbits. 
Key words: Bone marrow-derived cells, Rabbit, Skin, Wound healing 
 
 
 
 
 
Chapter 4.2  
116 
 
4.2.1 Introduction 
There are four stages of the process of wound healing, that is, inflammation, debridement, 
repair and remodeling, and maturation, which are clearly differentiated from each other but 
overlap in time (Fossum et al., 2007). Despite appreciable advances in understanding the 
basic principles of wound healing, problems in wound healing continue to cause significant 
morbidity and suffering in animals. Bone marrow-derived stromal cells (BM-MSC) exhibit 
extraordinary degree of plasticity and growth factor repertoire (Dulchavsky et al., 2008). 
Experimental study in mice suggested that adult bone marrow cells gave rise to epidermal 
keratinocytes, follicular epithelial cells, sebaceous gland cells, dendritic cells, and endothelial 
cells after transplantation (Goodell et al., 2001; Krause et al., 2001). In addition, treatment with 
BMSC increased the expression of growth factors critical to proper repair and regeneration of 
the dam- aged tissue (Kwon et al., 2008; Salvolini et al., 2009). Researchers have also noted 
that bone marrow-derived mesenchymal stem cells when injected around the wound or applied 
to the wound bed of in excisional wounds significantly enhanced wound healing in normal 
and diabetic mice (Wu et al., 2007). Clinical trials in people suggested that bone marrow-
derived cells (BMDC) applied directly to non-healing chronic wounds of greater than one 
year’s duration led to dermal rebuilding and healing (Badiavas and Falanga, 2003). The 
purpose of the study reported here was to test the hypothesis that bone marrow-derived 
nucleated cells injected into the wound margins in excisional wounds of rabbits can enhance 
the rate of wound healing. 
4.2.2 Material and methods 
Animals 
Twenty clinically healthy New Zealand white rabbits of either sex, weighing from 920 to 
2300 g (mean weight 1487 ± 377·54 g) and between 3 and 6 months of age, were used. The 
Institute Animal Ethics Committee of Indian Veterinary Research Institute Izatnagar, India 
approved the study.  All the animals were procured from Laboratory Animals Research (LAR) 
section, Animal Genetics Division of Indian Veterinary Research Institute, Izatnagar (UP), 
India. Animals were housed individually, provided with commercial diet and water ad libitum 
and maintained under uniform conditions. Animals were acclimatized to approaching and 
handling for a period of 10–15 days before the start of the study.  
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Animal preparation 
Wound creation and bone marrow aspiration were carried out aseptically under general 
anaesthesia using xylazine (6mg/kg intramuscularly) followed, 10 minutes later by ketamine 
(60 mg/kg intramuscularly). Anaesthesia was maintained by additional dose of intravenous 
ketamine, if required. Enrofloxacin (5 mg/kg intravenously) and meloxicam (0.2 mg/kg 
intravenously) were administered preoperatively in all the animals. The animals were 
restrained in lateral recumbency for collection of bone marrow aspirate and in sternal 
recumbency for creation of experimental wounds. For the purpose of bone marrow collection 
and creation of wounds, the antero-medial aspect of each proximal tibia and the dorsum 
(thoracolumbar region), respectively, were prepared for aseptic surgery. 
Bone marrow aspiration and separation of nucleated cells 
Aspiration of bone marrow was done under aseptic condition from the tibial metaphysis. An 
18-gauge biopsy needle was inserted with little force through the skin and muscle of 
anteriomedial aspect of proximal tibia. Once the needle (with stylet in place) had contacted 
with the bone, it was advanced further deep by rotating it slowly with steady pressure until 
the cortical bone was penetrated and the marrow cavity was entered. Usually a sudden 
change to the penetration force of the needle was felt at this point, which indicated that the 
needle was in the marrow cavity. The stylet of the biopsy needle was removed and it was 
connected to a 10-ml syringe containing 1000 IU of heparin and a negative pressure was 
applied by forcefully pulling back the plunger. Approximately 2.5 ml bone marrow aspirate 
was collected from each tibia. Bone marrow nucleated cells were collected from the marrow 
aspirate by volume reduction centrifuge ‘buffy coat’ protocol (Kasten et al., 2007). While 
collecting the buffy coat, it was ascertained that no trace of buffy coat was left in the tube 
and even a small quantity of plasma with red blood cells (RBC) was aspirated along with 
buffy coat. It was re-centrifuged for 10 minutes at 313 g to further reduce the volume.  The 
concentrated nucleated cells were mixed with 0.5 ml phosphate buffered saline (PBS) for 
application to the wounds. 
Bone marrow-nucleated cell count 
Bone marrow-nucleated cells (BMNC) were counted randomly in two samples to have an 
estimate of the number of cells being transplanted to the site of wound. The buffy coat was 
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collected and diluted with PBS and centrifuged at 1252 g for 10 minutes. The PBS was 
removed by decanting and aspiration and the pelleted cells at the bottom with some RBCs 
were diluted four times and centrifuged at 4000 rpm for 10 minutes. Re-suspension of the 
pelleted cells and counting were as per the method described by earlier researchers (Barker 
and Knoblock, 1982). The average number of cells counted by this method was 1.4 × 108 
cells/ml. 
Wound creation 
Using a clean transparency sheet template and a permanent marker, the vertices of the 
experimental wounds of 2 × 2 cm dimensions were outlined on the dorsolumbar region of the 
rabbits. Two full-thickness skin wounds including subcutaneous tissue, one on each side of 
the midline, were excised with a #11 BP blade in each animal. The wounds were created 2 
cm away from the midline on the two sides of the dorsum. The wounds were created at the 
same location on the trunk of each animal regardless of the differences in the body size. 
Haemorrhage, if any, was controlled by applying pressure with sterile cotton gauze. The two 
treatments bone marrow-derived nucleated cells into the wound margins (BI) and normal 
saline (NS) were assigned to the wounds randomly. In the wounds designated as BI group, 
bone marrow cells diluted with 0.5 ml of PBS were loaded in a 1-ml sterile syringe and the 
contents of the syringe were then injected subcutaneously around the wound edges through a 
26 G hypodermic needle. In the wounds designated as NS group, normal saline was applied 
topically using a piece of sterile cotton gauze. These wounds were taken as control. The 
antibiotic (enrofloxacin) and an anti-inflammatory-analgesic (meloxicam) were administered 
in all the animals for three consecutive days after the surgery. The animals were observed for 
restlessness, dullness, loss of appetite, panting, vocalization and elevated respiratory and 
heart rates, if any, for 1 week and for wound healing up to 28 days. 
Evaluation of wound healing 
Granulation tissue 
Granulation tissue evaluation was performed daily up to day and then on days 14, 21 and 28 
after surgery and categorized with some modifications as: (1) no granulation tissue seen, (2) 
granulation tissue depressed below the skin edge, (3) granulation tissue proliferated to the 
level of skin edges, (4) granulation tissue elevated above skin edges and (5) granulation 
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tissue elevated above skin edges, projecting over the advancing border of epithelium (Bigbie 
et al., 1991). A granulation score of 3 was considered better than 4 or 2, which were 
considered better than 5 or 1. Time of appearance of granulation tissue was recorded as the 
first day when the granulation tissue was observed.  
Wound contraction 
Wound  contraction  was  calculated  on  3rd, 7th,  14th,  21st  and  28th  postoperative days 
as a percentage reduction in wound area. Progressive decrease in the wound area was 
monitored periodically by tracing the wound margin on a tracing paper and the area assessed 
by using graph paper. The total open wound area at each tracing was subtracted from that of 
the initial tracing to determine the area of contraction and epithelization during the period 
since wounding. The area of contraction since wounding was divided by the total wound area 
of the initial wound tracing and multiplied by 100 to calculate the percentage of wound 
contraction (Bohling et al., 2004; Majeske, 1992). The wound area, percentage and the mean 
percentage of wound contraction were calculated in four animals for each interval for both 
groups of wounds. These four animals were then used for biopsy collection and excluded 
from the study. 
Time of complete healing 
Time of complete healing was recorded as the day on which wound healed completely. 
Healing was considered complete when epithelium covered the entire wound and the area of 
the remaining granulation tissue was zero (Bigbie et al., 1991). The number of days required 
for each type of wound to heal completely was recorded and mean days to complete healing 
were calculated for both treatment wounds. 
Histomorphological and histochemical evaluation 
Full-thickness skin tissue samples, including about 1cm normal skin around the healing 
wounds from both treatment group, were collected from four animals each on 3rd, 7th, 14th, 
21st and 28th postoperative days. After collection of tissues, these wounds were repaired by 
suturing and the animals were excluded from the study. The tissues were fixed in 10% 
buffered formalin. After fixation, the tissues were processed by paraffin- embedding 
technique to obtain 4–5 μm thick paraffin sections. The sections were stained with 
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haematoxylin and eosin (H&E) stain as per the standard procedure (Bancroft and Cook, 
1984). The H&E sections were evaluated microscopically by using histological scoring 
system with some modifications (Parameshwaraiah and Shivakumar, 1998; smith et al., 
2008). The histological parameters namely: epithelization, inflammation, fibroblast  were  
scored from 1 to 4 (1 standing for best similarity to  normal skin and 4 for least similarity) 
and neovascularization-score: 1: resembling  normal  skin, 0–1 new blood vessels; 2: mild, 
2–5 blood vessels; 3: moderate, 6–10 blood vessels and 4: severe, greater than 10 new blood 
vessels. Time of epithelization was recorded as the day when the epithelium was seen 
histologically for the first time. The duplicate sections of both types of wounds were stained 
using special staining techniques called Masson’s Trichrome stain (Masson, 1929) for 
detection and grading of collagen fibers in the healing wound. The scoring (Chamsari et al., 
1996) was done as follows: collagen fiber: density-score: 1, denser, 2, dense and 3, less 
dense; thickness-score: 1, thicker, 2, thick and 3, thin; arrangement-score: 1, best arranged, 2, 
better, 3, worse and 4, worst arrangement. The mean score of each parameter was calculated 
for each treatment group and compared. 
Statistical analysis 
The means of objective parameters were compared by analysis of variance (ANOVA), 
whereas data from subjective scorings were compared by Kruskal–Wallis one-way ANOVA 
(Snedecor and Cochran, 1989). For each comparison, differences between groups were 
considered significant at P < 0.05. 
4.2.3 Results 
Postoperatively, the animals appeared comfortable as evidenced by normal appetite and 
behavior and stable heart and respiratory rates.  
Granulation tissue 
The time (day) of appearance of granulation tissue was significantly (P < 0.05) less in BI- 
treated wounds (3.22 ± 0.22 days) than that in NS-treated wounds (4.56 ± 0.47 days) 
wounds. No significant (P > 0.05) difference was seen in the level of granulation tissue in the 
wounds of the two treatment groups at different intervals. 
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Epithelization 
On day 3 after surgery, there was no evidence of epithelization in NS-treated wounds, 
whereas regenerating epithelium was detected in one of four wounds in BI wounds. 
Epithelium was evident histologically in the sections taken from the center of the wounds in 
75% and 100% of the wounds on days 7 and 14 post-operation, respectively, in both BI-
treated and NS-treated wounds. 
Wound contraction 
Although the original wound were created measuring 2 cm × 2 cm dimensions, all  the 
wounds expanded to variable extents possibly because of loose nature of skin of the dorsum 
in rabbits; thus, after the surgery all the wounds had an area in excess  of  4 cm2 (Table 
4.2.1). However, there was no significant (P > 0.05) difference in the mean of wound area 
between the groups.  
Table 4.2.1 Mean ± SE value of wound area (cm2) and percent wound contraction (in parenthesis) in 
excisional wounds of rabbits.  
  Post-wounding days 
Treatment Day 0 Day 3 Day 7 Day 14 Day 21 Day 28 
NS 5.53 + 0.28a  
(0.00) 
4.75 + 0.27a  
(14.10) 
3.33 + 0.30a  
(39.78) 
1.79 + 0.37a 
(67.63)  
0.41 + 0.17a 
(92.59) 
0.07 + 0.04 
(98.73) 
BI 6.04 + 0.40a  
(0.00) 
5.23 + 0.37a  
(13.41) 
3.81 + 0.38a 
(36.92) 
1.63 + 0.46a 
(73.01) 
0.16 + 0.16b 
(97.35) 
0.00 + 0.00 
(100) 
 
 
* Values with different superscripts in the same column are significantly different (P < 0.05) BI = Bone 
marrow-derived nucleated cells injected into wound margins; NS = Normal Saline 
The wound area decreased gradually over time in both treatment groups. After day 7 post 
surgery, better contraction was recorded in BI-treated wounds as compared to NS group. The 
difference in wound area was significant (P < 0.05) between BI and NS on day 21 post-
operation where mean percent contraction of 97.35% and 92.59%,   respectively, was 
recorded. By day 28, difference in the mean wound size and percent contraction between the 
groups was not significant (P > 0.05), but 100% contraction was recorded in BI-treated group 
only (Figure 4.2.1). 
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Figure 4.2.1 Wound contraction after the different treatments over time 
Time of complete healing 
None of the wounds healed completely by 14th day of surgery in two treatment groups. Of the 
eight animals observed for wound healing, on 21st day after wounding, complete healing was 
observed in 75% animals in BI treatment group and in 37.5% animals of NS treatment group. 
On 28th post-wounding day, the percentage of completely healed wounds treated by BI and 
NS were 100% and 75%, respectively, of the four animals observed for wound healing at this 
stage (Table 4.2.2). 
Table 4. 2.2 Number and percentage of wound healed completely in excisional wounds of rabbits * 
Treatment Between 14 and 21 days (n = 8) Between 21 and 28 days (n = 4) 
NS 3/8 (37.50%) 3/4 (75.00%) 
NS 6/8 (75.00%) 4/4 (100.00%) 
 
BI = Bone marrow-derived nucleated cells injected into the wound margins; NS = Normal Saline. 
* n = number of wounds, number in the parenthesis indicates percentage of wounds completely healed 
 
Histomorphological and histochemical evaluation 
Day 3 
Granulation tissues were wider and compact in BI-treated wounds when compared with NS 
(Figure 4.2.2). The mean score values of inflammation were significantly (P < 0.05) higher 
(i.e. more inflammatory reaction) in the NS group than that in the BI group. With regard to 
neovascularization, significantly (P < 0.05) higher scores (i.e. more neovascularization) were 
recorded in BI-treated wounds than in NS-treated wounds. Although statistically insignificant, 
the mean score values for fibroblasts were higher in BI than in control group (Table 4.2.3). 
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Day 7 
As on day 3 after surgery, there was significantly (P < 0.05) more inflammatory reaction in 
NS-treated wounds than the BI-treated wounds. Higher mean score values for fibroblasts and 
neovascularization as well as denser and thicker collagen fibers were recorded in BI-
treated wounds than in NS-treated wounds, but the difference was not significant (P > 0.05) 
(Table 4.2.3; Figure 4.2.3). 
 
 
Figure 4.2.2 Photomicrographs showing healing pattern on day 3 wounds treated with normal saline (NS), 
and autologous bone marrow-derived cells injected to wound margins (BI). Healing tissue in BI-treated 
wound was better with compact and wider granulation tissue (arrows) than NS-treated wound (H&E 
sections 10×, day 3) 
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Figure 4.1.3 Photomicrographs of granulation tissue of control (normal saline, NS) and bone marrow-
derived nucleated cells into the wound margins (BI) treated animals showing thick epithelium covering 
wider surface (E), mild to nil inflammatory reaction and more neovascularization (arrow heads) by days7 
and 14 (shown in H&E) and moderate deposition of collagen fibers which are denser and thicker in the 
sections from BI group (arrow head) than in NS groups (shown in MTS) (HE 10× and MT Sections, 40×). 
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Day 21 
The mean scores of inflammation, fibroblast, neovascularization, collagen fibre density, 
collagen fibre thickness and collagen fibre arrangement were lower in BI-treated wounds than 
in NS-treated wounds; but no significant (P > 0.05) difference were found in mean scores of 
any parameter between the treatments (Table 4.2.3; Figure 4.2.4). 
 
Figure 4.2.4 Photomicrographs of granulation tissue from normal saline (NS), and bone marrow derived 
nucleated cells into the wound margins (BI) treated wounds showing histologically more mature 
granulation tissue of the wounds treated by BI than by NS. Sections of granulation tissue from BI-treated 
wounds showed denser and thicker collagen fibres and lesser fibroblasts than that of NS on days 21 and 28 
(H&E 10× and MTS 40×). 
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Day 14 
In comparison with NS group, BI-treated wounds had more dense and thick collagen fibres 
and showed more fibroblasts of collagen phenotype (Figure 4.2.3). 
Day 28 
Significant (P < 0.05) difference in the mean scores values of neovascularization, collagen 
fibre density and thickness was recorded during this period (Table 4.2.3). Better epithelization 
was seen in BI-treated wounds than in NS-treated wounds.BI-treated wounds had significantly 
less neovascularization than the control (NS). Collagen fibres were significantly (P < 0.05) 
thicker in BI-treated wounds than in NS-treated wounds (Figure 4.2.4). 
4.2.4 Discussion 
Bone marrow cells show the broadest differentiation potential among adult somatic cell 
populations and are considered as one of the most promising cell sources for clinical 
applications (Goodell et al., 2001; Krause et al., 2001; Poulsom et al., 2002). Bone marrow 
also contains mesenchymal stem cells (BM-MSC) that secrete a large number of growth 
factors and cytokines, which are critical for proper repair and regeneration of damaged tissue 
(Kwon et al., 2008). 
Considering the reported capacity of bone marrow cells to secrete growth factors and 
cytokines and the ability to trans-differentiate to the healing tissue components, we 
hypothesized that there would be quantitatively and qualitatively better healing in the 
wounds- treated bone marrow cells compared with the control. It was assumed that excisional 
wounds treated with BI would heal faster with more granulation tissue formation, 
epithelization, rapid wound contraction, early histological maturation and complete healing 
than control group. 
The injection of bone marrow cells in BI wounds might have caused some trauma and caused 
inflammation leading to release of cytokines, which may affect wound healing. However, the 
injection of bone marrow cells was made slowly using a fine hypodermic needle to minimize 
the trauma. Furthermore, the injection trauma was considered negligible compared with the 
surgical trauma inflicted in creation of wounds and thus may be of little significance.  
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Grossly, the granulation tissue appeared significantly faster in wounds treated with BI than in 
control group. These findings were also supported by the histopathological findings of early 
deposition of relatively wider granulation tissues with more cellularity in BI-treated wounds 
than in control wounds. This might be attributable to the role of BMNC in BI group as studies 
have shown that BMNC accelerate granulation tissue genesis (Kasten et al., 2007; Badiavas et 
al., 2003). 
Full-thickness skin wound healing occurs by granulation tissue formation, contraction and 
epithelization (Johnston, 1981; Lazarus et al., 1994; Waldron and Zimmerman, 
2003). epithelization occurs by migration of undamaged epidermal cells from the wound 
margins across the granulation bed (Fossum et al., 2007; Deodhar, 1997). Recently, there is 
evidence that adult bone marrow cells transplanted in skin defect had differentiated into 
epidermal keratinocytes, sebaceous gland cells, follicular epithelial cells, dendritic cells, and 
endothelial cells and fully differentiated skin with hair was reconstituted within 3 weeks 
(Kataoka et al., 2003). Many researchers also suggested that bone marrow stem cells can 
produce new skin cells (Krause et al., 2001; Badiavas et al., 2003). In the present study, early 
and better epithelization observed histologically in sections from BI-treated wounds when 
compared with con-trol wounds are possibly also attributed to differentiation of bone marrow 
cells into epidermal cells (Krause et al., 2004; Badiavas et al., 2003; Kataoka et al., 2003) or 
enhanced proliferation of resident epidermal cells in the presence of epidermal growth factor, 
possibly produced by bone marrow cells (Kwon et al., 2008). Wound contraction plays very 
important role in the healing of excisional skin wounds. There are two theories of wound 
contraction that have been proposed in the past. The ‘picture frame’ theory of wound 
contraction states that myofibroblasts located in the wound margins of an open wound are 
responsible for the centripetal forces that lead to wound contraction (Waldron and 
Zimmerman, 2003; Grillo et al., 1958). On the other hand, the ‘pull theory’ suggests that 
fibroblasts distributed throughout the granulation tissue generate the forces responsible for 
contraction (Abercrombie et al., 1956). More recently, it has been suggested that wound 
contraction occurs through a combination of these two processes (Swaim et al., 2001).  In vivo 
experiments showed that bone marrow cells differentiated into wound myofibroblasts after 
they entered the microenvironment of the wound (Abe et al., 2001; Yamaguchi et al., 2005). 
Another study showed adult BMDC participated in wound repair by differentiating into 
wound fibroblasts (Opalenik and Davidson, 2005). In the present study, many of the BMNC, 
which were injected into the wound margins, might have differentiated into myofibroblasts 
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and/or fibroblasts or recruited more fibroblasts from the surrounding tissues through 
chemotaxis (Dulchavsky et al., 2008) that resulted in significantly early and fast wound 
contraction and early closure of full- thickness wounds in BI group than control group. 
It was suggested that histopathological assessment of mode and rate of healing in open 
wounds allows more precision than clinical examination (Abramo et al., 2004). Inflammation 
is necessary for healing as it plays a role in combating infection and inducing the proliferation 
phase, but healing proceeds only after inflammation is controlled (Midwood et al., 2004; 
Diegelmann and Evans, 2004). Thus early disappearance of inflammation in BI wounds in the 
present study might have facilitated the progress to the next phase of wound healing. Because 
the activity of fibroblasts and epithelial cells requires oxygen, angiogenesis is imperative for 
other stages in wound healing, such as epidermal and fibroblast migration. Neovascularization 
occurs concurrently with fibroblast proliferation when endothelial cells, originating from parts 
of uninjured blood vessels, migrate to the area of the wound (Kuwahara and Rasberry, 2007). 
Bone marrow stem cells are reported to release factors that recruit macrophages and 
endothelial lineage cells into wound (Chen et al., 2008). In another study, it was suggested 
that bone marrow cells enhance neovascularization and promote wound healing through 
differentiation and release of proangiogenic factors (Badiavas and Falanga, 2003). This might 
be the main reason for the significantly higher neovascularization in early phases of wound 
healing in BI wounds than control wounds. 
The fibroblast is the connective tissue cell responsible for collagen deposition that is needed 
to repair the tissue injury (Fossum et al., 2007). In the present study, there were also more 
fibroblasts up to day 14 post-surgery, better collagen formation throughout the observation 
period were recorded in the BI-treated wounds than in the NS-treated wounds. These findings 
are in agreement with the earlier findings (Fathke et al., 2004) where BMDC were able to 
contract a collagen matrix and transcribe both collagen types I and III. In addition, BM-MSC 
secrete several growth factors critical to repair of damaged tissues (Kwon et al., 2008). 
Compared with NS, BI-treated wounds showed more compact and thicker granulation tissue 
with less fibroblasts and better- arranged fibrocytes, and denser and thicker collagen fibres by 
day 21, which indicated the maturation phase of the wound healing. By day 28 post-
wounding, there were significantly denser and thicker collagen fibres in the BI wounds than in 
the control wounds. epithelization was also more comparable with the normal skin in the BI 
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wounds than the control wounds. All these findings indicate early histological maturation of 
test wounds than the controls, which conform to the observations of earlier researchers, who 
reported that the wounds treated with BM-MSC were found to be histologically mature earlier 
when com-pared with the untreated wounds (Liu et al., 2006). Early deposition and 
maturation of collagen in BI wound may also be attributable to the reported interaction of 
BM-MSC with fibroblasts, which results in promotion of growth and chemotaxis of 
fibroblasts (Dulchavsky et al., 2008). 
It was concluded that injection of bone marrow-derived nucleated cells to the wound margins 
facilitated early and better healing than the normal saline. Histological and histochemical 
observations showed that the bone marrow cells augmented wound healing activity 
significantly by increasing cellular proliferation, formation of granulation tissue, neo- 
vascularisation, synthesis of collagen, epithelization and early histological maturation in 
excisional wounds. Bone marrow-nucleated cells can be used clinically in the management of 
large skin wounds in rabbits. 
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Abstract 
Mammal skin plays a pivotal role in several life preserving processes and extensive damage 
may therefore be life threatening. Physiological skin regeneration is achieved through 
ongoing somatic stem cell differentiation within the epidermis and the hair follicle. However, 
in severe pathological cases, such as burn wounds, chronic wounds, and ulcers, the 
endogenous repair mechanisms might be insufficient. For this reason, exogenous purification 
and multiplication of epithelial-like stem/progenitor cells (EpSC) might be useful in the 
treatment of these skin diseases. However, only few reports are available on the isolation, 
purification and characterization of EpSC using suspension cultures. Therefore, in the present 
study, skin was harvested from 6 mares and EpSC were isolated and purified. In addition to 
their characterization based on phenotypic and functional properties, sphere formation was 
assessed upon isolation, i.e. at passage 0 (P0), and at early (P4) and late (P10) passages using 
different culture conditions. On average 0.53 + 0.28% of these primary skin-derived cells 
showed the capacity to form spheres and hence possessed stem cell properties. Moreover, 
significantly more spheres were observed in EpSC medium versus differentiation medium, 
corroborating the EpSC privileged ability to survive in suspension. Furthermore, the number 
of cells per sphere significantly increased over time as well as with subsequent passaging. 
Upon immunophenotyping, the presumed EpSC were found to co-express cytokeratin (CK) 
14, Casein kinase 2 beta and Major Histocompatibility Complex (MHC) I and expressed no 
pan CK and wide CK. Only a few cells expressed MHC II. Their differentiation towards 
keratinocytes (at P4 and P10) was confirmed based on co-expression of CK 14, Casein kinase 2 
beta, pan CK and wide CK. In one of six isolates, a non-EpSC cell type was noticed in 
adherent culture. Although morphological features and immunohistochemistry (IHC) 
confirmed a keratinocyte phenotype, this culture could be purified by seeding the cells in 
suspension at ultralow clonal densities (1 and 10 cells/cm2), yet with a significantly lower 
sphere forming efficiency in comparison to pure EpSC (P = 0.0012). In conclusion, the 
present study demonstrated sphere formation as a valuable tool to purify EpSC upon their 
isolation and assessed its effectiveness at different clonal seeding densities for eliminating a 
cellular contamination. 
Key words: Purification; Skin; Epithelial; Stem Cells; Horse; Sphere formation 
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5.1 Introduction 
Adult stem cells possess a low antigenicity (Hoynowski et al., 2007) and can be isolated from 
a variety of sources including bone marrow (Pittenger et al., 1999; Jiang et al., 2002), adipose 
tissue (Zuk et al., 2002), peripheral blood (Spaas et al., 2013) and skin (Toma et al., 2001). 
Unlike embryonic stem cells, little or no ethical issues are related to the use of their adult 
counterparts. Being the body's largest organ, the skin is a highly accessible source and the 
largest reservoir of epithelial stem cells (EpSC), at least in humans (Barthel et al., 2005). 
Furthermore, their surprisingly diverse differentiation potential has also contributed to a 
significant recent interest in adult skin stem cells (Toma et al., 2005). Permanently residing 
EpSC in mammalian skin are able to differentiate into multiple lineages and have been 
reported in the epidermis (Broeckx et al., 2014), hair follicle (Braun et al., 2003) as well as 
dermis (Toma et al., 2001).  
Like stem cells from other tissues, epidermal EpSC play a central role in tissue homeostasis 
and wound repair, but also represent a major target of tumor initiation and gene therapy 
(Lavaker and Sun, 2000). These EpSC can differentiate into interfollicular epidermis, hair 
follicles and sebaceous glands (Niemann and Watt, 2002). The extensive regenerative 
capacities of the epidermis is due to the presence of EpSC that continuously produce 
keratinocytes, which further undergo terminal differentiation towards a keratinized layer and 
provide the skin’s barrier properties in mammals (Chen et al., 2009). Furthermore, the 
epidermis contains a population of stem cells with apparently different levels of maturity 
(Terskikh and Vasil’ev, 2001). This heterogeneous population displays subpopulations of a 
different morphology than its more differentiated progeny at the homing site (Staniszewska et 
al., 2011). Interestingly, the bulge of the hair follicle is a major repository of skin keratinocyte 
stem cells and the latter have been regarded as the ultimate EpSC (Costarelis et al., 1999; 
Lavker and Sun, 2000; Taylor et al., 2000; Braun et al., 2003). However, it should be 
emphasized that lineage tracing in vivo demonstrated the existence of interfollicular stem cells 
(Ito et al., 2005; Langton et al., 2008) and indicated that epidermal and hair follicle stem cells 
represent distinct populations (Ito et al., 2005).  
Stem cells are being isolated from different tissues, have been evaluated in numerous human 
clinical trials and are since recently commercially used in veterinary medicine to treat horses 
and dogs (Hoynowski et al., 2007). However, purification of stem cells is technically difficult 
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because of their scarcity in the tissue of origin and the lack of universal morphologic traits for 
stem cells (Blau et al., 2001). Many of the methods developed for the isolation and analysis of 
specific cell types cannot be used for medical experimentation on living materials because of 
the damaging nature of these techniques, such as isotope radiation and cell fixation (Yano et 
al., 2005). For isolation of EpSC, in vitro methods describe the use of (i) colony forming 
culture to localize multipotent stem cells in the hair follicle bulge region (Rochat et al., 
1994a), (ii) Hoechst exclusion technique to isolate a side population in the hair follicles 
(Rochat et al., 1994b), (iii) cell sorting using CD71 and α6-integrin expression markers for 
harvesting keratinocyte stem cells (Li et al., 2004) and (v) sphere formation (Broeckx et al., 
2014).  
Once skin-derived precursor cells differentiate, they lose typical stem cell properties and their 
survival in suspension is substantially reduced (Ruetz et al., 2013). In the mammary gland, 
another ectodermal organ, so-called mammospheres are also intensively studied for 
stem/progenitor cell purification purposes (Dontu et al., 2003; Spaas et al., 2012). 
Unfortunately, a major disadvantage of this 3-D technique is contamination with other adult 
cell types surviving between the sphere-forming stem cells (Dontu et al., 2003). Moreover, no 
reports are available concerning sphere forming capacities of skin-derived EpSC and their 
differentiated progeny during long-term serial passaging. Furthermore, only limited 
information is available concerning cell impurities in skin-derived sphere cultures. For all 
these reasons, this study was designed to extend the existing knowledge of EpSC purification 
through sphere formation in different culture circumstances.  
5.2 Materials and methods 
Donor animals and skin harvesting 
Six healthy French trotter mares with an age between 5 and 7 years and in good general health 
condition (no clinical or hematological signs of infections) were used for skin sample 
collection. The isolation and characterization of skin-derived EpSC was performed as 
previously described (Dontu et al., 2003; Broeckx et al., 2014) with some minor 
modifications. Briefly, horses were sedated with an intravenous injection of detomidine 
hydrochloride (0.01mg/kg, Medesedan®, VIRBAC, Belgium) and the analgesic butorphanol 
(0.01mg/kg, Dolorex®, Intervet, Belgium). After surgical preparation (clipping, scrubbing 
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and disinfecting) and local anesthesia of the neck region with 4% Procaine-Adrenalin, one full 
thickness skin sample of about 2cm2 was excised.  Samples were kept in transport medium 
consisting of Hank’s balanced salt solution (HBSS, Gibco) with 2% of penicillin-
streptomycin-amfotericine B (P/S/A, Sigma-Aldrich). The experimental procedure was 
approved by the ethical committee of Global Stem Cell Technology (EC_2012_002,  
EC_2013_003 and EC_2014_001) and the Faculty of Veterinary Medicine, Ghent University 
(EC_2014_020). 
Isolation and culture of skin-derived epithelial-like stem cells 
In the laboratory, the samples were maintained at 4°C overnight in 0.25% trypsin-
ethylenediaminetetraacetic acid (EDTA) (Gibco) solution with the hair side down. 
Afterwards, the epidermis was mechanically disconnected from the dermis by deep scraping 
using sterile scalpel and forceps on a sterile petri dish. Subsequently, a second enzymatic 
dissociation step with 1% collagenase III (Worthington Biochemical Corporation) at 37° C for 
60 minutes was performed in order to remove epidermal cells. The suspension was poured 
through a 40µm filter (BD Falcon) in a 50ml tube containing 2ml of fetal bovine serum (FBS, 
Gibco) to inactivate the collagenase III and washed by centrifugation at 300G for 8 minutes at 
room temperature. The pellets were re-suspended in epithelial-like stem cell (EpSC) medium, 
consisting of Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Gibco), 20% FBS, 2% 
P/S/A, 20 ng/ml human recombinant-basic fibroblast growth factor (hr-bFGF) and 20 ng/mL 
epidermal growth factor (EGF) (all from Sigma-Aldrich). The suspension was then filtered 
again and cells were counted using Trypan blue staining (1:1 dilution). Subsequently, the cells 
were cultured on ultralow attachment plates to induce sphere formation. After 7 days of 
suspension culture, spheres were centrifuged and seeded on adhesive tissue culture flasks for 
further characterization.  
Sphere formation assay  
From the cells harvested by the procedure above, an average of  (0.4±0.2)x105 cells/cm² were 
planted per well of an ultralow attachment 6-well plate for all 6 skin samples (Corning, 
Elscolab) in EpSC medium to induce primary spheres. The spheres were counted at day 4 and 
7 and the medium was refreshed by means of centrifugation at 300G for 8 min at both time 
points. Sphere forming efficiency was calculated by dividing the average number of spheres 
counted in a well by the number of cells planted and multiplied by 100 to express as a 
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percentage. After the first sphere cycle (7 day culture on ultralow attachment plates), all 
spheres were collected and planted onto adherent tissue culture flasks in EpSC medium. Upon 
80% confluency, the adherent cells were trypsinized with 0.25% trypsin-EDTA and cultured 
in fresh medium from passage 1 (P1) to P10. At P4 and P10 cells were seeded in duplicate at a 
clonal density of 100cells/cm2 on 6-well ultralow attachment plates to initiate a second and 
third sphere cycle for all 6 skin samples, respectively. The second and third sphere cycle were 
performed in both EpSC and differentiation medium. Differentiation medium consisted of 
DMEM/F12 (Gibco), 20% FBS (Gibco), 5µg/ml insulin, 1µg/ml hydrocortisone and 0.1mM 
beta-mercaptoethanol (all from Sigma-Aldrich). The medium was refreshed every two days 
and the following parameters were recorded in 10 fields on day 1, 4 and 7 post-seeding: 
number of cell units/field (a separate cell or a sphere is counted as 1 cell unit at each time 
point), number of spheres/field and number of cells/sphere (all at 200x magnification). 
Purification of EpSC  
For purification of an impure EpSC culture, adherent cells from P10 of this culture and a pure 
culture as a positive control were cultured in suspension on 6-well ultralow attachment plates 
at different densities: 1 cell/cm² (=10 cells/6-well), 10 cells/cm² (=100 cells/6-well) and 100 
cells/cm² (=1000 cells/6-well) using EpSC medium. The experiment was performed three 
times in triplicate for each seeding density and the number of spheres and number of 
cells/sphere were compared on day 1, 4 and 7 post-seeding with a pure culture. On day 7, the 
spheres were centrifuged and reseeded on adherent tissue culture plates and grown for 7 days 
to assess morphological differences and perform IHC. 
Population doubling time (PDT) 
After culturing the spheres in adherent tissue culture flasks, EpSC were trypsinized at 80% 
confluency using 0.25% trypsin-EDTA. Cells were counted using trypan blue staining and 
subcultured at 1x104/cm² until P10. The proliferation rate was quantified using the population 
doubling time (PDT), which was calculated for each passage from P1 to P10 as previously 
described by Martinello et al. (2010) and Spaas et al. (2013), using the formula: 
T/[Log(Nf/Ni)/Log2], where T is the time in days, Nf the final number of cells and Ni the 
initial number of cells. 
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Flow cytometry assay 
A flow cytometric technique was used to characterize sphere-derived cells for the expression 
of major histocompatibility complex (MHC) I and MHC II.  Adherent cells from P4 and P10 
were first detached using 0.25% trypsin-EDTA (Gibco) and frozen at 400,000 cells per vial 
using 10% DMSO (Sigma) as a cryoprotectant (for analysis of the different time points at the 
same time). Per series, 400,000 cells were thawed and labeled with the following primary 
antibodies: mouse anti-horse MHC class I IgG2a (Washington State University, 1:50) and 
mouse anti-horse MHC class II IgG1 (Abd Serotec, 1:50). Cells were incubated with the 
primary antibodies for 15 minutes on ice in the dark and washed twice in washing buffer, 
consisting of DMEM with 1% bovine serum albumin (BSA). Rabbit anti-mouse-FITC (Dako, 
1:40) antibodies were used to identify positive cells after 15 minutes of incubation on ice in 
the dark. Finally, all cells were washed three times in washing buffer and at least 10,000 cells 
were evaluated using the FACSCanto™ flow cytometer (Becton Dickinson). All analyses 
were based on (i) autofluorescence and (ii) control cells incubated with isotype-specific IgG’s, 
in order to establish the background signal. All isotypes were matched to the immunoglobulin 
subtype and used at the same protein concentration as the corresponding antibodies. To 
evaluate cell viability the cell impermeable DNA dye propidium iodide (Sigma-Aldrich, 
1µg/ml) was added just before measurement. 
Induction of differentiation 
Differentiation of the isolated cells towards keratinocytes was induced using a distinct 
differentiation protocol for EpSC developed by Broeckx et al. (2014). Briefly, adherent cells 
from P4 and P10 were trypsinized using 0.25% trypsin-EDTA and EpSC were seeded into 24-
well plates at a density of 2.5x103 per cm². The cells were induced in differentiation medium 
for 7 days and the medium was refreshed every 2 days. In parallel to this, EpSC were also 
cultured in similar plates at the same density using EpSC medium as a control.  
Immunohistochemistry (IHC) 
To identify whether the skin-derived cells expressed previously reported EpSC markers 
(Broeckx et al., 2014) and to qualitatively assess the success of keratinocyte differentiation 
and EpSC purification, IHC at P4, P10 and P11 was performed. Adherent cells were washed 
with HBSS, fixed for 10 minutes with 4% paraformaldehyde and permeabilized for 2 minutes 
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with 0.1% Triton X, both at room temperature. Cells were then incubated with hydrogen 
peroxide for 5 minutes followed by washing with HBSS before incubation for 2 hours at room 
temperature with the following primary mouse IgG1 monoclonal antibodies: anti-human 
cytokeratin 14 (CK 14) (Abcam, clone LL002, 1:50) and anti-human Pan CK (Dako, clone, 
AE1/AE3, 1:50) and the following rabbit antibodies: anti-human Wide CK (Abcam, 1:50) and 
anti-human IgG Ab casein kinase 2β (CK-2β) (Abcam, clone EP1995Y, 1:50). After washing 
with HBSS, secondary ready to use either goat anti-mouse or anti-rabbit peroxidase (PO)-
linked antibodies (Dako) -depending on the primary antibody used- were added and incubated 
for 30 minutes at room temperature. Finally, 3, 3’-diaminobenzidine (DAB) was added for 2-
10 minutes and a counter staining with hematoxylin was performed to visualize the 
surrounding cells. Identical staining performed on undifferentiated EpSC was used as a 
control for the differentiation experiment and background staining was assessed by using the 
proper isotype-specific IgG’s. All isotypes were matched to the immunoglobulin subtype and 
used at the same protein concentration as the corresponding antibodies. The staining was then 
observed using an inverted light microscope and pictures were taken using a digital 
microscope camera. 
Statistical analysis  
The statistical analysis for the sphere formation assay and the population doubling time was 
based on the mixed model with horse as random effect and medium, time, sphere cycle and 
the two-way interactions as fixed effects. For testing the difference in sphere forming 
efficiency between a pure and impure EpSC isolate, a fixed effects model was fitted with the 
number of seeded cells (10, 100 and 1000), isolate (pure vs impure) and their interaction as 
fixed effects factors. SAS Version 9.3 was used for the analyses (SAS/STAT Software, 
Version 9.3, SAS Institute Inc.). The relationship between the number of cell units/field and 
the number of spheres/field was determined by the Pearson correlation coefficient. Values are 
given as mean ± standard error and a global significance level of 5% was used.  
5.3 Results 
Isolation and culture of skin-derived epithelial-like stem cells 
Presumed EpSC were isolated from all 6 equine skin samples following mechanical and 
enzymatic digestion. First, the isolated primary skin-derived epithelial cell suspensions were 
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grown in non-adherent (spherical) culture conditions for stem cell purification. Secondly, 
these spheres were further expanded in adhesive culture circumstances. The impurities 
detected in one of the six horses were thirdly effectively purified as reported in detail in the 
“Purification of EpSC” section.  
The first and thus very small “spheres” consisting of on average 2 cells/sphere were observed 
in all cultures as early as 1day post seeding. With time the size of these initial spheres 
significantly increased at all passages as illustrated in Figure 5.1. At P0 other cell structures 
such as floating fragments, keratinocytes and melanocytes were visible and no adherent cells 
could be noticed in all suspension cultures (Figure 5.1). Upon subsequent seeding on adherent 
tissue culture flasks, the cells in the spheres dispersed and reached 70-80% confluence at 
approximately 4-5 days post-seeding. Moreover, trypsinization and reseeding from adherent 
plates on ultralow attachment plates resulted in the formation of subsequent generations of 
spheres (Figure 5.1).  
Sphere formation assay 
To test the self-renewal capacity of the presumed EpSC, the sphere-initiating capacity of 
serially passaged cells cultured as spheres was assessed (Figures 5.1 and 5.2). A similar assay 
has been previously used for the characterization of human mammospheres (Dontu et al., 
2003). An average sphere-forming efficiency of 0.53 + 0.28% (means + SD, n=6; Table 5.1) 
was recorded from the primary skin-derived epithelial cells seeded on the non-adherent plates 
at an average density of 0.4x105 cells/cm².  
Sphere formation was successful at P4 (second sphere cycle) and P10 (third sphere cycle) from 
seeding 100 cells/cm² (Figure 5.1), which indicated that these cultured cells were capable of 
self-renewal, proliferation and clonal expansion in suspension. The number of cell units/field 
increased over time in EpSC medium, but decreased over time in the differentiation medium 
(P < 0.0001). By day 7, a significantly (P < 0.0001) higher number of cell units/field was 
observed in EpSC medium versus differentiation medium (Figure 5.2A). Regardless the 
medium used, the number of cell units/field was significantly (P < 0.0001) higher at the 
second cycle (P4) than at the third cycle (P10) (Figure 5.2A). The number of cells/sphere 
significantly increased from day 4 to day 7 post-seeding (P < 0.0001) and with sphere cycle 
(P < 0.0001 and Figure 5.2B), and the increase was larger in the third cycle (P < 0.0001). 
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Figure 5.1 Sphere formation in epithelial stem cell (EpSC) and differentiation medium at different 
passages cultured on ultralow attachment plates for 7 days. Primary spheres in EpSC medium at Passage 
(P) 0, second cycle sphere formation in EpSC and differentiation medium at P4 and third cycle sphere 
formation in both media at P10. The picture indicates the increase in number of cells/sphere over time 
(200x magnification, scale bar = 50µm). 
 
Regarding the number of spheres/field on both day 4 and day 7, this parameter was 
significantly higher in EpSC than in differentiation medium (P = 0.008, P < 0.0001, 
respectively and Figure 5.2C). A strong correlation (R2 = 0.9) between the number of cell 
units/field and of the number of spheres/field existed in both media. However, unlike the 
number of cell units/field, the number of spheres/field was not significantly affected by sphere 
cycle (P = 0.203, data not shown). Overall, these data indicated that presumed EpSC clonally 
expanded in suspension, however, they experienced difficulties in sphere formation when 
going into the differentiation process.   
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Figure 5.2 Epithelial-like stem cell (EpSC) proliferation assays. Sphere generating cells from adherent 
culture of passage 4 and 10 were cultured in suspension at a density of 100cells/cm² in ultralow attachment 
plates using EpSC and differentiation medium to generate 2nd (P4) and 3rd (P10) cycle of spheres. 
Number of units/field (A), number of cells/sphere (B) and number of spheres/field (C) were counted per 
200x magnification field and compared between both media.  
 
Table 5.1 Sphere forming efficiency (SFE) from the primary skin-derived epithelial cells planted on non-
adherent plates. The SFE (in %) was calculated by dividing the average number of spheres counted per 
well by the seeded cells multiplied by 100.  
 
Horse number Seeding density No. of spheres SFE (%) 
1 0.15 x 106 1089.17 0.73 
2 0.75 x 106 968.15 0.13 
3 0.54 x 106 2299.36 0.43 
4 0.35 x 106 1452.23 0.42 
5 0.26 x 106 2420.38 0.95 
6 0.45 x 106 2299.36 0.51 
Average 0.42 x 106 1754.78 0.53 
Standard deviation 0.21 x 106 661.74 0.28 
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Population doubling time of EpSC 
The population doubling time (PDT) of isolated skin-derived epithelial cells from fresh 
adherent cultures (i.e. not cryopreserved) was used as an indicator of self-renewal and 
proliferation potential and was calculated from P1 up to P10 (Table 5.2). Our results indicate 
that there was no statistically significant (P = 0.319) difference in the population doubling 
time of the different passages. The PDT in the adherent cultures for all the passages was 
positive and varied between 0.89 + 0.13 days and 1.39 + 0.35 days (means + SD, n = 6; Table 
5.2).   
Immunophenotyping of the isolated and differentiated cells 
Flow cytometric analysis was performed to immunophenotypically characterize the isolated 
skin-derived epithelial cells and to evaluate their expression of typical immunological proteins 
over time and after differentiation towards keratinocytes. Compared to the relevant isotype 
controls, most of the presumed EpSC and differentiated cells expressed MHC I concomitant 
with only a limited number of cells expressing MHC II at P4 as well as at P10 (Figure 5.3). No 
significant differences in number of cells expressing MHC I and II could be noticed between 
the two cell types at different time points (Figure 5.3). 
Table 5.2 Population doubling time (PDT) in days of 6 adherent EpSC cultures calculated from passage 
(P) 1 to 10. 
 
Horse P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 
1 1.28 0.68 1.11 1.19 1.12 1.24 1.11 1.01 2.02 0.70 
2 0.93 0.99 1.20 1.17 1.30 1.48 1.48 1.30 1.50 0.94 
3 1.12 1.03 1.02 1.11 1.11 1.12 1.38 1.16 1.31 1.04 
4 1.14 0.78 1.09 1.08 1.14 1.13 1.23 1.03 1.14 0.90 
5 1.51 0.96 1.01 0.97 1.20 1.04 1.25 1.08 1.04 0.87 
6 1.10 0.88 1.22 1.12 1.27 1.13 1.38 1.13 1.31 0.92 
Average 1.18 0.89 1.11 1.11 1.19 1.19 1.31 1.12 1.39 0.89 
STD 0.20 0.13 0.09 0.08 0.08 0.15 0.13 0.10 0.35 0.11 
STD = standard deviation 
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Figure 5.3 Immunophenotypic characterization of skin-derived epithelial-like stem cells (EpSC) at passage 
(P) 4 and 10. Flow cytometery was performed to assess the number of undifferentiated EpSC and 
differentiated cells (Diff) expressing major histocompatibility complex (MHC) I and MHC II. The 
histograms show relative number of live cells versus fluorescence intensity with isotype control staining 
(light gray) and marker antibody staining (dark). Data represent the mean percentage of six samples + 
standard deviation. 
Immunohistochemistry of EpSC and cells differentiated towards keratinocytes 
The immunophenotypic characterization of sphere-derived cells and their differentiation 
potential was evaluated using immunohistochemistry analysis. Accordingly, the isolated 
undifferentiated skin-derived epithelial cells, which were used as control for the 
differentiation experiments, were negative for typical keratinocyte markers, namely Pan CK 
and Wide CK (Papini et al., 2003) while staining  positive for the epithelial markers Casein 
kinase 2β (Deshiere et al., 2013) and CK 14 (Figure 5.4). Differentiated cells on the other 
hand, were positive for all three cytokeratines tested i.e. CK 14, Pan CK and Wide CK as well 
as for the epithelial marker Casein kinase 2β. No positive staining cells were detected in the 
undifferentiated as well as differentiated cell culture upon relevant isotype control staining. 
Morphologically, the undifferentiated cells were elongated or typically spindle-shaped, 
whereas the differentiated cells were more stretched, stellate-shaped and formed cobblestone-
like cells (Figure 5.4).  
 
 
Chapter 5   
149 
 
Purification of EpSC  
Cellular contamination was detected in one out of the six skin samples. The impurity was 
detected at P4 on adherent plates and remained present over time (Figure 5.5). Both the 
average number of spheres/well and cells/sphere from seeding at clonal densities i.e.at 10 
cells/6-well and 100 cells/6-well increased from day 4 to day 7 post-planting in pure and 
impure cultures (Figure 6A and B). However, compared to pure EpSC, the sphere forming 
efficiencies were significantly lower (P = 0.0012) in impure cultures (Figure 5.6C). In marked 
contrast to the ultralow seeding densities, higher seeding densities (i.e.at 1000 cells/6-well) 
resulted in unsuccessful purification (Figure 5.7B) and a decrease in the number of spheres 
over time (data not shown), yet with an increase in sphere size (Figure 5.6D). The 
keratinocyte impurity was confirmed by IHC as shown in Figure 7A based on positive 
expression of a panel of selected appropriate markers as described (CK 14, Pan CK, Wide CK 
and Casein kinase 2).  During the process of purification by planting at different clonal 
densities, the impurity was still detected in several wells derived from the 1000 cells/6-well 
purification (Figure 5.7B). A successful purification of the cell culture was achieved by 
planting at a density of 10 cells/cm² (Figure 5.7C) and 1 cell/cm² (Figure 5.7D). This was 
confirmed by the spindle shaped cell morphology and negative expression of Pan CK and 
Wide CK. 
5.4 Discussion 
Being the body's largest organ, skin has been extensively used to study adult/somatic stem 
cells (Li et al., 2013). In particular, it has been suggested as the main source of epithelial-like 
stem cells (EpSC) (Grandi et al., 2012; Staniszewska et al., 2011). Besides the presence of 
somatic stem cells in hair follicles and dermis, the epidermis also contains a compartment of 
stem cells (Broeckx et al., 2014; Terskikh and Vasil’ev, 2001) which are of different maturity 
levels. However, there is no common criterion that allows to recognize individual stem cells 
with confidence (Terskikh and Vasil’ev, 2001). In a human skin study, it was identified that 
the latter stem cells are firmly adherent to the basal lamina and account for 10% of the cells in 
the basal layer at the dermal-epidermal junction (Papini et al., 2003). So far EpSC have been 
obtained either by dedifferentiating adult epidermal cells (Li et al., 2004; Zhao et al., 2012), 
or by inducing pluripotent stem cells (Li et al., 2012), or by their direct harvest from the 
epidermis (Yang et al., 2007; Broeckx et al., 2014). Isolation of sphere-forming skin-derived  
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Figure 5.4 Differentiation of epithelial-like stem cells (EpSC) into keratinocytes at passage (P) 4 and 10. 
Immunohistochemistry was performed on adherent undifferentiated and differentiated cells using 
markers including, CK14, Pan CK, Wide CK and casein kinase 2. Relevant isotype controls were also 
included. After Hematoxylin counterstaining, pictures were taken using a digital microscope camera, at 
400x magnification. Arrows indicate positive staining and bars represent 50µm. 
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Figure 5.5 Morphology of adherent keratinocyte impurities (colonies of cobblestone shaped cells) in the 
epithelial-like stem (EpSC) isolate at passage (P) 4 and 10. 
 
Figure 5.6 Sphere forming assay for purification of the impure samples (1000 cells seeded) in comparison 
to a pure isolate (10 cells and 100 cells seeded). Average number of spheres/well from planting 10 cells/6-
well and 100 cells/6-well (A), average number of cells/sphere from planting of 10 and 100 cells/6-well (B), 
sphere forming efficiency in percentage of cells that were able to form a sphere (C) and average number 
of cells/sphere from planting of 1000 cells/6-well (D) were compared between pure and impure epithelial-
like stem cells (EpSC). Systematic counts were done at 200x magnification. Data represent the average 
values of 3 wells per experiment + standard deviation.  
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Figure 5.7 Immunohistochemistry of adherent epithelial-like stem cells (EpSC) with keratinocyte impurity 
(A) before purification, keratinocyte detected in two of the 100 cells/cm² purification (B),  purified EpSC 
derived from seeding 10 EpSC/cm² (C) and from  1 cell/cm² (D). Pictures in rows show Isotype control and 
markers used as CK 14, Pan CK, Wide CK and Casein kinase 2β. Arrows indicate positive reaction in the 
cytoplasm at 400x magnification. Scale bars represent 50µm. 
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epithelial cells from suspension culture has been described already in 1986 (Soule and 
McGrath, 1986). Such a suspension commonly consists of stem cells and their transit-
amplifying progeny (Pastrana et al., 2011). A potential disadvantage of this isolation 
technique is the likely contamination with other cell types due to adult cells surviving 
between the sphere-forming stem cells (Dontu et al., 2003). So far, sphere formation was 
successful both from bulk skin tissue-derived cell suspension (Toma et al., 2001) and from 
culture of epidermis-derived cells at a clonal density (Broeckx et al., 2014) on ultralow 
attachment plates.  
In the current study, skin was harvested from six horses and an average sphere-forming 
efficiency of 0.53 ± 0.28% of these seeded cells was demonstrated. As is the case for primary 
mammary cells (Dontu et al., 2003), most of the primary skin-derived epithelial cells died in 
suspension culture. It has to be mentioned, that although the starting material from all donors 
had the same size, the initial cell seeding density varied 0.21 x106 cells between donors and 
might have caused a variation in sphere forming efficiency at the first cycle. In agreement 
with our results, it has been described that 0.4% of the seeded mammary cells were able to 
form mammospheres in humans (Dontu et al., 2003) a percentage which was higher in horses 
ranging from 0.8 to 3.2% depending on the lactation stage (Spaas et al., 2012). Moreover, 
subsequent generations of spheres could be generated from P4 and P10 with a relatively 
constant sphere-forming efficiency of almost all purified cells (data not shown). This finding 
corroborates a previous study (Broeckx et al., 2014) and is indicative for the fact that each 
sphere contained approximately one sphere-initiating cell. Thus, the self-renewal and clonal 
expansion capacities of the isolated cells being main characteristics of stem cells, was clearly 
demonstrated (Pastrana et al., 2011). Visual examination of suspension culture revealed that, 
although spheres could also grow in the differentiation medium, their number was 
significantly lower compared to that observed in the EpSC medium during both second and 
third sphere cycles. This clearly indicated an overall lower cell survival of the more 
differentiated EpSC progeny or of the undifferentiated EpSC in differentiation medium. 
Based on the first hypothesis, this difference could be attributed to the fact that once skin-
derived precursor cells are differentiated, they lose the typical stem cell properties and their 
survival in suspension is substantially reduced (Ruetz et al., 2013). The strong correlation 
between the numbers of cell units/field and of spheres/field was an indicator that most of the 
skin-derived purified EpSC resulted in sphere formation. Additionally, the number of 
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cells/sphere increased from day 4 to day 7 post seeding which indicated that clonal expansion 
of cells within the sphere occurred up to P10.  
Cellular contamination was noticed in one of the six horse skin isolates. Cell contamination is 
usually difficult to detect, and consequently is a potentially major culture problem than the 
problems caused by other types of biological contamination (Fogh et al., 1971). In the present 
study, cellular impurities were clearly visible microscopically based on morphology and on 
IHC staining for keratinocytes. This contamination could be noticed from P4 on and the level 
of impurity increased during passaging. Nevertheless, it has been reported that serial 
passaging would rather eliminate more committed progenitors and select for self-renewing 
stem cells (Pastrana et al., 2011). For that reason, cells were seeded at ultralow clonal 
densities varying from 1 cell to 100 cells per cm2 on 6-well ultralow attachment plates 
followed by adherent culture. Here, IHC staining demonstrated that only the lowest densities 
allowed EpSC to survive and removed the cellular impurities from culture. Although the 
purification in the present study consisted of cells from only one donor, the experiment was 
performed three times (in triplicate for each time point) and generated consistent results. 
Nevertheless, future studies should confirm the reported purification technique in different 
isolates with different degrees of impurities.  
Another key finding of the present study pertains to the immunophenotypic characterization 
of EpSC by flow cytometry. Expression of Major Histocompatibility Complex (MHC) I and 
MCH II was evaluated on equine EpSC and their differentiated progeny. These data showed 
that most EpSC and differentiated cells expressed MHC I and only a few cells expressed 
MHC II. This result is in contrast with a previous report using equine EpSC (Broeckx et al., 
2014), where only few cells expressed MCH I. It has to be mentioned though, that in the 
present study only live cells were gated, because a rather high death rate was present during 
measurement, whereas in the previous study all cells were measured including the dead ones. 
Nevertheless, the high number of cells expressing MHC I in this study is also in contrast with 
a previous study on differentiated keratinocytes, where a low number of cells expressing this 
marker was reported in a sub-population of basal human keratinocytes (Matic et al., 2005). It 
is known that the rejection response to grafted tissues/cells is caused by cell surface molecules 
that induce antigenic stimulus. MHC molecules are one of the families within the highly 
heterogeneous group of transplantation antigens that have been described so far (Ayala et al., 
2012). While MHC I antigens are present on all nucleated cells and are involved in antigen 
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presenting activities (King et al., 2000), MHC II are expressed on activated B-lymphocytes, 
macrophages, dendritic cells and epithelial cells (Klein et al., 2000) and involved in graft 
rejection (Natarajan et al., 2002). Therefore, the low number of undifferentiated as well as 
differentiated EpSC expressing MHC II suggest that these cells might be attractive candidate 
cells for allogenic transplantation in horses. Nevertheless, future studies will have to confirm 
this statement and should focus on the relative expression levels (per cell) of these and other 
immunomodulating molecules as well. 
In conclusion, the present study reports sphere formation as a valuable tool to purify stem 
cells in skin cell cultures upon isolation and after serial passaging. Further research should 
focus on the optimization and validation of this purification strategy of stem cells cultured 
from skin as well as from other tissues. 
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Abstract 
Several studies report beneficial effects of stem cells on wound healing, however, to date no 
comparison between autologous versus allogenic epithelial-like stem cells (EpSC) has been 
made in a large animal wound induction model. Therefore, 12 full-thickness skin wounds 
were created in six horses. Each group was subjected to: (i) autologous EpSC, (ii) allogenic 
EpSC, (iii) vehicle treatment or (iv) untreated control. Double-blinded macroscopic and 
histological evaluation of wound healing was performed at week 1, 2 and 5 through biopsies.  
In contrast with depth and volume, the circumference and surface of autologous EpSC-treated 
wounds were significantly smaller than vehicle treated wounds. Compared to vehicle 
treatment, a significantly lower amount of total granulation tissue was observed after 
autologous and allogenic EpSC treatment.  
Together, these results suggest that wounds treated with autologous EpSC heal significantly 
faster, but the observed differences in wound healing parameters were rather small, indicating 
a limited clinical relevance in the used model.  
Key words: Epidermis; Stem Cells; Wound; Autologous; Allogenic 
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6.1 Introduction 
The skin is the largest organ in mammalian vertebrates and plays a key role in several life-
preserving processes. Loss of skin integrity and function may therefore induce dysfunction or 
even death (Theoret, 2009a). For superficial wounds, the endogenous healing mechanisms in 
combination with traditional wound care should be sufficient to achieve functional repair. 
However, in larger, more complex wounds impaired wound healing can occur and result in 
fibrosis and scar formation (Reinke and Sorg, 2012). Such scar tissue is weaker than intact 
skin due to a disorganized extracellular matrix (Gurtner et al., 2008; Soo et al., 2003). Since it 
has been reported in different animal species that fetal wounds have the ability to heal without 
scar formation and with complete restitution of the skin architecture (Goss, 1977; Hallock, 
1985; Hallock et al., 1987; Soo et al., 2003), the scientific community has been focusing on 
regenerative strategies for many years.  
Most of the research on harvesting and characterizing adult equine MSC use bone marrow 
(Berg et al., 2009; Ranera et al., 2012; Violini et al., 2009), adipose tissue, peripheral blood 
(Martinello et al., 2010b; Spaas et al., 2013d) or umbilical cord (blood) (Cremonesi et al., 
2008b; Koch et al., 2007). Conversely, ongoing regeneration of the skin is achieved through 
differentiation of stem cells within the epidermis and the hair follicle. Currently, these skin 
stem cells have been isolated from dermis (McKenzie et al., 2006; Shim et al., 2013; Toma et 
al., 2005), hair follicles (Yu et al., 2006) and epidermis from humans, mice and horses 
(Broeckx et al., 2014d; Fujimori et al., 2009; Nowak and Fuchs, 2009). Beneficial effects of 
mesenchymal stem cells (MSC) for skin wound healing in laboratory animals have been 
described by several groups (Akela et al., 2012a; Borena et al., 2014; Borena et al., 2010). 
MSC also improved the healing capacity of persistent leg wounds in human diabetic patients 
(Jain et al., 2011b) and demonstrated enhanced wound closure, collagen synthesis, cellular 
proliferation and angiogenesis in dogs (Kim et al., 2013a). In horses, it has been recently 
reported that a combination of equine epithelial-like stem cells (EpSC) and platelet-rich 
plasma (PRP) significantly restricted granulation tissue and increased the vascularisation in 
comparison to PRP control wounds within the same horse (Broeckx et al., 2014d). Other 
authors described reconstruction of goat skin with hair formation and cellular repopulation 
using adult EpSC (Yang et al., 2007).  
Chapter 6 
165 
 
Both the EpSC harvesting and culture expansion are time consuming processes usually taking 
more than 3 weeks, thus excluding autologous EpSC treatment of wounds during the acute 
inflammatory peak. Therefore, allogenic EpSC treatment using cells obtained from a fully 
characterized master cell bank from only a few donors would substantially standardize the 
treatment modality. In this regard, it has been reported that MSC are immune-privileged 
(Bartholomew et al., 2002; Beyth et al., 2005; Carrade et al., 2014), allowing allogenic 
transplantations in horses (Broeckx et al., 2014a; Broeckx et al., 2014b; Broeckx et al., 2014c; 
Carrade et al., 2011a; Carrade et al., 2011b; Guest et al., 2008). Since both humans and horses 
are the only mammals reported to develop excessive granulation tissue during natural wound 
healing (i.e. keloid versus hypergranulation tissue), the horse can be considered as a robust 
animal model for evaluating novel therapies for human applications (Theoret et al., 2013).  
The aim of this study was to comparatively evaluate autologous and allogenic EpSC treatment 
in experimentally induced wounds in horses. Both macroscopic and histologic evaluation of 
relevant regenerative parameters at different time points were performed.  
6.2 Materials and methods  
Experimental horses and isolation of skin-derived epithelial-like stem cells 
The experimental procedure was approved by the ethical committee of Global Stem cell 
Technology (EC_2012_002,  EC_2013_003 and EC_2014_001) and the Faculty of Veterinary 
Medicine, Ghent University (EC_2014_020). Six healthy French trotter mares aged between 5 
and 7 years and in good general health condition were included in this study. Twelve weeks 
before the start of the experimental wound model, a 1 cm2 skin sample was retrieved from the 
neck region of each horse for isolation of epithelial-like stem cells (EpSC) as previously 
described (Borena et al., 2014). In the laboratory, the samples were processed and stem cells 
were characterized as previously reported (Borena et al., 2014; Broeckx et al., 2014d).  
Equine cutaneous wound model 
The horses were sedated with Detomidine (0.04 mg/kg IV; Medesedan®), and pain relief was 
established by administering Butorphanol (0.1 mg/kg IV; Dolorex®). Thereafter, a local 
subcutaneous anesthesia was administered with Procaine 4% plus adrenalin. In each horse, 
twelve full-thickness square shaped wounds (four groups of three wounds) were created in the 
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gluteus region. The wounds measured 2 cm by 3 cm and were at least 2 cm apart from each 
other (Figure 6.1). The day on which the wounds were created was designated as day 0 (T0). 
The removed skin was fixed in 10% buffered formalin and stored for subsequent 
histopathologic analysis. 
 
Figure 6.1 The dorsal area of the gluteus region was surgically prepared to induce 12 wounds per horse to 
cover 4 treatment groups (?) which were biopsied at 3 time points: week 1, 2 and 5. 
Topical and subcutaneous epithelial-like stem cell treatment and control groups 
Each group of three wounds was randomly assigned to one of the four treatments: (i) 
autologous EpSC treatment, (ii) allogenic EpSC treatment of a randomly chosen donor within 
the same group of horses (three recipients received EpSC from one and the same donor and 
the other three from one other donor), (iii) DMEM as a vehicle control and (iv) untreated 
controls. Twenty minutes after wound induction, when hemostasis was obtained, 4x106 cells 
(in 2 ml DMEM) were injected subcutaneously in the wound margins and 4x106 cells (in 1 ml 
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DMEM) were applied topically in the wound for the autologous and allogenic treatment. Two 
out of the six horses received half the doses in both the autologous and allogenic treated 
group, because the obtained number of cells for autologous treatment in these horses was 
insufficient. In the vehicle control wounds 2 ml DMEM was injected subcutaneously and 1 ml 
DMEM was applied topically. The remaining group of wounds was left untreated to monitor 
the normal healing process. Fresh wounds were covered with a sterile plastic foil (Oper 
Film©), which was replaced after the second topical application of EpSC in the stem cell 
treated or DMEM in the vehicle treated wounds at day 1. From day 3 onwards, a local non-
adherent dressing (Zorbopad) was used to cover the wounds and was changed at each 
macroscopic evaluation until day 16, after which no more wound protection was used. The 
horses did not receive any other medication and their general condition and wound covers 
were monitored daily.  
Macroscopic wound evaluation  
At days 0, 1, 3, 7, 14, 21, 28 and 35 a macroscopic evaluation and measurement of the wound 
dimensions were performed for those wounds that were not biopsied. 
Before each macroscopic evaluation, crusts (if present) were carefully removed and the 
adjacent skin was cleansed with a sterile 0.9% saline solution, in order to enhance visibility of 
the wound boundaries. Next, a subjective macroscopic evaluation of the wounds for presence 
of (exuberant) granulation tissue and signs of infection was performed. Subsequently, the 
wound dimensions were measured with a laser beam camera (SilhouetteStar, ARANZ 
Medical Ltd., Christchurch, New Zealand). The camera was held perpendicular to the wound 
surface, with the three laser lines projected by the camera crossing in a star shape and the ends 
of the lines lying on the adjacent skin. The central focus point of the star was positioned at or 
near the centre of the wound. Image analysis with the accompanying software 
(SilhouetteConnect, ARANZ Medical Ltd., Christchurch, New Zealand) was then used to 
calculate the circumference, surface, maximum depth and volume of the wounds. All 
measurements were made by the same assessor.  
Skin biopsy and histological analysis 
At 1, 2 and 5 weeks after treatment, the horses were sedated with a combination of 
Detomidine (0.04 mg/kg IV; Medesedan®), and Butorphanol (0.1 mg/kg IV; Dolorex®), and 
a local subcutaneous anesthesia was administered with Procaine 4% without adrenaline. One 
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wound per group was sacrificed. For each wound three punch biopsies were taken: one central 
(8mm) and two at the wound edges (8 and 3mm). The 3mm tissue samples were liquid frozen 
for future PCR analysis. The 8mm tissue samples were fixed in neutral buffered 10% 
formalin, embedded in paraffin, sectioned at 4 µm thickness and stained with Hematoxylin & 
Eosin according to standard protocols. All samples were blindly analyzed by an ECVP 
certified pathologist (SM) using a modified scoring system, as previously reported (Broeckx 
et al., 2014d).   
Briefly, the epidermis was scored for thickness, crust formation, dermo-epidermal separation 
and completeness of re-epithelization. The dermis was evaluated using following parameters: 
amount and morphology of dermal stroma, edema, thickness and morphology of the total 
granulation tissue and young granulation tissue and relative difference with the original 
thickness (= total granulation tissue/ dermal granulation thickness of removed intact skin x 
100). The skin removed when creating the wounds at T0 was used as positive control sample 
to compare the aforementioned parameters wherever applicable. All measurements were 
performed with a computer-based program (LAS V4.1, Leica Microsystems). 
Statistical analysis 
The statistical analysis for continuous measurements was based on the mixed model with 
horse as random effect and time, treatment and their interaction as categorical fixed effects. 
Histological scores were analyzed based on a mixed logistic regression model with horse as 
random effect and treatment as categorical fixed effect. SAS Version 9.3 was used for the 
analyses (SAS/STAT Software, Version 9.3, SAS Institute Inc.). A global significance level 
of 5% was used and Tukey’s adjustment technique was used for multiple comparisons with 
adjusted P-values reported.   
6.3 Results 
Harvesting of skin-derived epithelial-like stem cell  
Skin-derived cells were able to form spheres, multiply in adhesion and possessed all 
properties to be immunophenotyped as EpSC as previously described (Borena et al., 2014; 
Broeckx et al., 2014d). 
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Wound induction model 
In 5 out of 6 horses wounds could be induced in a standing position as reported in the 
materials and methods section (Figure 6.1). For safety reasons, one horse had to be positioned 
in lateral decubitus and the topical treatments were compromised. This horse was therefore 
excluded from the study. Daily inspection of all horses showed no signs of either clinical 
discomfort or fever.  
Macroscopic analyses of the wound healing process 
All measured macroscopic wound healing parameters significantly decreased over time (P < 
0.0001). Significant differences between treatments were observed for wound circumference 
(P < 0.0001), surface (P = 0.0283) and depth (P = 0.0100). The circumference of autologous 
EpSC-treated wounds was significantly smaller in comparison to vehicle treatment (P = 
0.0060) and untreated controls (P < 0.0001, Figure 6.2A). Compared to untreated controls, 
allogenic EpSC-treated wounds also displayed a smaller but not significantly different (P = 
0.0549) circumference. Also a significantly smaller surface was noticed in autologous EpSC-
treated wounds in comparison to vehicle treatment (P = 0.0284, Figure 6.2B). The untreated 
control wounds were deeper than autologous (P = 0.0720) and allogenic (P = 0.0919) EpSC-
treated wounds, however, statistical significance was only observed in comparison with 
vehicle treatment (P = 0.0077, Figure 6.2C). No significant treatment effect (P = 0.3198) 
could be observed for the volume (Figure 6.2D). Although in only 2 of the autologous (n=18) 
and 1 of the allogenic EpSC-treated (n=18) wounds hypergranulation tissue was noticed in 
comparison to 6 in vehicle treated group (n=18) and 4 in the untreated control group (n=18), 
no significant difference (P = 0.2035) could be demonstrated between the different treatment 
groups. 
Histological analysis of the skin biopsies 
No significant differences in the scores for epidermal thickness, crust formation, dermo-
epidermal separation and completeness of re-epithelization could be observed between the 4 
treatment groups. Epithelialization was completed in almost all wounds at 5 weeks after 
wound induction.  
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Figure 6.2. A laser camera measured the reduction in wound circumference (A), surface (B), depth (C) 
and volume (D) of all wounds over time (in days) in comparison to day 0.  
Also for the parameters edema, collagen amount and morphology, fibroblast maturation and 
granulation tissue morphology, no considerable differences could be noticed between the 4 
treatment groups. In contrast, total granulation thickness significantly increased over time (P 
< 0.0001) with a significant treatment effect (P = 0.0047). A significantly lower amount of 
total granulation tissue was observed in the autologous (4000 µm, P = 0.0077) and allogenic 
EpSC-treated wounds (4147 µm, P = 0.0199) compared to the vehicle treated group (5404 
µm) but not compared to the untreated control (4843µm). There was also a significant 
treatment effect (P = 0.0105) on the formation of young granulation tissue, yet without a 
significant difference over time (P = 0.1269). Significantly less young granulation tissue was 
found in the autologous (1594µm, P = 0.0121) and allogenic (1746µm, P = 0.0371) EpSC-
treated wounds in comparison with the vehicle treated group (2729µm) but not in comparison 
with the untreated control (2190µm). Comparing the formed granulation tissue thickness with 
the original dermal thickness, a significant treatment effect (P = 0.0189) and time effect (P < 
0.0001) was observed. The autologous (86.5%, P = 0.0171) but not the allogenic (92.2%, P = 
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0.0662) EpSC-treated wounds were significantly closer to the original normal skin thickness 
as compared to the vehicle treated wounds (118.5%) whereas no significant differences were 
found for the untreated control (101.8%). Five weeks after wound induction, the untreated 
wounds scored considerably better than the vehicle treated wounds and approached the 
allogenic treatment in terms of total granulation tissue formation and difference to original 
thickness.  
6.4 Discussion 
To date, several independent studies in different animal species reported beneficial effects of 
autologous and allogenic bone marrow-derived (stem) cell treatments on skin wound healing 
(Akela et al., 2012a; Borena et al., 2010; Jain et al., 2011b; Kim et al., 2013a). However, so 
far only one study described the clinical use of lineage committed skin-derived stem cells in 
an allogenic set-up in one patient (Broeckx et al., 2014d). The goal of this study was therefore 
to explore this treatment further in a large group of horses and compare wound treatment with 
allogenic EpSC’s to autologous EpSC’s, vehicle treatment and a negative control. Relevant 
macroscopic and histologic parameters were evaluated at different time points after wound 
induction.  
Standardized wound size measurements revealed a significant decrease in circumference, 
surface, depth and volume of all wounds over time for all treatment groups. Because the time 
effect was more pronounced than the treatment effect, the graphs of different treatments were 
closely approaching (Figure 6.2). Nevertheless, a statistically significant treatment effect 
could be noticed for wound circumference, surface and depth. In our hands, autologous 
EpSC-treated wounds displayed the smallest circumference and surface and allogenic EpSC 
did not significantly enhance any macroscopic wound healing parameter in comparison to 
both control groups. The largest and deepest wounds were found in the untreated controls. 
Although not significant, less formation of hypergranulation tissue was macroscopically 
noticed in both EpSC-treated groups compared to vehicle treatment. The non-significant 
difference (P = 0.7514) between allogenic EpSC-treated and vehicle treated wounds for all 
evaluated macroscopic parameters is in contrast with a previous equine study where a 
statistically significant improvement in manually measured wound circumference (referred to 
as “wound filling”) was noticed after treatment with allogenic EpSC in combination with 
platelet-rich plasma (PRP) compared to PRP treatment alone (Broeckx et al., 2014d). In this 
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regard, it might be postulated that PRP addition would have stimulated the pro-angiogenic 
effect of EpSC after platelet degranulation, as reported in epithelial cancer cell lines (Egan et 
al., 2011). Although others also observed macroscopic wound healing enhancement after both 
autologous (Jain et al., 2011b; Spaas et al., 2013a) and allogenic cell treatments (Auxenfans et 
al., 2014; Leigh et al., 1987), it has to be mentioned that the latter studies used visual clinical 
assessment, whereas our results are based on a more objective device, a 3D-laser camera. 
Nevertheless, further research is warranted to fully unravel the efficacy of allogenic cell 
therapies as a regenerative strategy for enhancing wound healing. 
In our study, total granulation thickness significantly increased over time (P < 0.0001), 
whereas young granulation tissue did not significantly alter over time (P = 0.4226). In 
addition, an overall significant decrease in total granulation thickness (more than 1000 µm) 
could be noticed in both EpSC treatment groups in comparison to control groups. This is in 
accordance with the histological data of a previous equine study where allogenic EpSC/PRP-
treated wounds contained approximately 1300 µm less granulation tissue than PRP-treated 
wounds at 30 days after treatment (Broeckx et al., 2014d). Moreover, this study demonstrated 
a significant overall decrease of young granulation tissue in both allogenic and autologous 
treated wounds compared to vehicle treated wounds. Furthermore, the dermal thickness was 
considerably closer to the intact skin after autologous (P = 0.0144) and allogenic EpSC 
treatment (P = 0.0501) compared to the vehicle treatment. Since horses easily develop 
excessive granulation tissue during natural wound healing (hypergranulation tissue) (Theoret 
et al., 2013), the reduction in young granulation tissue and enhanced dermis normalization are 
promising findings. However, in our study, the untreated wounds scored considerably better 
than the vehicle treated wounds and approached the allogenic treatment concerning the total 
granulation tissue and comparison to original dermal thickness at 5 weeks after wound 
induction. Whether EpSC counteract possible negative effects caused by vehicle treatment 
remains to be proven.  
Two horses in the present study received a dose of 0.67x106 EpSC/cm² (=4x106/6cm² total 
wound surface), which was half the dose of the other horses (1.33x106 EpSC/cm²). One of the 
low-dose horses was omitted from the study due to peroperative complications. Therefore, a 
comparison of the clinical efficacy of a low or high dose is hardly possible. This is in 
agreement with  a previous study in dogs where no significant differences were noticed in 
wound healing parameters after using doses ranging from 0.01 to 1x106 MSC/0.28cm² and the 
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cell number also decreased at day 14 (Kim et al., 2013a). In contrast, a human study reported 
that at least 1x106 MSC/cm² were needed in order to obtain the required therapeutic effect in 
diabetic foot ulcer healing (Falanga, 2005a). This might be explained by the fact that diabetic 
microangiopathy might cause a lower response to pro-angiogenic effects of EpSC, which has 
been reported to be one of the healing mechanisms induced by EpSC (Broeckx et al., 2014d). 
Nevertheless, all the aforementioned strongly suggest that stem cells exert a paracrine effect, 
as reported by others (Wu et al., 2010a), and their modus operandi is probably not affected by 
the dose of cells above a certain minimum. Comparable to the observed effect of EpSC in our 
study, the use of growth factors has also demonstrated to increase vascularization and several 
other wound healing parameters in mouse models (Chen et al., 2008a; Galiano et al., 2004). 
Whether growth factors are an equal substitute for stem cells, remains to be determined.  
Conclusion 
In conclusion, these results suggest that wounds treated with autologous EpSC heal 
significantly faster, but the observed differences in wound healing parameters were rather 
small, indicating a limited clinical relevance in the used model. 
6.5 References 
Akela, A., Nandi, S.K., Banerjee, D., Das, P., Roy, S., Joardar, S.N., Mandal, M., Das, 
P.K.,and Pradhan, N.R. (2012). Evaluation of autologous bone marrow in wound healing in 
animal model: a possible application of autologous stem cells. Int Wound J 9, 505-516. 
Auxenfans, C., Shipkov, H., Bach, C., Catherine, Z., Lacroix, P., Bertin-Maghit, M., Damour, 
O., and Braye, F. (2014). Cultured allogenic keratinocytes for extensive burns: a retrospective 
study over 15 years. Burns 40, 82-88. 
Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., 
Devine, S., Ucker, D., Deans, R., Moseley, A., and Hoffman, R. (2002). Mesenchymal stem 
cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp 
Hematol 30, 42-48. 
Chapter 6 
174 
 
Berg, L., Koch, T., Heerkens, T., Bessonov, K., Thomsen, P., and Betts, D. (2009). 
Chondrogenic potential of mesenchymal stromal cells derived from equine bone marrow and 
umbilical cord blood. Vet Comp Orthop Traumatol 22, 363-370. 
Beyth, S., Borovsky, Z., Mevorach, D., Liebergall, M., Gazit, Z., Aslan, H., Galun, E.,and 
Rachmilewitz, J. (2005). Human mesenchymal stem cells alter antigen-presenting cell 
maturation and induce T-cell unresponsiveness. Blood 105, 2214-2219. 
Borena, B.M., Meyer, E., Chiers, K., Martens, A., Demeyere, K., Broeckx, S.Y., Duchateau, 
L., and Spaas, J.H. (2014). Sphere-Forming Capacity as an Enrichment Strategy for 
Epithelial-Like Stem Cells from Equine Skin. Cell Physiol Biochem 34, 1291-1303. 
Borena, B.M., Pawde, A.M., Amarpal, Aithal, H.P., Kinjavdekar, P., Singh, R., and Kumar, 
D. (2010). Evaluation of autologous bone marrow-derived nucleated cells for healing of full-
thickness skin wounds in rabbits. Int Wound J 7, 249-260. 
Broeckx, S., Borena, B.M., Zimmerman, M., Marien, T., Seys, B., Suls, M., Duchateau, 
L.,and Spaas, J.H. (2014a). Intravenous Application of Allogenic Peripheral Blood-Derived 
Mesenchymal Stem Cells: a Safety Assessment in 291 Equine Recipients. Curr Stem Cell Res 
Ther 9, 452-457. 
Broeckx, S., Suls, M., Beerts, C., Vandenberghe, A., Seys, B., Wuertz-Kozak, K., Duchateau, 
L., and Spaas, J.H. (2014b). Allogenic Mesenchymal Stem Cells as a Treatment for Equine 
Degenerative Joint Disease: a Pilot Study. Curr Stem Cell Res The 9, 497-503. 
Broeckx, S., Zimmerman, M., Crocetti, S., Suls, M., Marien, T., Ferguson, S.J., Chiers, K., 
Duchateau, L., Franco-Obregon, A., Wuertz, K., and Spaas, J.H. (2014c). Regenerative 
therapies for equine degenerative joint disease: a preliminary study. PloS one 9, e85917. 
Broeckx, S.Y., Maes, S., Martinello, T., Aerts, D., Chiers, K., Marien, T., Patruno, M., 
Franco-Obregon, A., and Spaas, J.H. (2014d). Equine epidermis: a source of epithelial-like 
stem/progenitor cells with in vitro and in vivo regenerative capacities. Stem Cells Dev 23, 
1134-1148. 
Carrade, D.D., Affolter, V.K., Outerbridge, C.A., Watson, J.L., Galuppo, L.D., Buerchler, S., 
Kumar, V., Walker, N.J., and Borjesson, D.L. (2011a). Intradermal injections of equine 
Chapter 6 
175 
 
allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit 
immediate or delayed hypersensitivity reactions. Cytotherapy 13, 1180-1192. 
Carrade, D.D., Owens, S.D., Galuppo, L.D., Vidal, M.A., Ferraro, G.L., Librach, F., 
Buerchler, S., Friedman, M.S., Walker, N.J., and Borjesson, D.L. (2011b). Clinicopathologic 
findings following intra-articular injection of autologous and allogeneic placentally derived 
equine mesenchymal stem cells in horses. Cytotherapy 13, 419-430. 
Carrade, D.D., Wood, J.A., Granick, J.L., Walker, N.J., Clark, K.C., and Borjesson, D.L. 
(2014). Equine mesenchymal stem cells inhibit T cell proliferation through different 
mechanisms depending on tissue source. Stem Cells Dev 23, 1258-1265. 
Chen, L., Tredget, E.E., Wu, P.Y., and Wu, Y. (2008). Paracrine factors of mesenchymal stem 
cells recruit macrophages and endothelial lineage cells and enhance wound healing. PloS one 
3, e1886. 
Cremonesi, F., Violini, S., Lange Consiglio, A., Ramelli, P., Ranzenigo, G., and Mariani, P. 
(2008). Isolation, in vitro culture and characterization of foal umbilical cord stem cells at 
birth. Vet Res Commun 32 Suppl 1, S139-142. 
Egan, K., Crowley, D., Smyth, P., O'Toole, S., Spillane, C., Martin, C., Gallagher, M., 
Canney, A., Norris, L., Conlon, N., McEvoy, L., Ffrench, B., Stordal, B., Keegan, H., Finn, 
S., McEneaney, V., Laios, A., Ducree, J., Dunne, E., Smith, L., Berndt, M., Sheils, O., Kenny, 
D., and O'Leary, J. (2011). Platelet adhesion and degranulation induce pro-survival and pro-
angiogenic signalling in ovarian cancer cells. PLoS One 6, e26125. 
Falanga, V. (2005). Wound healing and its impairment in the diabetic foot. Lancet 366, 1736-
1743. 
Fujimori, Y., Izumi, K., Feinberg, S.E.,and  Marcelo, C.L. (2009). Isolation of small-sized 
human epidermal progenitor/stem cells by Gravity Assisted Cell Sorting (GACS). J Dermatol 
Sci 56, 181-187. 
Galiano, R.D., Tepper, O.M., Pelo, C.R., Bhatt, K.A., Callaghan, M., Bastidas, N., Bunting, 
S., Steinmetz, H.G., and Gurtner, G.C. (2004). Topical vascular endothelial growth factor 
Chapter 6 
176 
 
accelerates diabetic wound healing through increased angiogenesis and by mobilizing and 
recruiting bone marrow-derived cells. Am J Pathol 164, 1935-1947. 
Goss, A.N. (1977). Intra-uterine healing of fetal rat oral mucosal, skin and cartilage wounds. J 
Oral Pathol 6, 35-43. 
Guest, D.J., Smith, M.R., and Allen, W.R. (2008). Monitoring the fate of autologous and 
allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of 
horses: preliminary study. Equine Vet J 40, 178-181. 
Gurtner, G.C., Werner, S., Barrandon, Y., and Longaker, M.T. (2008). Wound repair and 
regeneration. Nature 453, 314-321. 
Hallock, G.G. (1985). In utero cleft lip repair in A/J mice. Plastic Reconstr Surg 75, 785-790. 
Hallock, G.G., Rice, D.C., and McClure, H.M. (1987). In utero lip repair in the rhesus 
monkey: an update. Plastic Reconstr Surg 80, 855-858. 
Jain, P., Perakath, B., Jesudason, M.R., and Nayak, S. (2011). The effect of autologous bone 
marrow-derived cells on healing chronic lower extremity wounds: results of a randomized 
controlled study. OstomywWound Manage 57, 38-44. 
Kim, J.W., Lee, J.H., Lyoo, Y.S., Jung, D.I., and Park, H.M. (2013). The effects of topical 
mesenchymal stem cell transplantation in canine experimental cutaneous wounds. Vet 
Dermatol 24, 242-e253. 
Koch, T.G., Heerkens, T., Thomsen, P.D., and Betts, D.H. (2007). Isolation of mesenchymal 
stem cells from equine umbilical cord blood. BMC Biotechnol 7, 26. 
Leigh, I.M., Purkis, P.E., Navsaria, H.A., and Phillips, T.J. (1987). Treatment of chronic 
venous ulcers with sheets of cultured allogenic keratinocytes. Br J Dermatol 117, 591-597. 
Martinello, T., Bronzini, I., Maccatrozzo, L., Iacopetti, I., Sampaolesi, M., Mascarello, F., and 
Patruno, M. (2010). Cryopreservation does not affect the stem characteristics of multipotent 
cells isolated from equine peripheral blood. Tissue Eng Part C Methods 16, 771-781. 
Chapter 6 
177 
 
McKenzie, I.A., Biernaskie, J., Toma, J.G., Midha, R., and Miller, F.D. (2006). Skin-derived 
precursors generate myelinating Schwann cells for the injured and dysmyelinated nervous 
system. J Neurosci 26, 6651-6660. 
Nowak, J.A., and Fuchs, E. (2009). Isolation and culture of epithelial stem cells. Methods Mol 
Biol 482, 215-232. 
Ranera, B., Remacha, A.R., Alvarez-Arguedas, S., Romero, A., Vazquez, F.J., Zaragoza, P., 
Martin-Burriel, I., and Rodellar, C. (2012). Effect of hypoxia on equine mesenchymal stem 
cells derived from bone marrow and adipose tissue. BMC Vet Res 8, 142. 
Reinke, J.M., and Sorg, H. (2012). Wound repair and regeneration. Eur Surg Res 49, 35-43. 
Shim, J.H., Lee, T.R., and Shin, D.W. (2013). Enrichment and characterization of human 
dermal stem/progenitor cells by intracellular granularity. Stem Cells Dev 22, 1264-1274. 
Soo, C., Beanes, S.R., Hu, F.Y., Zhang, X., Dang, C., Chang, G., Wang, Y., Nishimura, I., 
Freymiller, E., Longaker, M.T., Lorenz, H.P., and Ting, K. (2003). Ontogenetic transition in 
fetal wound transforming growth factor-beta regulation correlates with collagen organization. 
Am J Pathol 163, 2459-2476. 
Spaas, J.H., Broeckx, S., Van de Walle, G.R., and Polettini, M. (2013a). The effects of equine 
peripheral blood stem cells on cutaneous wound healing: a clinical evaluation in four horses. 
Clin Exp Dermatol 38, 280-284. 
Spaas, J.H., Schauwer, C.D., Cornillie, P., Meyer, E., Soom, A.V., and Van de Walle, G.R. 
(2013b). Culture and characterisation of equine peripheral blood mesenchymal stromal cells. 
Vet J 195, 107-113. 
Theoret, C. (2009). Tissue engineering in wound repair: the three "R"s--repair, replace, 
regenerate. Vet Surg 38, 905-913. 
Theoret, C.L., Olutoye, O.O., Parnell, L.K., and Hicks, J. (2013). Equine exuberant 
granulation tissue and human keloids: a comparative histopathologic study. Vet Surg 42, 783-
789. 
Chapter 6 
178 
 
Toma, J.G., McKenzie, I.A., Bagli, D., and Miller, F.D. (2005). Isolation and characterization 
of multipotent skin-derived precursors from human skin. Stem Cells 23, 727-737. 
Violini, S., Ramelli, P., Pisani, L.F., Gorni, C., and Mariani, P. (2009). Horse bone marrow 
mesenchymal stem cells express embryo stem cell markers and show the ability for tenogenic 
differentiation by in vitro exposure to BMP-12. BMC Cell Biol 10, 29. 
Wu, Y., Zhao, R.C., and Tredget, E.E. (2010). Concise review: bone marrow-derived 
stem/progenitor cells in cutaneous repair and regeneration. Stem cells 28, 905-915. 
Yang, X., Qu, L., Wang, X., Zhao, M., Li, W., Hua, J., Shi, M., Moldovan, N., Wang, H., and 
Dou, Z. (2007). Plasticity of epidermal adult stem cells derived from adult goat ear skin. Mol 
Reprod Dev 74, 386-396. 
Yu, H., Fang, D., Kumar, S.M., Li, L., Nguyen, T.K., Acs, G., Herlyn, M., and Xu, X. (2006). 
Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J 
Pathol 168, 1879-1888. 
 
  
 
 
 
 
CHAPTER 7 
 
 
General Discussion
  
 
Chapter 7   
181 
 
7.1 Overview 
The present thesis describes the isolation of bone marrow-derived nuclear cells (BMNC) in 
rabbits and skin-derived epithelial-like stem cells (EpSC) in horses. In adult mammals, 
BMNC can be obtained from bone marrow (BM) aspirate while EpSC are obtained from skin 
biopsies. Both isolates contain adult stem cells, which preferentially generate differentiated 
cells of the same lineage as the tissue of origin, but also have the capacity to transdifferentiate 
into cell types different from their lineage due to their plasticity (Jopling et al., 2011; Sasaki et 
al., 2008; Toma et al., 2001). Although BMNC are derived from the mesodermal germ layer 
(Woodbury et al., 2002),  it has been demonstrated that besides the resident skin cells, BMNC 
also contribute to skin healing in physiological and pathological conditions (Higashiyama et 
al., 2011). Since BM contains hematopoietic (HSC) and mesenchymal stem cells (MSC), long 
term reconstitution of the healed dermis and collagen type I and III  production could be 
supported by both stem cell populations (Fathke et al., 2004). Moreover, BMNC such as MSC 
have the ability to regulate the immune response and inflammation and possess powerful 
tissue protective and reparative mechanisms (Abbas and Mahalingam, 2009; Chen et al., 
2008; Kim et al., 2013). On the other hand, skin-derived EpSC originate from the ectodermal 
germ layer and are physiologically designed to regenerate local skin defects (Grapin-Botton 
and Melton, 2000). For all these reasons, both cell types possess a potential for enhancing 
wound regeneration in mammals. Different aspects of the use of these two cell types in stem 
cell based therapy are discussed in the following subsections. 
7.2 In vitro studies  
7.2.1 BMNC harvesting  
BM cells have demonstrated the broadest differentiation potential among adult somatic cell 
populations and are therefore one of the most promising cell sources for clinical applications 
(Krause et al., 2001; Poulsom et al., 2002). BM has been used by different researchers either 
as a source of autologous BMNC or BM-MSC after isolation and characterization. The 
contribution of autologous BMNC to cutaneous wound healing in experimental wounds in 
rabbit (Akela et al., 2012; Akela et al., 2013) and clinical cases particularly for chronic 
wounds in human have been reported in many studies (Badiavas and Falanga, 2003; Dabiri et 
al., 2013; Jain et al., 2011). Although the BM-derived cells described in the present thesis 
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have not been further characterized, quantitative and qualitative enhanced healing effects 
could be demonstrated after clinical application in skin wounds in rabbits.  
There are different techniques for concentrating and/or isolating MSC from BM aspirate. 
Separation methods that include immune-magnetic beads or flow cytometry generate BM-
MSC with higher purity, however, the expense, procedural complications and cell damages 
that occur during cell processing restrict their usage (Zhang et al., 2014). Routinely, the 
mononuclear cell (MNC) fraction containing MSC is being isolated using a Ficoll density 
gradient separation method (Beeres et al., 2007; Van Tongeren et al., 2008). After isolation, 
the MSC can be multiplied to obtain high cell numbers, but this comes at a high cost. 
Omission of such expansion step would dramatically lower the cost and facilitate the use of 
MSC for clinical cases where such facilities are not available (Dozza et al., 2014). Moreover, 
it is also difficult for clinicians to utilize cultured BM-MSC for the purpose of wound healing 
due to issues regarding the health authorities that consider the product as an advanced therapy 
medicinal product (ATMP) which requires cleanroom circumstances and good manufacturing 
production (GMP) guidelines from the moment cell culture techniques are involved. 
Moreover, human ATMP require authorization by the European Medicines Agency (EMA) 
for clinical application in Europe or Food and Drug Administration (FDA) covering the USA. 
In addition, rigorous and expensive quality tests are a requirement from both agencies before 
batches of cells are allowed to be released for clinical application. On the other hand, 
uncultered BM aspirates, such as the BMNC fraction as reported in the present thesis, are 
considered as a one-step surgical procedure and do not require the aforementioned tests. This 
has a substantial implication on the costs, feasibility and time frame in which the product is 
being prepared. On the other hand, BM aspiration requires a certain expertise and uncultured 
cells are less uniform than cultured MSC produced under GMP conditions. Further research 
should definitely focus on the comparison between cultured or purified cells and unpurified 
BMNC or BM-MNC and demonstrate is superior for which applications. 
7.2.2 EpSC harvesting   
For our research, EpSC were isolated from 1 cm2 full thickness skin biopsies collected from 6 
horses. Mechanical deep scraping of the epidermis followed by enzymatic digestion and serial 
centrifugations in combination with filter processes were employed to harvest epithelial cells 
from the equine skin. An average of 0.4 x 106 cells were obtained after this procedure, yet 
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with a standard deviation of 0.2 x 106 cells, indicating a large variation in initial cell number. 
This might influence the efficacy of the purification protocol and should be further 
investigated in future studies. The cells were subsequently cultured in suspension on ultralow 
attachment plates for 7 days to induce primary sphere formation. Sphere formation was 
successful in all the samples with only two medium changes. So far, the isolation of sphere 
forming stem cells have been successfully performed from bulk skin tissue cultured on 
adherent plates (Toma et al., 2001) or  from epidermal-derived cells seeded at a clonal density 
on ultralow attachment plates (Broeckx et al., 2014). In the latter experiment, 1 cm2 full 
thickness skin biopsies were used and EpSC were harvested by peeling the epidermis from the 
dermis followed by enzymatic digestion. Both studies reported no impurities in their cultures, 
so the fact that more material was used at the start in the present thesis might have been at the 
origin of the impurity in one culture. Nevertheless, more protracted studies should confirm 
this hypothesis. 
It has been found that stem cells in mammalian skin are firmly adherent to the basal lamina 
and account for 10% of the cells in the basal layer at the dermo-epidermal junction (Blanpain 
et al., 2007; Papini et al., 2003). Thus, separation of this skin layer from the underlying 
dermis might avoid contamination by a large number of unwanted non-epithelial cells. 
Therefore, manual detachment of the epidermis from the dermis by using a sterile forceps 
(Ruetze et al., 2013), peeling (Broeckx et al., 2014) or deep scraping technique (Borena et al., 
2014) followed by enzymatic digestion could be other alternatives for isolating EpSC. There 
has been an assumption that ultralow attachment culture conditions purify EpSC, since only 
these cells have the ability to clonally expand in suspension (a stem cell-specific property) 
(Ruetze et al., 2013), thereby substantially reducing the survival of differentiated cell clusters. 
However, in the present thesis it has been demonstrated that if impurities initially exist, they 
can still survive and proliferate within the clonally expanding EpSC seeded at high density of 
100 cells/cm2 or more. In this regard, the present thesis reports that a seeding density of 10 
cells/cm2 or less on ultralow attachment plates is necessary to purify cellular impurities in 
EpSC cultures after harvesting equine skin cells. Nevertheless, further studies are required to 
demonstrate whether this technique is suitable for stem cell purification of other origins and 
sources and whether 10 cells/cm² is sufficient in those cases as well.  
Even though the existence of adult stem cells has been demonstrated in many tissues, their 
unexpected plasticity and potential in cell based therapy have created a lot of excitement 
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(Weissman, 2000). Nevertheless, the functional and phenotypic characterization of these cells 
is not completely addressed to date. Failure to characterize the isolated cells might result in 
contamination with other cell lines which might cause unexpected or even unsatisfactory 
results in stem cells studies. In contrast with MSC, where the International Society for 
Cellular Therapy (Dominici et al., 2006) have set clear criteria, no guidelines and minimal 
standards have been set for equine EpSC so far, which makes the comparison of different 
studies difficult. Therefore, this thesis focused on expanding the existing knowledge of 
functional characterization of EpSC through sphere formation in different culture 
circumstances and seeding at ultralow clonal densities on ultralow attachment plates. 
Functional characterization 
Different methods have been investigated to study the fate, self-renewal and differentiation 
potential of EpSC (Blanpain and Fuchs, 2014). The first functional demonstration of EpSC 
was made when methods were identified to culture human epidermal keratinocytes under 
conditions where they could be maintained and propagated for hundreds of generations 
without losing stem cell properties (Rheinwald and Green, 1975). Besides immunophenotypic 
properties, the following functional characteristics of the isolated cells were assessed in the 
present thesis: (i) proliferation potential, (ii) self-renewal rate as spheres and (iii) 
differentiation capacity into keratinocytes. 
(i) Proliferation potential 
Population doubling time (PDT) experiments were performed to determine the cell 
proliferation potential and rate of EpSC under adherent culture conditions (Eslaminejad et al., 
2010) using 6 samples from different horses. Adherent EpSC from all 6 samples were found 
to have the capacity to proliferate consistently over the 10 passages studied as indicated by 
PDT values that varied between 0.89 and 1.37 days. The overall average PDT was 1.14 + 0.16 
and there were no considerable differences in the PDT at different passages. Indeed, the PDT 
remained relatively constant with passaging, indicating a stable proliferation capacity of the 
cells in culture over time. This is in agreement with a previous study where the PDT varied 
between 0.78 and 1.16 for multiple passages of 3 skin samples from the same species 
(Broeckx et al., 2014). Also for equine peripheral blood-derived MSC (PB-MSC) a rather 
consistent PDT has been reported (Spaas et al., 2013). This is in contrast with another report 
concerning equine PB-MSC where an increased PDT (in hours, hr) could be noticed with 
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increasing passage number: P1 ~ 30.57 + 1.3; P4~ 40.37 + 2.5 and P8~ 47.35 + 4.3 
(Martinello et al., 2010). Other studies considering equine MSC also recorded a similar PDT 
(days) as reported in the present thesis of 1.24 (+  0.28) for umbilical cord blood-derived 
MSC (UCB-MSC) and 1.64 (+ 0.69)  for umbilical cord matrix-derived MSC (UCM-MSC) 
(De Schauwer et al., 2014). In general, the PDT of MSC from different sources was slightly 
higher than the PDT of EpSC as described in this thesis and reported by Broeckx (Broeckx et 
al., 2014). Nevertheless, the PDT of EpSC was considerably higher than reported for rbBM-
MSC (6.4 + 1.3 hr) and hBM-MSC (7.6 + 1.7 hr) (Tan et al., 2013). Since the latter PDTs 
relate to rabbit and human MSC, a difference in animal species is expected to be at the origin 
of the noticed discrepancy. 
It has to be mentioned though, that a study in humans demonstrated that the doubling time of 
cultivated hBM-MSC was age dependent (Altaner et al., 2013). The hBM-MSC from old 
donors had an average doubling time of 56.3 hr, which was considerably higher than their 
younger counterparts (48.7 hr). In addition, there was a great individual variation in the values 
of cell doubling time, reflecting an influence of other physiological parameters, such as life 
style and co-morbidity (Altaner et al., 2013). From these findings it can be concluded that 
more research is warranted before any conclusion can be drawn concerning the causes of a 
difference in PDT and whether this is related to the stem cell type or not. Nevertheless, the 
consistent and rather rapid proliferation of the EpSC in the present thesis corresponds with 
one of the major criteria of stem cells, being a high proliferative potential (Roh and Lyle, 
2006). 
(ii) Sphere cell-renewal rate 
Sphere forming assays are being used in stem cell biology  for assessing the self-renewal and 
differentiation capacity at a single cell level (Pastrana et al., 2011). Stem cells from diverse 
tissues are typically cultured under adherent conditions, but can also be maintained as spheres 
under non-adherent conditions (Pastrana et al., 2011). In the present thesis, sphere formation 
capacity was used as a tool for isolating, enriching and purifying EpSC from equine skin 
biopsies. Sphere formation was successful from all 6 biopsies and an average of 0.53% of the 
± 0.4x106 seeded cells were able to form a sphere (sphere forming efficiency or SFE). The 
SFE recorded in this thesis was in agreement with the 0.4% reported for human 
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mammospheres (Dontu et al., 2003) and a bit lower than the 0.8 - 3.2% (depending on the 
lactation stage) described in equine mammospheres  (Spaas et al., 2012). 
The sphere formation assay has been proposed as a functional assay for uniquely detecting 
stem cells in vivo and as a valuable in vitro assay to study stem cells during different 
physiological phases (Spaas et al., 2012). However, spheres do not only consist of stem cells, 
but also of a mixture of progenitor cells, their progeny and non-stem progenitor cells 
(Broeckx et al., 2014; Pastrana et al., 2011; Stingl, 2009). In line with this finding, an 
assessment of the sphere formation capacity and subsequent growth of pure EpSC in 
maintenance versus differentiation medium in the present thesis resulted in significantly less 
number of spheres during differentiation. However, the sphere formation assay still evaluates 
the potential of cells to behave as stem cells when removed from their original in vivo niche 
(Pastrana et al., 2011). Moreover, the subsequent generation of spheres in the present thesis, 
demonstrated a relatively constant SFE, a strong correlation between the number of cell 
units/field and spheres/field and an increase in the number of cells/sphere over time. The 
aforementioned properties clearly confirm self-renewal and clonal expansion capacities of the 
isolated cells which are main functional characteristics of stem cells (Blanpain et al., 2007; 
Moore and Lemischka, 2006; Nadig, 2009).  
Contamination or impurity of cell culture is a common problem and sometimes ends up with 
serious consequences (Stacey, 2011). Contaminations in the cell culture can be classified as 
chemical contaminants and biological contaminants such as bacteria, mycoplasma yeast, 
molds, viruses and contamination by other cell lines (Lincoln and Gabridge, 1998). Cell line 
contamination is usually difficult to detect and a potentially more serious culture problem than  
biological contamination (Fogh et al., 1971). Cellular impurities may result in invalid research 
outcomes (Stacey, 2000). Therefore, regular checking of cellular morphology and growth 
characteristics during subsequent passages and comparison with the reference cell/sample 
might assist in early detection of impurities (Dirks et al., 2010).  
(iii) Keratinocyte differentiation capacity 
There have been several studies demonstrating that skin adult stem cells show a surprisingly 
diverse differentiation repertoire (Toma et al., 2005). Differentiation of rodent skin derived 
precursors (SKP) into both neural and mesodermal cell types, including neurons, glia, smooth 
muscle cells, and adipocytes has been reported (Toma et al., 2001). Furthermore, human scar 
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tissue-derived stem cells (hSTSC) differentiated into neurogenic progenitor cells (Yang et al., 
2010) and bilineage differentiation of equine EpSC towards two major skin cell types, 
keratinocytes and adipocytes, has been demonstrated (Broeckx et al., 2014). In our 
experiment we have successfully differentiated equine EpSC into keratinocytes in adherent 
culture conditions. Although IHC was performed more rapidly (7 days) in the present thesis 
than in the report by Broeckx et al. (10 days), this does not allow to conclude that the 
differentiation process was completed earlier in our study. Differentiated cells (i.e. 
keratinocytes) were detected visually based on their cobblestone-like shaped morphology and 
IHC confirmed that the cells became positive for Pan cytokeratin (CK), Wide CK, CK14 and 
Casein kinase 2β. It should be mentioned though, that the typical keratinocyte morphology 
was not reached yet after 7 days of differentiation, whereas this was the case after 15 days of 
differentiation (data not shown). Based on both criteria, it has been concluded that induction 
towards keratinocytes was successful. Further research should focus on differentiating EpSC 
towards multiple cell types. In order to assess the plasticity of the EpSC, differentiation 
towards cell types of another germ layer would be an interesting addition to the currently 
available data. In vitro differentiation capacity towards keratinocytes does not implicate, 
however, in vivo keratinocyte reconstitution. Further studies should confirm whether or not 
EpSC have the capacity to actually regenerate functional keratinocytes in vivo. 
Immunophenotypic characterization  
It has been suggested that phenotypic characterization using stem cell markers will provide 
novel insights to better understand stem cell biology and behavior (Abbas and Mahalingam, 
2009). Therefore, in addition to uncovering EpSC from equine skin based on their 
proliferation and differentiation potential, the expression of several markers has been 
evaluated to enhance the phenotypic characterization of this cell type. There are specific 
products, such as antibodies and substrates that assist the immunophenotypic characterization 
of stem cells making use of different methods such as flow cytometry and IHC staining (Tan 
et al., 2013). Even though different markers are available for stem cell localization in 
mammalian skin, such experiments are difficult to interpret because these markers lack 
cellular specificity. In this regard, stem cell factor (SCF) has been reported as a marker for 
skin stem cells, although it is also expressed by mature melanocytes (Takahashi et al., 1995). 
Also CK19 (Li et al., 2012) and ß-catenin are expressed in skin stem cells (Ridgway et al., 
2012), however, both are also expressed in adult epidermal cells (Zhao et al., 2012). More 
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recently purified cells from epidermis were characterized as EpSC by means of positive 
expression for a set of markers: CD29, CD44, CD49f, CD90, Casein Kinase 2β, p63, and 
Ki67 (Broeckx et al., 2014). In addition, a low expression for cytokeratin (CK)14 and 
negative expression for CD105, CK18, Wide CK, and Pan CK was previously reported 
(Broeckx et al., 2014). In our study, the isolated EpSC were positive for CK 14 and Casein 
Kinase 2β and negative for Pan CK and Wide CK. Flow cytometric analysis on the other 
hand, has shown that both EpSC and the differentiated cells expressed high levels of MHC-I 
but low levels of MHC-II. Except for MHC-I, all the results of the IHC and flow cytometric 
analysis in this study were in agreement with the previous studies by Broeckx et al. (2014). 
Further research should determine the cause of different MHC-I expression and its clinical 
implication. Stem cells are functionally defined by their ability to self-renew and differentiate 
into the cell lineages of their tissue of origin (Abbas and Mahalingam, 2009; Moore and 
Lemischka, 2006). Therefore, it can be concluded that the isolated cells showed the main 
characteristics of stem cells. Absence of minimum set criterion to define EpSC like that of 
hMSC, makes comparison between different reports more difficult. Nevertheless, also in the 
present thesis no single protein could be identified as the ideal “EpSC marker”.. Future 
studies should therefore focus on analyzing specific markers for the identification and 
purification of EpSC.  
7.3 In vivo studies  
In vivo evaluation of the wound healing effects of BMNC and EpSC on full thickness skin 
wounds in rabbits and horses, respectively, were performed in the experiments described in 
Chapters 4, 5 and 6. 
Macroscopic evaluation of the wounds treated by BMNC or EpSC was performed in our 
study by adjusting wound evaluation protocols developed by other researchers (Abramov et 
al., 2007; Babaeijandaghi et al., 2010; Bigbie et al., 1991). For subjective evaluation in the 
clinical BMNC studies, the analysis was based on the average score of a pathologist who was 
blinded to the treatment assignment. In the present thesis, rabbit full thickness excisional 
wounds treated by injecting autologous BMNC into wound margins (BI) showed earlier 
appearance of granulation tissue and significantly more contraction than those wounds treated 
by topical application of autologous BMNC (BT) and control groups (wound dressed by 
normal saline solution: NS and wound dressed by povidone iodine solution: PI). Even though 
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injection of autologous BMNC into the wound margin was superior than the topical 
application in the overall wound healing effect, both routes showed beneficial and promising 
wound healing potential for treating full thickness skin excisional wounds in rabbits. On the 
other hand, equine full thickness excisional skin wounds treated with autologous EpSC also 
showed significant improvement compared to both control groups for different macroscopic 
parameters, which was not the case for allogenic EpSC.  
Whether the macroscopic improvement after autologous EpSC treatment has any clinical 
relevance, remains to be demonstrated. In addition, the inferior macroscopic improvements of 
allogenic EpSC deserve more attention. Indeed, several aspects might be at the basis of the 
noticed discrepancy. First of all, an enhanced cellular immune response or graft rejection 
might have counteracted beneficial effects of EpSC. Secondly, one might postulate that donor 
EpSC could have been of inferior quality in comparison to the autologous EpSC. However, in 
the present thesis the same donor horses were used to harvest both autologous and allogenic 
EpSC. A third hypothesis might be that paracrine effects of autologous cells are not/less 
inhibited, and therefore, might influence local leukocytes and even fibroblasts and/or 
myofibroblasts in order to enhance the healing process. Probably the first and third 
hypotheses were at the basis of the noticed difference between both treatments, yet further 
analyses of the biopsies might clarify certain issues. More research is also warranted to 
provide new answers concerning the plasticity of skin-derived EpSC and the regenerative 
pathways they use in order to assist wound healing. 
Healing of cavity wounds such as full thickness excisional wounds can be monitored by 
measuring the circumference of the wound, which is directly related to both volume and area 
(Flanagan, 2003). In previous studies, improved macroscopic wound healing using whole BM 
aspirate (Lee et al., 2008; Nishimoto et al., 2013; Nishimoto et al., 2009), BM derived cells 
(Badiavas and Falanga, 2003; Jain et al., 2011), BM-MSC (Akela et al., 2012; Akela et al., 
2013; Chen et al., 2008; Kim et al., 2013; Wu et al., 2007b) and EpSC (Broeckx et al., 2014) 
have been reported. Most of the macroscopic findings in this section were also supported and 
explained by the histological findings detailed below. The discrepancy between treated and 
untreated wounds can be attributed to the above reported (trans)differentiation capacity of 
stem cells, however, releasing paracrine factors such as growth factors and cytokines might 
also be at the basis of the noticed clinical effects, as demonstrated by several researchers (Kim 
et al., 2013; Maxson et al., 2012; Wu et al., 2010). 
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Histomorphologically, the autologous BM treated wounds of rabbits showed an earlier 
disappearance of inflammatory reaction, better epithelialization, significantly more 
neovascularization and more fibroplasia than the control wounds. In addition, the BM 
treatment also resulted in earlier lay down and histological maturation of collagen. Several 
studies indicate that BM contains stem cells with a potential for differentiation into a variety 
of tissues including skin (Huttmann et al., 2003; Jones and McGonagle, 2008; Kang et al., 
2013). Therefore, it may be plausible that the wound healing effect of BMNC in this thesis is 
due to its progenitor and/or stem cell content. Nevertheless, further studies should confirm 
whether or not these cells actually integrate and regenerate the damaged tissue.    
Inflammation is essential to establish cutaneous homeostasis following injury and to recruit 
inflammatory cells, which act as a source of cytokines that affect the wound healing process 
(Singer and Clark, 1999; Theoret, 2009). However, massive or prolonged inflammation can 
delay wound healing, thus local suppression of the inflammatory process is required for the 
wound healing to proceed. The treatment of canine wounds with BM-MSC resulted in the 
reduction of pro-inflammatory cytokines (interleukin-2 and interferon-) from which it has 
been concluded that MSC exhibit paracrine effects by decreasing inflammation post-injury 
(Kim et al., 2013). In addition to attenuating inflammation in the wound site, BM-MSC are 
also involved in reprogramming the resident immune and wound healing cells to favor tissue 
regeneration and inhibit fibrotic tissue formation. As a result, these cells have been considered 
and tested as likely candidates for a cellular therapy to promote scarless wound healing 
(Jackson et al., 2012). Therefore, the earlier disappearance of inflammatory reaction in the BI 
and BT group observed in our studies can be attributed to this anti-inflammatory effect of 
BM-MSC that were present within the cell mixture. The disappearance of inflammatory 
reaction will assist wound progression to the next phase of the healing process, which is the 
proliferative stage (Broughton et al., 2006; Janis and Harrison, 2014).  
Autologous cell therapy (ACT) is a novel therapeutic intervention which minimizes the risk of 
systemic immunological reactions (bio-incompatibility) and of disease transmission 
associated with grafts or cells not cultivated from the individual (Kazmi et al., 2009). 
However it has been found that adult MSC also possess a remarkably diverse array of 
immunosuppressive characteristics and could thus also suppress an allogenic rejection 
(English and Mahon, 2011; Fu and Li, 2009). In vitro studies in the present thesis showed that 
EpSC expressed a very low level of major histocompatibility complex-II (MHC-II), which is 
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involved in graft rejection (Natarajan et al., 2002). In this regard, it has been reported that 
allogenic MSC, which were also negative for MHC II did not induce an immune response 
after intravenous and intradermal injections in horses (Broeckx et al., 2013; Carrade et al., 
2011). Allogenic MSC have also been used to treat graft-versus-host rejection diseases in 
humans (Le Blanc et al., 2008; Ringden et al., 2006). Therefore, absence of any adverse 
effects after allogenic EpSC administration in the present thesis could have been due to low 
level expression of MHC-II or other immunomodulative effects. Nevertheless, the allogenic 
treatment groups demonstrated lower macroscopic and histologic therapeutic effects. 
Concerning the difference between autologous and allogenic EpSC, more studies are 
definitely warranted. In this regard, it has been reported that no differences between 
autologous and allogeneic umbilical cord tissue-derived MSC were noticed concerning 
adverse local or systemic responses after two intradermal injections. Indeed, both physical 
and histomorphologic alterations did not significantly differ between both MSC treatments 
(Carrade et al., 2011). Although our macroscopic and histological results indicate a superior 
effect of autologous EpSC, more in depth research will have to confirm this hypothesis and 
postulate possible reasons. 
BM-MSC promote the proliferation of fibroblasts, which are responsible for deposition of 
collagen and granulation tissue formation (Branski et al., 2009; Chen et al., 2008; Jeon et al., 
2010). Fibroblasts will initially synthesize proteoglycans and fibronectin to create the 
extracellular matrix, which contains transforming growth factor-beta (TGF-β). Following this, 
fibroblasts together with macrophages release proteases that activate TGF-β, which stimulates 
further fibroblast proliferation and collagen synthesis (Broughton et al., 2006). Therefore, 
earlier lay down of collagen and more fibroplasia in autologous BM treated wounds of rabbits 
in the present thesis might be due to this effect of the BM-MSC. Nevertheless, BM 
supernatant contains other regenerative factors, such as growth factors and cytokines as well 
and this might have caused a similar effect on wound healing. In addition, the other cells in 
the BMNC namely white blood cells and progenitor cells might have interacted among 
themselves and with other wound cells through paracrine mechanism and contributed for the 
healing effect recorded. Studies show that such type interaction with vascular endothelial cells 
and immunomodulation has been found  to play significant role in accelerating wounds 
(Sorrell and Caplan, 2010). 
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To date, a large number of studies have been using mice, rabbits and other laboratory animals 
for investigating wound repair and scarring (Aksoy et al., 2002; Dorsett-Martin, 2004; Morris 
et al., 1997). However, the wound healing process in these laboratory animals is significantly 
different when compared with humans (Greenhalgh, 2005) and horses (Theoret and Wilmink, 
2013). Unfortunately, the skin healing process in horses is often being hampered by 
complications, leading to excessive scarring and granulation tissue formation (exuberant 
granulation tissue), which are detrimental to functional and esthetic outcomes (Theoret and 
Wilmink, 2013). In a previous studies, allogenic EpSC in combination with autologous PRP 
resulted in thinner and more normal granulation tissue than PRP alone (Broeckx et al., 2014). 
In agreement with this finding, a significant inhibition of granulation tissue formation was 
also recorded using both autologous and allogenic EpSC without PRP in the present thesis. 
However, the reduction in granulation thickness was higher after using autologous EpSC than 
after allogenic EpSC and comparison with the untreated negative controls were not significant 
anymore. Also young granulation tissue formation was affected by the treatment with most 
reduction in the autologous EpSC treatment group. Young granulation tissue has been 
described as poorly oriented/disorganized granulation tissue, which is deficient in contractile 
activity (Theoret and Wilmink, 2013). Besides unravelling how EpSC improve granulation 
tissue formation and maturation in comparison to vehicle treated wounds, more protracted 
studies are required to confirm a superior granulation tissue in comparison to untreated 
controls. In addition to epithelialization and granulation tissue formation, neovascularization 
is also a crucial parameter in wound healing (Falanga, 2005; Singer and Clark, 1999) because 
it is required to sustain the newly formed granulation tissue and the survival of keratinocytes 
(Wu et al., 2007a; Wu et al., 2007b). Neovascularization occurs concurrently with fibroblast 
proliferation when endothelial cells, originating from parts of uninjured blood vessels, migrate 
to the area of the wound (Cerqueira et al., 2014). Differentiation of MSC into endothelial cells 
has been reported in several in vitro (Liu et al., 2008; Pittenger and Martin, 2004) and in vivo 
studies (Tang et al., 2006). Moreover, enhanced capillary density in wounds due to promotion 
of angiogenesis by BM-MSC through releasing angiogenic factors has been reported by many 
researchers (Badiavas et al., 2007; Chen et al., 2008; Nakagawa et al., 2005; Wu et al., 
2007b). In the present thesis, only a subjective vascularization score was given in the rabbit 
biopsies, and therefore, no binding conclusions can be made concerning the effect of BMNC 
or EpSC on wound vascularization.  
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Researchers have been using different routes of administration of stem cells to the 
experimental animal or human. Indeed, besides stem cell injection into the wound edge or bed 
and/or topical application over the wound, intramuscular injection to the affected site and 
intra-arterial infusion have been reported for skin wound application. An enhanced wound 
healing rate was reported in rabbit incisional wounds by topical application of autologous 
BMNC (2 x 106) with placental extracts (Akela et al., 2013) and in excisional wounds by 
injecting autologous BMNC in plasma into the wound margin (Akela et al., 2012) by 
administering the cells only once on the day the wounds created . For the treatment of 
different types of human chronic wounds with size ranging from 15.4 cm2 to 44 cm2, topical 
application and injection into the wound bed of BM aspirate plus three additional topical 
treatments with cultured BM cells (ranging from 4.5 x 106 to 1.1 x 107 cells/wound) resulted 
in engraftment of the applied cells in combination with clinical and histological evidence of 
reduced scaring (Badiavas and Falanga, 2003). Kim et al. also reported positive results from 
intradermal injection of 104 to 107 BM-MSC in full thickness excisional circular punch 
wounds of 6mm diameter in dogs  (Kim et al., 2013).  In this thesis, autologous BMNC 
application (1.4 x 108 cell) to excisional full thickness wounds of 4 cm² resulted in improved 
wound healing in rabbits for both treatment groups (i.e. subcutaneous injection around wound 
margin and topically spraying over the wound).   
Besides the variations in the route of administration, other differences between the currently 
reported clinical studies are definitely worth mentioning. The type of cell vehicle used in 
wound healing studies differs greatly between the different experiments. The following 
substances have been reported as a carrier for applying stem cells in experimentally induced 
skin wounds in different animal species and clinical wounds in human: autologous plasma, 
autologous platelet rich plasma (PRP), phosphate buffered saline, normal saline, placental 
extracts, Hanks balanced saline solution (HBSS), amongst others (Akela et al., 2012; Akela et 
al., 2013; Badiavas et al., 2003; Badillo et al., 2007; Broeckx et al., 2014; Castilla et al., 2012; 
Wu et al., 2007b) . Another important variation between the different studies is the time of 
cell application to the wound. Most studies use cellular transplantation immediately after 
wound creation with or without a repetition after 24 hr (Akela et al., 2012; Akela et al., 2013; 
Wu et al., 2007b), where others apply the cell-based therapy only after 24 hr or even later 
(Kim et al., 2013). It was suggested that an injection of at least 1 x 106 MSC cells/cm²  into 
the wound bed is needed for a significant therapeutic effect (Kim et al., 2013) and that the 
appropriate number of cells required for treatment may differ according to the route of 
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delivery. No scientific information is available on the optimal frequency of the administration 
of stem/progenitor cells for wound therapy. Some have reported successful chronic wound 
treatments just by single administration (Akela et al., 2012; Akela et al., 2013; Jain et al., 
2011; Kim et al., 2013; Klepanec et al., 2012), while others have reported at least two 
(multiple) administrations (Badiavas and Falanga, 2003; Broeckx et al., 2014). Even though 
promising clinical outcomes are reported by a number of studies using BM-MSC or BMNC, 
comparison between the different results is difficult due to number of variations in the 
techniques of preparation of the cells and administration mentioned above. Therefore, the 
appropriate route of administration, number of cells and frequency of administration for 
efficient wound healing should be further investigated. Based on these results a guideline for 
using BMNC or EpSC for cutaneous wound therapy should be developed. 
7.4 Conclusions 
A variety of therapeutic modalities has been proposed to accelerate acute and/or chronic 
wound healing in the past decades. The development of novel approaches for wound 
treatment remains a clinical challenge. In line with the results from the present thesis, recent 
advances in regenerative medicine are providing encouraging data from both in vitro and in 
vivo studies. 
Autologous bone marrow-derived cells, promoted healing of full thickness excisional skin 
wounds in rabbits when injected into wound margin or applied topically over the wound 
(Chapters 4.1 and 4.2).  
Isolation and purification of EpSC was successful from all the horse (n = 6) skin samples 
using sphere formation as a valuable tool for EpSC enrichment. Indeed, sphere formation 
purified EpSC upon their isolation and successfully eliminated cellular contaminations 
(Chapter 5).  
In comparison with the vehicle treated groups, significantly enhanced macroscopic and 
histological wound healing was demonstrated in both autologous and allogenic EpSC-treated 
groups. Compared with the untreated control wounds no significant differences with EpSC 
treatments could be demonstrated (Chapter 6). Further research will have to determine why 
the untreated wounds scored considerably better than the vehicle treatments and how EpSC 
counteracted this effect. 
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7.5 Future research perspectives 
Even though BMNC cell mixture,  adult stem cells including BM-MSC and EpSC offer great 
therapeutic promise for a diverse range of medical applications, optimization of cell-based 
therapies is required at different levels, including defining donor cell characteristics (such as 
age of donor or site of harvest), pre-delivery strategies (isolation, enrichment, the length of 
time for the cells to be maintained after harvesting and still retain viability, pre-delivery 
conditioning and vehicle used for the cells), and delivery (ideal number of cells to be 
transplanted, time and frequency of transplantation, route of delivery, fate of transplanted 
cells and precise in vivo localization of the stem cells and recipient characteristics). 
There are several animal studies and many human pilot studies demonstrating an enhancing 
effect on skin wound healing of BMNC. However, the primary contribution of the 
administered cells to cutaneous regeneration and long term systemic effects need to be 
investigated. In addition, it needs to be determined if there are other types of stem/progenitor 
cells which might be more effective than BMNC.  
Although seeding EpSC at lower densities in suspension cultures could successfully remove 
the cellular impurities, further studies should be conducted to optimize and validate this 
purification method with skin stem cells as well as with stem cells from other tissues. Also 
minimal criteria for the characterization of EpSC should be set, as reported for human MSC 
by the international society for cellular therapy (ISCT). In addition, there is a need to conduct 
further in vitro and in vivo research in order to investigate the exact mechanism how EpSC 
treatment resulted in reduced macroscopic wound healing parameters and in normalized 
granulation tissue formation in comparison with vehicle treated wounds. Such future studies 
might need to consider the paracrine and immunomodulatory role of the transplanted EpSC in 
wound healing. 
The use of stem cell-based therapies has potential for advancing treatment options for 
companion animals, however, further evidence-based studies in clinical patients are warranted 
to substantiate their efficacy. When appropriate and clinically relevant veterinary models have 
been identified, these clinical trials will also be critical in predicting efficacy and optimizing 
therapies for human patients. To establish cell therapy as a standard treatment, more 
randomized clinical trials with a larger number of patients are required. Future research 
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should also focus on improving wound bed preparation and infection control to maximize cell 
engraftment, expediting cell culturing and looking at long term patient follow-ups at a 
functional and aesthetic level.  
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Summary 
Veterinary patients are frequently affected by complex skin wounds. Skin injury may induce 
loss of skins’ integrity with functional imbalance accompanied by disability or even death. 
Despite a variety of therapeutic modalities proposed to accelerate the healing of acute and/or 
chronic wounds over the past decades, it remains important to develop novel and more 
successful approaches for wound treatment. Recently, various wound healing technologies 
that promote cell activity or minimize scar formation have been developed and some of them 
are being actively used at present. Regenerative medicine is among those new technologies. It 
aims to restore, maintain and improve body function. Regenerative wound therapy might 
prove to be one of the best alternatives where current conventional therapies fail or lead to 
inadequate results.  
Cell therapy is a part of the broad field of regenerative medicine and it is defined as a set of 
strategies which use live cells with therapeutic purposes. Cells used in cell therapy can be 
broadly categorized as stem cells and adult/differentiated cells. Stem cells are undifferentiated 
cells, which have the capacity to differentiate into more specialized daughter /adult cells and 
have the ability to self-regenerate. Traditionally, they are divided into embryonic stem cells 
(ESC) and adult stem cells (ASC). Since ASC escape the ethical issues associated with ESC, 
they are the prime source for cell-based therapies and thus find their way through the 
regenerative landscape for treatment of several diseases in mammals.  
This dissertation contains a literature overview and own experimental work. The general 
introduction (Chapter 1) consists of a literature review on different aspects of stem cell based 
therapies for cutaneous wounds. The isolation and characterization of adult stem/progenitor 
cells from bone marrow and skin is reviewed, followed by a description of the different routes 
of administration of stem cells and the evaluation of wound healing. This chapter introduces 
background knowledge on techniques used in the experimental work of the dissertation. 
Chapter 2 is devoted to an overview on regenerative skin wound healing in mammalian 
species. It highlights the adult mammalian wound healing as compared to the scarless wound 
healing in the mammalian embryos and amphibians and further discusses wound management 
in a general way. It gives an account of the current knowledge on cutaneous regenerative 
wound healing techniques with special emphasis on growth factors and cell based therapies. 
The most commonly cited growth factors and stem cells with positive effects on skin wound 
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healing of mammals are discussed, particularly for rabbit and horse, the two animals species 
studied in this thesis. 
The experimental work focuses on two different types of cells in two different animal models: 
(1) Autologous bone marrow-derived nucleated cells (BMNC) and their potential use in 
cutaneous regenerative therapy in rabbit full thickness excisional (thoracolumbar region) 
wounds (Chapters 4.1 and 4.2) and (2) Epithelial-like stem cells (EpSC) and their in vivo 
regenerative capacity in full thickness excisional wound in horses (Chapter 6). New isolation 
and purification techniques for EpSC in horse are also developed in this work (Chapter 5)   
The objective of Chapters 4.1 and 4.2 was thus to investigate the use of BMNC in rabbits (n = 
20) for wound healing. Wounds were treated by either (i) injection of bone marrow-derived 
cells into wound margin (BI), (ii) topical application of bone marrow-derived cells over the 
surface of the wound (BT), (iii) wound dressing with povidone iodine (PI) or (iv) with the 
normal saline (NS). The latter two constituted the two control treatments.  The wounds were 
followed for 28 days after wound induction for evaluating the status of granulation tissue 
formation and the wound contraction, and for assessing the wound histomorphologically and 
determining the time to complete wound healing. Granulation tissue appeared significantly 
faster in BI (3.22 + 0.22) than in BT (3.89 + 0.40), PI (4.89 + 0.47) and NS (4.56 + 0.47). On 
day 21 wound contraction was significantly higher in BI (97.35%) than in BT (84.87%), PI 
(84.6%) and NS (92.59%) treated wounds. Histological examination of the healing wound 
indicated earlier disappearance of inflammatory reaction, significantly more 
neovascularization and fibroplasias, earlier laydown and histological maturation of collagen 
and better epithelialization were in BI and BT than in control wounds. 
Before applying EpSC in a clinical setting in horse skin wounds, the production of an EpSC 
dose was optimized in Chapter 5. The sphere-forming capacity was used as an enrichment 
strategy in EpSC from equine skin. Skin samples were harvested from horses (n = 6, mares) 
and EpSC were isolated and purified from all the samples. In addition to their characterization 
based on immunophenotypic and functional properties, subsequent sphere formation was 
assessed upon isolation at passage 0 (P0) and at early (P4) and late (P10) passages in 
suspension culture using different culture media. An average of 0.53% (+ 0.28%) of the 
primary skin-derived cells could form spheres and hence showed stem cell properties. 
Significantly more sphere formation occurred in EpSC medium than in differentiation 
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medium verifying the EpSC’ privileged ability to survive in suspension. Immunophenotypic 
characterization showed that EpSC express cytokeratin (CK) 14, Casein kinase 2 beta and 
Major Histocompatibility Complex (MHC) I but not Pan CK and wide CK, while only few 
cells expressed MHC II. Keratinocyte differentiation of EpSC at early and late passages was 
successful for all six isolates (as confirmed by co-expression of CK 14, Casein kinase 2 beta, 
pan CK and wide CK). A non-EpSC cell type, which was confirmed to be a keratinocyte by 
immunohistochemistry, was detected in one of the six isolates in adherent culture. The isolate 
with keratinocyte impurity was purified by seeding the cells in suspension culture at ultralow 
clonal densities of 1 and 10 cells/cm2 yet with a significantly lower sphere forming efficiency 
in comparison to pure EpSC.  
Different studies in animal and human models have demonstrated beneficial effects of 
autologous and allogenic mesenchymal stem cells on skin wound healing. Only a few reports 
are available on the difference between autologous and allogenic EpSC for the treatment of 
skin wounds. Therefore, Chapter 6 deals with the in vivo assessment of autologous and 
allogenic EpSC-treated skin wounds in horses (n = 6, mares). In the gluteus region, 12 full 
thickness skin wounds of 2 x 3 cm were created and four treatment groups were considered: 
(i) autologous EpSC, (ii) allogenic EpSC, (iii) vehicle treatment (placebo) and (iv) sham 
operated. Each treatment group contained 3 wounds for double-blind macroscopic and 
histologic examination at week 1, 2 and 5. The results revealed significantly reduced 
circumference in wounds treated by autologous EpSC compared allogenic EpSC and placebo. 
The total granulation tissue thickness was 1257 µm smaller in allogenic EpSC treated wounds 
(p = 0.0103) and 1403 µm smaller in the autologous EpSC treated wounds (p = 0.004) as 
compared to vehicle treated wounds. Moreover young granulation tissue was 983 µm smaller 
in allogenic EpSC treated wounds (p = 0.0247) and 1135 µm smaller in the autologous EpSC 
treated wounds (p = 0.0084) as compared to vehicle treated wounds. Finally, In comparison to 
the vehicle treated wounds, the allogenic and autologous treated wounds were 26% (P = 
0.0501) and 32% (P = 0.0144) closer to the intact skin thickness, respectively. 
In conclusion, it has been demonstrated that regenerative skin wound treatment and more 
particularly cell-based therapies have a lot of potential, both from in vitro and in vivo studies 
of skin wounds in different animal models. In line with this, the experimental work in the 
present thesis indicates that full thickness skin excisional wound healing can be promoted 
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using autologous bone marrow-derived cells and autologous and allogenic EpSC in rabbits 
and horses, respectively. 
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Samenvatting 
Huidwonden met een complex karakter komen vaak voor in de diergeneeskundige praktijk. 
Huidwonden kunnen leiden tot verlies van de integriteit van de huidbarrière en een 
functioneel onevenwicht, met als mogelijk gevolg een infectie of zelfs de dood. Hoewel er de 
afgelopen jaren verschillende nieuwe behandelingsmodaliteiten zijn voorgesteld om de 
genezing van zowel acute als chronische huidwonden te bespoedigen, blijft het belangrijk om 
innovatieve en meer succesvolle therapieën voor huidwonden te ontwikkelen. Recent zijn 
verschillende nieuwe technieken ontwikkeld die gebaseerd zijn op het verhogen van de cel 
activiteit binnen de wonde om de vorming van littekenweefsel zoveel mogelijk te 
minimaliseren. Deze technieken worden momenteel al toegepast in de diergeneeskundige 
praktijk. De regeneratieve geneeskunde is één van die nieuwe technologieën. Ze beoogt het 
herstel, behoud en verbetering van de lichaamsfunctie. Regeneratieve wondheling zou een 
goede alternatieve therapie kunnen zijn waar de conventionele therapieën falen of tot een 
weinig bevredigend resultaat leiden.  
Celtherapie maakt deel uit van de bredere discipline van regeneratieve geneeskunde en wordt 
gedefinieerd als een set van behandelingsstrategieën die levende cellen gebruiken voor 
therapeutische doeleinden. De cellen gebruikt in celtherapie kunnen opgedeeld worden in 
stamcellen en volwassen/gedifferentieerde cellen. Stamcellen zijn ongedifferentieerde cellen, 
die de capaciteit hebben om te differentiëren in meer gespecialiseerde dochter /volwassen 
cellen maar ook om zichzelf te vermenigvuldigen. Traditioneel worden stamcellen opgedeeld 
in embryonale stamcellen (ESC) en volwassen stamcellen . Omdat er met volwassen 
stamcellen veel minder ethische problemen zijn dan met ESC worden ze meest ingezet in cel-
gebaseerde therapie; aldus vinden ze hun weg in de regeneratieve geneeskunde voor de 
behandeling van verschillende ziekten, vooral dan bij zoogdieren.  
Deze dissertatie bevat een literatuuroverzicht en eigen experimenteel werk. De algemene 
introductie (Hoofdstuk 1) bestaat uit een literatuuroverzicht met focus op stamcel-gerelateerde 
therapieën voor huidwonden. De isolatie en karakterisatie van volwassen stam/progenitor 
cellen van beenmerg en huid wordt besproken, gevolgd door een beschrijving van de 
verschillende wijzen van toedienen van stamcellen en van de evaluatiewijzen voor 
wondheling. In dit hoofdstuk wordt ook een overzicht gegeven van de huidige kennis over de 
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verschillende technieken die in het experimentele onderzoek van deze dissertatie worden 
gebruikt. Hoofdstuk 2 geeft een beschrijving van het begrip regeneratieve huidwondheling bij 
zoogdieren. Het vergelijkt de wondheling bij volwassen zoogdieren met die bij amfibieën en 
embryo’s van zoogdieren en bespreekt ook het management van wonden in het algemeen. Het 
geeft een overzicht van de bestaande kennis over regeneratieve huidwondheling technieken 
met speciale aandacht voor therapieën gebaseerd op groeifactoren en stamcellen. De meest 
geciteerde groeifactoren en stamcellen met positieve effecten op huidwondheling bij 
zoogdieren wordt besproken, voornamelijk voor paard en konijn, de twee diersoorten die in 
deze dissertatie gebruikt worden voor het experimentele werk. 
Het experimentele werk maakt gebruik van twee verschillende celtypen in twee verschillende 
diermodellen: (1) Autologe gekernde cellen van beenmerg (BMNC) voor het gebruik van 
regeneratieve therapie in ‘full thickness’ excisiewonden (thoracolumbale regio) bij konijn 
(Hoofdstukken 4.1 en 4.2) en (2) Epithelieel-gelijkende stamcellen, (EpSC) en hun in vivo 
regeneratieve capaciteit in ‘full thickness’ excisiewonden bij het paard (Hoofdstuk 6). Voor 
de EpSC bij het paard worden in dit werk ook nieuwe isolatie- en purificatie technieken 
ontwikkeld (Hoofdstuk 5).   
Hoofdstukken 4.1 en 4.2 bespreken de resultaten van de experimenten uitgevoerd bij 
konijnen. Ze geven een antwoord op de vraag of BMNC geschikt zijn als therapie bij 
wondheling van het konijnen (n = 20). Wonden werden behandeld met ofwel (i) een injectie 
in de aflijning van de wonde met cellen afkomstig van het beenmerg (BI), (ii) lokale 
toediening van cellen afkomstig van het beenmerg over de volledige oppervlakte van de 
wonde (BT), (iii) povidone iodine (PI) of (iv) een normale zoutoplossing (NS). De laatste 
twee behandelingen zijn de controlebehandelingen. De wonden werden gedurende 28 dagen 
opgevolgd en geëvalueerd voor (1) de vorming van granulatieweefsel, (2) de contractiegraad 
van de wonde, (3) de evolutie van de wonde over de tijd op gebied van histomorfologie en (4) 
de tijd nodig voor volledig wondgenezing. Granulatieweefsel ontstond significant sneller in 
BI (3.22 + 0.22) dan in BT (3.89 + 0.40), PI (4.89 + 0.47) en NS (4.56 + 0.47). Op dag 21 was 
er significant meer wondcontractie bij BI (97.35%) dan bij BT (84.87%), PI (84.6%) en NS 
(92.59%) behandelde wonden. Op histologisch niveau verdween de inflammatoire reactie 
sneller en was er significant meer neovascularisatie en fibroplasia bij BI en BT in vergelijking 
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met de controlewonden en was er een snellere histologische maturatie van collageen en een 
betere epithelialisatie. 
Voor EpSC werden gebruikt in de klinische proef bij paarden, werd de productie van de EpSC 
geoptimaliseerd zoals beschreven in Hoofdstuk 5. De sfeer-vormende capaciteit werd gebruikt 
als een verrijkingsstrategie bij EpSC van paardenhuid. Huidstalen werden geoogst bij paarden 
(n = 6, merries) en EpSC werden geïsoleerd en gezuiverd voor alle stalen. Eerst werden de 
cellen gekarakteriseerd op basis van immunofenotypische en functionele eigenschappen. 
Vervolgens werd sfeerformatie geëvalueerd in passage 0 (P0) en tijdens vroege (P4) en late 
(P10) passages in suspensiecultuur waarbij verschillende cultuurmedia werden gebruikt. Een 
gemiddelde van 0,53% (+ 0,28%) van de oorspronkelijke huidcellen kon sferen vormen en 
vertoonde aldus stamceleigenschappen. Significant meer sfeervorming trad op in EpSC 
medium in vergelijking met differentiatiemedium; dit komt overeen met de capaciteit van 
EpSC om te overleven in suspensie. Immunofenotypische karakterisatie toonde aan dat EpSC 
cytokeratin (CK) 14, Casein kinase 2 beta en Major Histocompatibility Complex (MHC) I tot 
expressie brengen, maar niet Pan CK en ‘wide CK’. Slechts bij een beperkt aantal cellen werd 
MHC II tot expressie gebracht. Keratinocyt differentiatie van EpSC bij vroege en late 
passages was succesvol voor alle zes isolaten (bevestigd door co-expressie van CK 14, Casein 
kinase 2 beta, pan CK en ‘wide CK’). Een non-EpSC celtype (geïdentificeerd als keratinocyt 
door immunohistochemie) was aanwezig in één van de zes isolaten. Het isolaat met de 
keratinocyt werd opgezuiverd door het uitzetten van de cellen in suspensiecultuur met ultra 
lage klonale dichtheden van 1 en 10 cellen/cm2 met bijgevolg een significant lagere efficiëntie 
van sfeervorming in vergelijking met een zuivere EpSC cultuur.  
Verschillende studies bij zoogdieren en bij de mens hebben aangetoond dat de toepassing van 
autologe en heterologe mesenchymale stamcellen een positief effect kan hebben op de 
wondheling. Een beperkt aantal studies bestuderen het verschil tussen autologe en heterologe 
EpSC voor de behandeling van huidwonden. Hoofdstuk 6 evalueert de in vivo behandeling 
van huidwonden bij het paard met autologe en heterologe EpSC (n = 6, merries). In het gebied 
van de m. gluteus werden 12 ‘full thickness’ huidwonden van 2 x 3 cm aangebracht en vier 
verschillende behandelingen werden toegepast: (i) autologe EpSC, (ii) heterologe EpSC, (iii) 
behandeling met enkel oplossingsvloeistof (OV) en (iv) onbehandeld (OB). Aan elke 
behandelingsgroep werden per paard 3 wonden toegewezen voor dubbelblinde 
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macroscopische en histologische evaluatie op week 1, 2 en 5. De resultaten toonden aan dat 
de omtrek van de wonde significant kleiner was voor wonden behandeld met autologe EpSC 
in vergelijking met heterologe EpSC en OV. De totale granulatieweefsellaag was 1,257 mm 
dunner bij heterologe EpSC behandelde wonden (p = 0.0103) en 1,403 mm dunner bij 
autologe EpSC behandelde wonden (p = 0.004) in vergelijking met OV. Bijkomend was de 
jonge granulatieweefsellaag 0,983 mm dunner bij heterologe EpSC behandelde wonden (p = 
0.0247) en 1,135 mm dunner bij autologe EpSC behandelde wonden (p = 0.0084) in 
vergelijking met OV. Tenslotte, in vergelijking met OV behandelde wonden was de dikte van 
heterologe en autologe behandelde wonden 26% (p = 0.0501) en 32% (p = 0.0144) dichter bij 
de dikte van intacte huid, respectievelijk. 
Er werd tot besluit in deze dissertatie aangetoond dat regeneratieve huidwondbehandelingen 
en meer specifiek de cel-gebaseerde therapieën, een potentieel hebben, zoals blijkt uit zowel 
de in vitro als de in vivo studies van huidwonden uitgevoerd in verschillende diermodellen. 
Ook het experimentele werk voorgesteld in deze dissertatie duidt aan dat de genezing van 
‘full thickness’ excisiewonden van de huid kan bespoedigd worden door het toedienen van 
autologe cellen afkomstig van beenmerg en autologe en heterologe EpSC respectievelijk bij 
konijn en paard.  
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